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Abstract
Poor physical stability is a limiting factor in the pharmaceutical development of APIs.
Amorphous drugs are attractive due to increased dissolution; however can unpredictably
revert to the thermodynamically stable crystalline form. Accurate prediction of molecular
level physical stability would be advantageous. Research surrounding stability prediction is
evolving; but challenging, including thermodynamic, molecular and kinetic factors.
This study focussed on gaining a molecular level understanding of the structure and dynamics
of amorphous dispersions using three model drugs. We aimed to develop solid-state NMR
methods to provide invaluable information on molecular mobility; to ultimately use NMR for
the prediction of crystallisation outcomes from stability studies, leading to quicker prediction
of potential storage issues, since mobility is a key factor affecting stability in the amorphous
state.
VT solid-state NMR was used to probe differences in local mobility between drug and
polymer; and to monitor polymorphic transitions/crystallisation in high loaded dispersions.
Methodologies were verified using additional physicochemical approaches.
We demonstrated:
• Differences in local mobility of drug/polymer dependent on model system and drug
loading.
• Miscibility detection down to 2 nm, including important temperature dependent
observations. VT relaxation curves could become important visual tools for
quantification of drug loading and prediction of miscibility during initial development.
• VT NMR was a useful tool for quick and accurate prediction of high temperature
stability study outcomes
• Insight into crystallisation of pharmaceuticals in formulation, demonstrating mapping
complex phase transitions in high loaded dispersions
• Detection of different dynamic features of tolbutamide, including the identification of
motional processes responsible for the detection of its structural transitions
VT solid-state NMR has provided a significant quantity of data surrounding the mobility and
stability of our systems of study. These methods provide us with a valuable characterisation
‘toolkit’ for probing molecular mobility in solid dispersions, therefore aiding the prediction
of potential long term stability issues.
Glossary
τ c Correlation time.
API Active Pharmaceutical Ingredient.
BPP/KT Bloembergen Purcell Pound / Kubo Tomita theory.
C-K Couchman-Karasz equation.
CP/MAS Cross polarisation magic angle spinning.
CSA Chemical shift anisotropy.
DRS Dielectric Relaxation Spectroscopy.
DSC Differential scanning calorimetry.
EA Activation energy.
FFA Flufenamic Acid.
FWHH Full width half-height.
G-T Gordon-Taylor equation.
G-T/K-B Gordon-Taylor/Kelley-Bueche equation.
IMC Indomethacin.
mDSC Modulated temperature DSC.
NMR Nuclear magnetic resonance.
PVP Polyvinylpyrrolidone.
PVP-VA Polyvinylpyrrolidone-co-vinylacetate.
PXRD Powder X-ray diffraction.
RTP Room temperature and pressure.
T1ρ Spin lattice relaxation time in the rotating frame.
i
T1 Spin lattice relaxation time.
T2 Spin-spin relaxation time.
Tg Glass transition temperature.
TK Kautzmann temperature.
Tm Melting point.
TLB Tolbutamide.
VT Variable temperature.
WISE WIdeline SEparation.
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Chapter 1
Introduction
1
To put this thesis into context, the literature covered in this chapter highlights the
important topics associated with the study of pharmaceutical amorphous solid dispersions.
The formulation of solid dispersions of amorphous drugs with polymers is a technique
employed in the pharmaceutical industry to improve the dissolution rate of crystalline
APIs, and stability of amorphous APIs. The ultimate aim of successful formulation is to
prepare a fully amorphous, fully miscible drug/polymer system which remains
physically stable upon storage for the full shelf-life duration. The literature included in
this chapter will explore these three areas, describing the importance, relevance and
characterisation techniques employed to investigate each one. The important role
solid-state NMR has played to date in the understanding of molecular mobility and
physical stability of solid dispersions will also be discussed.
1.1 Amorphous and Crystalline Active Pharmaceutical
Ingredients (APIs)
Knowledge of the amorphous form is of paramount importance when determining the
solid-state physical and chemical properties of many pharmaceuticals. The word
‘amorphous’ is from the Greek ’a morphe´,’ meaning without shape [16]. An amorphous
material can simply be defined as a disordered non-crystalline solid [59] which lacks the
long range three-dimensional order of the crystalline form. Molecules in amorphous
materials characteristically have some short-range chemical and topological order with near
neighbours, but an overall more randomly disordered molecular structure [16]. A crystal
can be defined as ‘a solid body having a characteristic internal structure and enclosed by
symmetrically arranged plane surfaces, intersecting at definite and characteristic
angles’ [60]. Therefore, crystalline APIs exhibit ordered three-dimensional structures, with
repeated unit cells providing long range order and high physical stability. The difference in
structure between amorphous and crystalline solids can be seen in figure 1.1.
Figure 1.1: Structural differences between crystalline and amorphous materials, adapted from [15]
O’Donnell and Woodward [61] recently reported that an estimated 70 % of pipeline APIs
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are poorly water soluble. Poor aqueous solubility is therefore currently one of the biggest
hurdles for the pharmaceutical industry in the development of oral formulations [62]. The
formulation of low solubility crystalline APIs in the amorphous form is a popular technique
used to greatly improve dissolution rate and bioavailability [17, 63, 64]. Mullins and
Macek [65] first demonstrated improved dissolution of APIs with the formation of
amorphous novobiocin. Haleblian et al. [66] further demonstrated the lack of long range
order in a number of amorphous APIs, which led to improved dissolution rates. Common
methods of producing amorphous materials are highlighted in figure 1.2. The method of
preparation and sample history are important factors for amorphous materials, as the
amorphous state does not have a tightly defined energy, therefore the different dynamic
and energetic properties can be affected by the method of preparation and the sample
history [51]. For example, Fukuoka at al. [67] found that melt cooled indomethacin
remained amorphous for two years at room temperature, whereas milled indomethacin
showed evidence of crystallisation after two months of storage.
Figure 1.2: Schematic representation of common methods of producing amorphous pharmaceutical
materials, adapted from [16]
It was later demonstrated that amorphous APIs lack the stability of the crystalline form due
to their thermodynamically metastable nature, resulting from a higher enthalpy, entropy and
Gibbs free energy [67–71]; and greater molecular mobility [51]. This leads to the likelihood of
physical instability [62,72], with formulations tending towards crystallisation, accelerated by
environmental factors such as temperature or humidity [73]. Knowledge and understanding
of the amorphous form is therefore of paramount importance when determining the solid-
state physical and chemical properties of many pharmaceuticals.
1.2 Amorphous Solid Dispersions
Amorphous solid dispersions are defined as ‘dispersions of one or more active ingredients in
an inert and hydrophilic carrier or matrix in the solid state, prepared by melting or solvent
method’ [74] and provide molecular level mixing of drug and polymer [17].Polymers have
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been found to be highly effective in stabilising amorphous pharmaceuticals through
formulation as amorphous solid dispersions [68, 75–79]. Van den Mooter et al. [80] found
that physical mixing of amorphous ketoconazole (KET) and polyvinylpyrrolidone (PVP)
did not prevent crystallisation, but formulating the drug and polymer into a solid
dispersion was a highly effective way to prevent crystallisation, and therefore improve
physical stability. Yoshioka et al. [81] additionally demonstrated that inhibition of
crystallisation of amorphous indomethacin (IMC) in the absence of polymer required
storage temperatures of ca. 50 K below Tg, whereas in the presence of as little as 5 %
PVP, crystallisation of IMC was inhibited at room temperature, with significant inhibition
occurring with the presence of 20 % polymer. Widely used polymer examples include
polyethylene glycol (PEG), hydroxypropylmethylcellulose (HPMC) [41, 82],
hydroxypropylmethylcellulose-acetyl succinate (HPMC-AS) [83], polyvinylpyrrrolidone
(PVP) [77–79,84, 85] and polyvinylpyrrolidone-co-viynlacetate (PVP-VA) [79]. Preparation
of an amorphous solid dispersion enables the drug to retain the favourable dissolution
profile of the amorphous form, whilst improving physical stability through the prevention
of crystallisation [77].
The overall formulation aim is to reduce the transformation of amorphous to crystalline
material through inhibition of nucleation and crystal growth within the system [80]. Different
stability mechanisms have been frequently discussed in the literature in recent years [62], with
current understanding highlighting: 1) increased Tg of the mixture with high Tg polymers,
through an anti-plasticising effect; 2) reduced molecular mobility of the amorphous drug; and
3) stability through specific drug/polymer interactions as important factors [62, 78, 80, 86].
Hydrophilic polymers have also been shown to improve both wetting and dissolution rate of
amorphous APIs [78]. Additionally, amorphous solid dispersions can provide advantages for
the pharmaceutical industry in early formulation development by improving drug exposure
to APIs with low aqueous solubility [87, 88]; and by slowing the release of highly soluble
APIs in extended-release preparations [88–90]. Common formulation methods include solvent
evaporation [91], spray drying [92], cryo-milling [51], hot melt extrusion (HME) [17,93], nano-
solid suspension formation via controlled precipitation [94] and solvent-free supercritical fluid
processing [95].
Despite the numerous literature examples of successful stabilisation of amorphous drugs
with polymers, there are still relatively few commercial solid dispersions available [96–99].
This is likely due to the lack of understanding of the structure and dynamics of amorphous
solid dispersions, and how these factors relate to improved dissolution rate and physical
stability [17]. Accurate prediction of physical stability on a molecular level would be a great
advantage. Research in the field of predicting physical stability is active and evolving; but is
a challenging topic, which includes overlapping considerations of thermodynamic, molecular
and kinetic factors [100]. Additionally, very few techniques are able to probe miscibility at a
molecular level, particularly in solid solutions as they require nanoscale detection limits [19],
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leading to limitations of the use of a number of commonly used characterisation techniques.
The ability to accurately predict physical stability of amorphous solid dispersions would be
of great advantage to the pharmaceutical industry and therefore knowledge of how changes
in the local molecular mobility of amorphous materials leads to reduced physical stability is
of paramount importance.
1.2.1 Classification of amorphous solid dispersions
Solid dispersions are classified by a number of terms, depending on the level of mixing (or
miscibility) between drug and polymer. This ranges between ’ideal’ systems of molecular
level dispersions (often termed solid or glass solutions), which are fully miscible, and
intimately mixed [88, 101]; to phase separated systems containing nano or micro
domains [17, 102]. Phase separation in an amorphous solid dispersion generally occurs due
to the presence of both amorphous and crystalline API, leading to the formation of
domains in the polymer matrix [11, 88], which are not always evenly distributed [103]. The
successful formation of solid/glass solutions is most likely to fulfil the sought after
characteristics of a fully miscible, fully amorphous, physically stable solid
dispersion, offering beneficial high aqueous dissolution rate with the lowest possibility of
phase separation [88, 104–106]. Phase separation, or heterogeneity of solid dispersions can
occur during formulation, handling and storage, and results in complex systems, which are
often difficult to characterise [107]. Both solubility and miscibility of the API in the chosen
polymer help to determine the maximum drug loading level of an amorphous solid
dispersion, above which the likelihood of phase separation and/or crystallisation
increases [108, 109] as at high drug loading levels, amorphous solid dispersions can become
metastable. It is therefore crucially important to understand the factors contributing to
the crystallisation of materials from the amorphous state [17, 74]. Figure 1.3 outlines the
important physicochemical properties associated with amorphous dispersions, and the
differences in phase separation behaviour associated with introduction of stress (e.g
increased temperature, humidity or mechanical stress).
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Figure 1.3: Scheme to understand the important physicochemical properties of amorphous solid
dispersions, with a demonstration of the outcomes of exposure of these systems to stress, for example increased
temperature, humidity or mechanical stress. Adapted from [17]
1.3 Glass transition temperature (Tg)
Tg is a physical property of solid amorphous systems. It describes a kinetic event which
results in the change of the thermodynamic properties of the material as it moves from a hard
’glassy’ to a soft ’rubbery’ state [18,110]. In the field of amorphous pharmaceutical systems,
Tg is generally regarded as the most important indicator of physical stability [61], as it
describes a major change in the properties of amorphous materials [29]. The Tg can provide
local structural information, reflecting the chemical and physical stability of amorphous
materials [111]. A fully miscible dispersion should have a Tg value which is intermediate
between the individual components, (i.e drug and polymer). The theoretical Tg value of
’ideally mixed’ amorphous solid dispersions can be predicted using a number of equations,
including the Gordon-Taylor (G-T) [112], Gordon-Taylor/Kelley-Bueche (G-T/K-B) [113]
and Couchman-Karasz (C-K) [114], which are discussed in further detail in chapter 2.
There is no widely accepted definition of Tg, but it is generally defined as the ‘temperature
of onset of the heat capacity increase during heating’ [16]. The Tg can be measured using
differential scanning calorimetry (DSC), with the midpoint of the transition calculated as
the Tg temperature. Figure 1.4 highlights the change in specific volume and enthalpy as a
function of temperature for a typical liquid. The transition between the glassy and crystalline
states is often described with the aid of such diagrams. Upon cooling, a liquid can either:
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[18, 115,116]
• Crystallise at Tm: → first order phase transition associated with a sharp reduction in
volume/enthalpy; OR
• Cool below Tm without crystallisation: → formation of a ’supercooled’ liquid, with a
change in volume/enthalpy which follows the liquid equilibrium line.
Further cooling of the supercooled liquid results in a change in slope gradient, at
temperature Tg. At this point, the ’glassy’ material is in a non-equilibrium state which is
accompanied by an increase in viscosity and a decrease in molecular mobility. The change
in the properties of the systems results in the enhancement of the thermodynamic
properties. The enhanced thermodynamic properties account for the increased dissolution
rate of the amorphous material as compared to the crystalline form [18,115,116].
Figure 1.4: Specific volume/enthalpy vs. Temperature for a liquid which can both crystallise and form
a glass, where Tm = melting point, Tg = glass transition temperature and TK = Kautzmann temperature,
adapted from [18]
1.3.1 Molecular Mobility around Tg
Current literature places a large emphasis on molecular motions as the main factor
affecting physical stability [117, 118], but the interpretation of dynamic phenomena in
amorphous solids is difficult due to the presence of molecular motions on different
timescales. At temperatures around Tg molecular motions are very slow, sometimes taking
minutes to hours for a molecule to reorientate [116]. In the supercooled rubbery state, the
average timescale of molecular motions is < 100 s, with a viscosity around 10 12 Pa
s−1 [116]. The timescale of molecular motion dramatically increases as the material is
cooled towards Tg [118], with further cooling resulting in the loss of kinetic equilibrium,
leading to a change in the temperature dependence of specific volume and enthalpy: the
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experimentally observed Tg (figure 1.4). Below Tg, the material exists in a
thermodynamically unstable glassy state, where the timescale of molecular motions is
hugely reduced, with viscosities of > 1012 Pa s−1 [16, 116,119].
There are two main types of molecular mobility which are described in association with the Tg
for amorphous materials: global mobility and local mobility, which are described in terms
of α-relaxation and β-relaxation times respectively [100]. Global mobility (α relaxations)
describes the motions associated with the glass transition temperature. These motions are
more widely studied, and are thought to be directly related to physicochemical stability.
Local mobility (β relaxations) describes the molecular mobility below the Tg, thought to
be slower intramolecular motions, resulting from restricted rotation around bonds, such
as motions of polymer side chains. They have lower activation energies, and are thought
to be precursors to α relaxation [100, 117, 118]. Local mobility is currently not directly
characterised, but measured by extrapolation from the data above Tg [100].
Molecular mobility of amorphous materials is often expressed as it’s reciprocal: the
relaxation time (τ). Relaxation in amorphous materials may result from a number of
processes, including enthalpic relaxation [69], volume relaxation [69], dielectric
relaxation [120] or spin-lattice relaxation [4]. Molecular mobility is often indirectly
measured using DSC above and below the Tg, through estimation of τ using a number of
equations including Kohlrausch-Williams-Watts (K-W-W) [102, 121], Adam Gibbs
(AG) [100] and Vogel–Tammann–Fulcher (VTF) [100]. However, techniques such as
dielectric relaxation spectroscopy, and solid-state NMR spectroscopy can provide a direct
measure of the molecular mobility of an amorphous material [100]. It is generally thought
that crystallisation is restricted to the region above Tg, as diffusional processes required for
nucleation cannot occur below this temperature [59]. Local mobility obviously plays an
important role in physical stability and it is therefore important to increase understanding
of β relaxations. The understanding of the molecular mobility around and below the Tg
value of amorphous solid dispersions therefore plays an important role in providing vital
information about physical stability during formulation development.
Studies of amorphous materials have found that storage temperature greatly influences rate
and occurrence of crystallisation [68, 81, 122] which highlights that Tg can help to dictate
the optimal storage conditions for an amorphous system as it represents the border between
an area of high and low molecular mobility [74]. Storing an amorphous material close to,
or above Tg ultimately allows increased molecular mobility, reduced physical stability and
eventual crystallization. The general ’rule of thumb’ is that storage at temperatures of Tg
- 50 K (the ’Kautzmann temperature’ (TK) [69, 116]) molecular mobility is virtually non-
existent, therefore crystallisation should not occur in an amorphous system [61, 64, 69, 100,
123]. However, as molecular mobility can still occur below Tg, crystallization may still occur
upon product storage [123]. There are many examples of studies where Tg measurements
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have proved an inaccurate stability predictor as nucleation or crystallisation has still occurred
at temperatures well below Tg [68, 124]. For example nifedipine has a Tg of 319 K, but has
been shown to crystallise at temperatures as low as 40 K below this [125], extremely close
to TK . Additionally, many amorphous APIs exhibit low Tg temperatures, therefore storage
at TK is not realistically achievable for patients outside the laboratory setting.
1.4 Polymorphism of crystalline APIs
The investigation of physical stability of amorphous solid dispersions often requires the
characterisation of crystalline forms of the API, as detection of crystallisation from the
amorphous state is employed as a measure of reduced physical stability, particularly in
accelerated stability studies. It is widely known that many APIs exist in multiple
crystalline forms, or polymorphs [126]. Polymorphism describes the ability of a crystalline
material to exist as more than one crystalline structure, each with a different molecular
arrangement due to differences in packing and/or molecular conformation [127].
McCrone [128] was first to highlight why polymorphism was particularly important from a
pharmaceutical perspective. He outlined two main factors which were imperative for full
understanding of polymorphism, both of which are mainly still somewhat of a mystery
today. The main question he asked was ”What are the factors which determine what
particular crystal form will be generated from vapour, liquid or solution when the
thermodynamic phase region of the solid-state is entered?” [129]. This question remains
largely unanswered to date. Understanding the polymorphic behaviour of pharmaceutical
APIs is of paramount importance, as different polymorphs display different
physicochemical properties (e.g. melting point, morphology) which can affect physical and
chemical stability and bioavailability (table 1.1) [48,126,130].
Table 1.1: Properties which can differ between polymorphic forms [48]
Thermodynamic Kinetic Packing Surface Mechanical
Melting temperature Dissolution rate Density Surface free energy Hardness
Enthalpy, entropy, heat capacity Solid state reaction rates Conductivity Interfacial tensions Tensile strength
Free energy Physical/chemical stability Morphology Habit Compactability
Rate of nucleation Colour Flow properties
The literature is littered with examples of polymorphic issues, ranging from the photographic
industry, to food additives, and the pharmaceutical industry [129]. Whether an API exists
in different polymorphic or solvated crystal forms is still a huge part of pharmaceutical
research [77]. It is fundamentally important to determine knowledge of this information
about the compound, as the different thermodynamic properties of these forms can have a
massive effect further along the manufacturing process on the properties of the drug during
storage and handling [16]. It is well known that polymorphism can affect the final quality of
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a drug product and is recognised by regulatory authorities as an issue [131]. The European
Medicines Agency ICH Q6A test specifications of new drug substances and products contains
guidelines of how to identify, monitor and control polymorphic forms of new drugs products,
including both solvation and hydration products as pseudopolymorphs [33]. These properties
must be identified in early stage drug development, to prevent major problems later in the
drug development process and once the drug is available as a treatment.
One well documented pharmaceutical example of the outcomes of lack of understanding of
polymorphism during the development process is that of ritonavir, an antiretroviral
medication first marketed by Abbott Laboratories [132]. It was originally available on the
market in 1996 as an oral semi-solid capsule, with ritonavir in ethanol/water based
solutions. Guidelines state that when a drug is formulated in the solution state, polymorph
control has little scientific rationale. Only one polymorphic form (form I) was identified
during development [132]. However, in 1998, reduced oral bioavailability of the marketed
dosage form was highlighted and was found to be due to a polymorphic transformation to
the lower energy, more stable polymorph form II [133]. This seriously threatened supply of
an extremely important, lifesaving treatment. The oral capsule was completely removed
from the market and re-formulated as form II in a refrigerated gelcap, to prevent the
polymorphic transition to form I occurring [132]. Later, three more forms including two
solvates and one unsolvated form were discovered by high-throughput screening [133].
Polymorphic transitions occur to increase the system stability, through changes to free
energy. Polymorphic relationships are commonly described by energy-temperature (E-T)
phase diagrams. Thermodynamically, polymorphic transitions can be categorised as
monotropic or enantiotropic. In monotropic systems, an irreversible transformation
between polymorphs occurs to produce the more stable polymorph at a particular
temperature. In an enantiotropic system, a reversible phase transition can occur between
polymorphs, which is dependent on temperature [129]. In general, the ’rules’ of
polymorphism are based upon Frankheim’s princlples [48, 129, 134], which ultimately
conclude that polymorphic transitions are dependent on relative polymorphic stability:
• The most stable polymorph has the lowest free energy
• The transition between forms (A and B) is distinguished by a specific transition
temperature
• Under specific experimental conditions, only one polymorph can have the highest
stability: known as the thermodynamically stable form
• Additional polymorphs are referred to as metastable forms. Metastable polymorphs
can lower their free energy in order to convert to the more stable form
• An increase in temperature ultimately leads to the formation of the more stable form,
as described by Ostwald’s rule of steps [135]
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APIs can be at risk of polymorphic transitions throughout pharmaceutical processing
procedures, for example during wet granulation, which is commonly used to formulate oral
dosage forms [136]. Polymorphic transitions can occur through dissolving in solvents,
through changes in temperature during manufacture and drying, or changes in mechanical
stress, e.g. during milling [137]. Polymorphic relationships are therefore important to
understand for new pharmaceutical solids, firstly to identify the best candidate to take
forward into development; and secondly to fully predict the behaviour of the API
throughout formulations development and manufacturing [48].
.
1.5 Monitoring the physical stability of amorphous solid
dispersions
In the pharmaceutical industry, API and formulation stability is monitored through the use
of accelerated stability studies, as part of quality and performance monitoring during drug
development, clinical trials and beyond into the life-cycle of the drug [19]. Throughout the
stability study, the formulation is monitored for changes in physical stability under a range
of conditions, including increased temperature and humidity. Ultimately, stability studies
are used to predict the shelf-life, and necessary storage conditions of the formulation. The
important regulatory guidelines for APIs and formulations are outlined in figure 1.5.
Figure 1.5: Regulatory (ICH) guidelines, adapted from [19]
A recent review of physical stability of pharmaceutical formulations by Guo et al. [19]
highlighted that changes in physical stability, as compared to chemical stability of APIs,
and oral formulations are more difficult to quantify, with extrapolations from accelerated
stability conditions often found to be unreliable in relation to ambient conditions. FDA
recalls throughout 2011 to 2013 were mostly related to oral formulations [19]. Therefore, it
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is of great importance to understand the physical/chemical mechanisms which result in
physical instability of such systems.
1.6 Characterisation of amorphous solid dispersions
A wide range of techniques are available for the characterisation of amorphous materials,
including differential scanning calorimetry (DSC) [102, 138], powder X-ray diffraction
(PXRD) [139], microscopic (scanning electron microscopy (SEM), optical microscopy) and
spectroscopic techniques; including Raman [140], FT-infrared (IR) [71] and solid-state
nuclear magnetic resonance (NMR) [17, 88]. These techniques are often combined to
provide a more complete understanding of the physical properties of an amorphous system,
including thermal behaviour, physical stability, drug/polymer interactions crystallisation
behaviour and miscibility information [62,107].
1.6.1 Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) is an established thermal analysis technique for the
estimation of stability of amorphous materials through the measurement of Tg and detection
of thermal events relating to crystallisation and melting [29]. DSC is also commonly used to
detect miscibility of individual components within amorphous solid dispersions, where the
observation of a single Tg indicates miscibility with a domain size detection limit of ca. 20
- 30 nm [17, 88]. Comparing experimental Tg values of solid dispersions with theoretical
predictions based on the Gordon-Taylor equation [112] additionally provides information
regarding the miscibility and interactions between drug and polymer components within the
system [62].
Many previous studies have focused on DSC to characterise amorphous solid dispersions,
mainly to confirm the formation and stability of an amorphous material through
observation of Tg [74] and to detect the miscibility of drug and polymer within the
dispersion [69, 84, 141]. Molecular mobility has also been investigated with DSC, for
example: Van den Mooter et al. [80] used modulated temperature DSC (mDSC) to
investigate the molecular mobility of pure amorphous ketoconazole below Tg; and Zhou et
al. [125] who used a similar method for ritonavir and nifedipine by analysing
thermodynamic quantities and molecular relaxation time constants. DSC can also provide
thermodynamic information including enthalpy, entropy and free energy of crystallisation
measurements, demonstrated using felodipine and nifedipine by Marsac et al. [102].
Additionally, DSC studies are very commonly employed during initial characterisation of
amorphous solid dispersions. A comprehensive review by Baird and Taylor [138] outlined
the major uses of DSC for analysis of amorphous solid dispersions, and should be referred
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to for further information. Van den Mooter et al. [80] investigated the miscibility of
ketoconazole/PVP dispersions, and found that PVP prevented crystallisation by forming a
compatible blend highlighted by a single Tg value, which gradually increased with
increasing polymer content. Drug/polymer interactions were also detected in a number of
dispersions, including ketoprofen with poly(lactic-co-glycolic acid) (PLGA) where the
polymer acted as a plasticizer, forming hydrogen bonds between carboxylic acid and
carbonyl groups along the polymer backbone [142]. Aso et al. [143] additionally used DSC
to estimate the stability of solid dispersions (nifedipine and phenobarbital with PVP) by
probing molecular mobility at various temperatures, finding that molecular mobility of the
amorphous drug was reduced in the presence of PVP. Song et al. [62] recently demonstrated
a strong intermolecular ionic interaction between lapatinib and HPMC-P amorphous solid
dispersions through deviation of experimental and predicted Tg values of up to 40 K.
In summary, DSC methods are useful characterisation techniques as they can provide
important information regarding the bulk properties of amorphous systems, but are lacking
in their ability to provide the detailed structural, dynamic and molecular level information
required for full understanding of amorphous solid dispersions [88].
1.6.2 Powder X-Ray Diffraction (PXRD)
Powder X-ray diffraction is mainly used for the detailed study of crystalline materials, but
can be useful when studying amorphous solid dispersions to confirm the amorphous nature
(or absence of crystalline material) through the presence of a broad halo pattern [88,129,144].
However, it is difficult to extract further information from the often featureless pattern [17].
PXRD is a useful technique to track the crystallisation of amorphous drugs, particularly in
larger scale stability studies [139], however it is not always suitable due to the lower detection
limit as compared to other techniques [145]. PXRD can also be used to investigate the
polymorphic behaviour following crystallisation of amorphous materials, particularly in high
drug loaded dispersions. More recently, PXRD methods have been extended for amorphous
solid dispersions to investigations with pair-distribution functions (PDF-PXRD), which are
able to provide some additional structural information [139,144].
1.6.3 Vibrational spectroscopy
In the field of pharmaceutical solids, vibrational spectroscopy is more commonly applied to
investigate crystalline APIs, with the most commonly used techniques being infrared (IR)
and Raman spectroscopy [146]. For amorphous solid dispersions, IR spectroscopy can
provide detailed information regarding drug-polymer specific interactions, for example
hydrogen bonding, which are thought to be important as a stabilisation mechanism of these
systems [146].
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The Zografi group [71, 84] found that Indomethacin and PVP interact in solid dispersions
through drug-polymer hydrogen bonding, using IR and Raman spectroscopy. Other studies
have employed similar techniques to detect hydrogen bonding in dispersions of
nifedipine/PVP, ketoprofen/PVP and droperidol/PVP [146]. Additionally confocal Raman
microscopy has been widely employed to study amorphous solid dispersions, for example in
assessing homogeneity of diflusinal/PVP [147] and ebselen/PVP-VA systems [148]. These
techniques are extremely useful in providing qualitative information on intermolecular
interactions, but do not allow the acquisition of direct information regarding proximity and
molecular conformations in more complicated multicomponent systems. [17].
1.6.4 Dielectric Relaxation Spectroscopy (DRS)
Dielectric relaxation spectroscopy (DRS) has been used in a number of studies to study
molecular mobility around Tg [17], including with amorphous aspirin, ibuprofen, quinidine
[149] and indomethacin [150] systems. The molecular mobility probed using this technique
is often in the MHz - GHz range [146], and therefore motions on a different timescale to
those measured through solid-state NMR spectroscopy. However, DRS has not been widely
employed for the study of amorphous solid dispersions [146].
1.6.5 Solid-state Nuclear Magnetic Resonance (NMR)
The following discussion provides a brief overview of the range of solid-state NMR methods
which have been employed for the characterisation of amorphous pharmaceuticals. For
more detailed information, a number of excellent literature examples of recent
developments in solid-state NMR techniques, especially regarding the characterisation of
amorphous solid dispersions should be referred to: Paudel et al. [17] ’Structural and
Dynamic Properties of Amorphous Solid Dispersions: The Role of Solid-State Nuclear
Magnetic Resonance Spectroscopy and Relaxometry’ ; Vogt [146] ’Solid-State
Characterisation of Amorphous Dispersions’ ; Pham et al. [88] ’Analysis of Amorphous
Solid Dispersions Using 2D Solid-State NMR and 1H T1 Relaxation Measurements’ and
Geppi et al. [151] ’Solid-State NMR studies of Pharmaceutical Systems.’
Throughout pharmaceutical development of a particular dosage form, solid-state
characterisation is essential to understand as much as possible about the individual
components, and about how they interact once fully formulated. Solid-state NMR can
provide detailed molecular level structural information of multicomponent pharmaceutical
formulations, encompassing amorphous, polymorphs, hydrates, co-crystals and
solvates [17, 88]. Additional information about multicomponent systems can also be
obtained including molecular dynamics, domain morphology and miscibility [152],
drug-polymer inter and intra-molecular interactions, crystallisation and
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polymorphism [17, 130, 153], and local dynamics via relaxation studies [41]. Variable
temperature solid-state NMR is a valuable tool for prediction of the physical stability of
drugs in formulations [101]. Graeser et al. [100] found that DSC was a limited technique to
predict stability of amorphous systems below Tg, but that solid state NMR could provide a
direct measure of global and local mobility, but has had limited exploitation in the field of
amorphous pharmaceutical systems [100].
Koga et al. [154] investigated molecular mobility above and below Tg of a stable amorphous
CCK2 receptor antagonist (AG-041R) using variable temperature 1H-13C CP/MAS NMR
kinetics, finding that smaller functional groups (methyl) were mobile at lower temperatures,
but carbonyls were restricted by interactions and therefore had low molecular mobility below
Tg; and
2H-NMR was used to investigate the molecular reorientations around the Tg of
supercooled and glassy aspirin [155]. 1H-13C CP/MAS NMR methods have been used to
investigate interactions of drug and polymer and dispersion homogeneity between ketoprofen
and PVP [156]; and the prediction of recrystallisation behaviour of troglitazone in a solid
dispersion with PVP [145]; 1H-13C CP/MAS NMR and 13C{1H} MAS NMR have been
used to investigate the local dynamic behaviour of ibuprofen/Eudragit dispersions [157],
ketoprofen/PEO dispersions [30] and IMC/cyclodextrin systems [158]. Schantz et al. (2008)
[159] used VT 1H-13C CP/MAS NMR and T1ρ
H times to investigate molecular mobility and
interactions in blends of paracetamol and citric acid, to help understand physical instability
in such systems.
Solid-state NMR relaxation studies, mainly involving the detection of T1
H and T1ρ
H/C
have been employed to investigate the molecular mobility and intermolecular interactions of
solid dispersions, including for nifedipine and phenobarbital/PVP dispersions [160], where
changes in local mobility were linked with stability of amorphous dispersions; and nifedipine
in amorphous solid dispersions with PVP and HPMC where analysis was successfully used
to determine domain size and therefore polymer-drug miscibility [152]. Aso et al. [161]
used kinetic studies to look at the relationship between crystallization rate and molecular
mobility measured with 1H T1, T1ρ and T2 relaxation times of a number of amorphous drugs.
Additionally, VT studies (1H MAS alongside 13C T1 times) to monitor phase transition and
molecular mobility of a blend of ketoprofen/POLYOX highlighted the changes in mobility
detected in the blend as compared to the pure amorphous drug [162]; and multivariate
analysis of solid-state 13C MAS NMR has additionally been used to investigate differences in
the physical stability of troglitazone/PVP dispersions prepared via different methods [145].
Tobyn et al. [78] pooled information from modulated DSC, FT-IR, Raman and solid state
NMR (1H MAS NMR and variable contact time (VCT) CP/MAS NMR kinetics) to study
an investigative drug compound formulated with PVP which confirmed the presence of
stabilising hydrogen bonding interactions between the drug and polymer, and found that
similar interactions were present in the both the crystalline and amorphous forms as
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intermolecular bonds. Pham et al. [88] carried out an excellent study focusing on
determining detailed structural information using a large number of amorphous
drug/polymer dispersions, prepared using different methods, using 2D solid-state NMR
approaches. They particularly focused on 1H-1H, 1H-13C and 1H-19F HETeronuclear
CORrelation (HETCOR) NMR to identify the presence of intimately mixed solid solutions.
Molecular mobility was not reported in the extensive study, although this was highlighted
as another important area for which solid-state NMR can be extremely useful, as mobility
is often correlated with physical stability of amorphous solid dispersions [88].
Additionally, the detection of miscibility and phase separation of solid dispersions is a vital
part of formulation development, as successful formulation of miscible drug/polymer
amorphous dispersions is crucial for maintaining acceptable physical stability during
manufacture and storage of pharmaceuticals [62, 108]. The miscibility of solid dispersions
has traditionally been studied using differential scanning calorimetry (DSC), where a single
Tg value (intermediate between the Tgs of the individual components) is thought to
indicate molecular level homogeneity [78, 106, 108, 163], with a detection limit of 20-30
nm [46, 164–166]. However, the detection of miscibility using DSC has been shown to be
unreliable [144]. The use of NMR spin-lattice relaxation times (T1ρ
H and T1
H) in the
solid-state has proven to be extremely useful in providing additional information about the
miscibility and phase separation of solid dispersions, with differences in T1ρ
H times
allowing estimation of much smaller domains than with DSC; with a demonstrated
detection down to ca. 2 nm in size [46,62,88].
Differences in the physical stability and behaviour of amorphous systems are often related to
very subtle changes in the local structure and mobility [17]. Solid state NMR is a versatile and
non-destructive technique which can probe on a local molecular level, providing information
about the molecular environments, dynamics, correlations and mobility to provide molecular
level information on the structure and dynamics of solid dispersions [100]. The available
literature provides evidence that it could be an extremely powerful tool to understand and
predict the physical stability of polymer-stabilised amorphous systems, but is an area that
needs utilising further [101]. Solid-state NMR is an invaluable technique and should be
employed in combination with other well established solid-state characterization methods
such as DSC and PXRD, in other to maximise the understanding of the structure and
physical stability of solid amorphous dispersions [101].
1.7 Selection of model amorphous drug compounds
A systematic literature review was carried out, with the aim of choosing three model
amorphous drugs with a range of different stabilities; and one polymer which would be
compatible for the formulation of amorphous solid dispersions. The choice of model
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compounds was based upon rationale used in previous large scale studies of amorphous
solid dispersions (see table 1.2). Pham et al. [88] analysed a number of amorphous solid
dispersions using 2D solid-state NMR and 1H T1 relaxation measurements. Bhugra et
al. [167] analysed a number of pure amorphous drugs using DSC and dielectric relaxation
spectroscopy to probe molecular mobility below Tg.
Table 1.2: Summary of rationale of drug choice in two large scale studies
Rationale from Pham et al. (2010) [88] Rationale from Bhugra et al. [167]
Paracetamol Simple molecule, extensively studied Nifedipine H-bonding comparison (stronger in crystalline state)
Diflusinal Fluorinated drug allowed for 19F NMR analysis Felodipine H-bonding comparison (stronger in amorphous state)
IMC Small molecule but with greater structural complexity IMC Wealth of information available
Telithromycin High molecular weight, not yet studied Ketoconazole High heat of fusion
Voriconazole Large complex molecule, not yet studied Flopropione High heat capacity change at Tg
Using a similar rationale, model amorphous compounds were chosen by highlighting desirable
properties and parameters to study, gradually ruling out unsuitable compounds. The drugs
were ranked according to the number of desirable properties including: Tg and Tm values;
amount of information available in the literature; the presence of alternative magnetic nuclei
present; range of functional groups; separation of chemical shifts between drug and chosen
polymer in 13C NMR spectra; range of molecular weight, and complexity of structures.
Indomethacin (IMC) was chosen as the starting point for the investigation of drug-polymer
systems, alongside flufenamic acid (FFA) and tolbutamide (TLB) as the remaining model
amorphous materials. All three were formulated as amorphous solid dispersions with PVP-
VA, which was the chosen polymer.
1.7.1 Indomethacin (IMC)
IMC was chosen as the initial investigative compound as it has been widely formulated and
studied both as amorphous drug and as an amorphous dispersion [29, 71, 77, 84]. There is a
wealth of information available in the literature, with studies being carried out using a
variety of techniques including solid-state NMR, PXRD, DSC, FT-IR, Raman and
dielectric relaxation spectroscopy. The first reporting of the success of using a solid
dispersion to stabilise amorphous IMC was reported by Imaizumi et al. in 1983 [168], where
the IMC solid dispersion was found to remain amorphous for 6 months of storage at 313 K.
Many studies have since found that the physical stability of IMC at room temperature is
greatly improved when formulated as an amorphous dispersion with a polymer, due to the
formation of hydrogen bonds between the drug and polymer [77, 84, 91], despite the high
level of molecular mobility of amorphous IMC observed below its Tg value [150]. IMC is a
small molecule non-steroidal anti-inflammatory pain killer which is poorly soluble in water
leading to a limited oral bioavailability, and exhibits predictable polymorphism [29,77,130].
Two polymorphic forms with known structures [31, 130] are widely recognised as α and
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γ [169]. Form γ is stable under ambient conditions, with a melting point of 433 - 434 K [29]
and form α is metastable with a melting point of 425 - 427 K [31].
1.7.2 Flufenamic Acid (FFA)
FFA is another non-steroidal anti-inflammatory drug and is part of the fenamates drug
class, used to treat rheumatoid and osteoarthritis. It was chosen as part of this study as
it has a simple structure which contains a CF3 group, which can be utilised through
19F
MAS NMR. 19F is an ideal magnetic nucleus to study as it has 100 % natural abundance
and a high gyromagnetic ratio and can be utilised to assess drug molecular mobility as
almost all pharmaceutical excipients do not contain fluorine but many drug products do [41].
FFA is reported to have extremely poor solubility (0.0067 mg/ml at 298 K in water [170]),
alongside the rest of the fenamate compounds. Compared with IMC, there are few literature
studies where FFA has been formulated as an amorphous dispersion and studied via solid-
state NMR. Additionally, FFA exhibits rich polymorphism and has nine known polymorphic
forms, eight of which have solved crystal structures [39]. Lopez-Meijas et al. recently solved
the structures six of these polymorphs, meaning FFA has a record number of structurally
characterized polymorphs in the Cambridge Structural Database (CSD) [39]. Amorphous
FFA is thought to have a lower stability than IMC. No amorphous material has been formed
under common conditions [131], so no value for the Tg of the pure amorphous material is
known in the literature. However, 80/20 drug/polymer dispersions with PVP and HPMC
have been studied and the Tg temperatures were calculated as 296 and 288 K respectively
[41].
1.7.3 Tolbutamide (TLB)
Tolbutamide (TBM) is a potassium channel blocker for the management of type II diabetes.
It is poorly water-soluble (0.11 mg/ml at 298 K in water for form I [170]) and has a low
bioavailability [171]. The reported Tg for TLB is 278 K, therefore TLB has low physical
stability at ambient temperatures [100], as compared to IMC and FFA. Graeser et al. [100]
demonstrated that amorphous TBM was stable at 258 K after 30 days storage, but unstable
at ambient temperatures. TLB is a very flexible molecule, with seven rotatable bonds, leading
to different arrangements of the butyl chain, and therefore interesting polymorphism. TLB
has six reported polymorphic forms (forms IL, IH , II-V) [42–44,172–174], with its ability to
crystallize into different forms due to the flexibility of the rotatable alkyl bonds [42]. Form
IH has the highest melting point, and is the most stable form at high temperatures. TLB
has been studied as a solid dispersion with PVP [175] and PEG-4000 [176], but such studies
focused on techniques such as DSC, PXRD and molecular dynamics, with solid-state NMR
very rarely employed as a technique for characterisation of TLB in the amorphous form.
Solid-state NMR is an ideal technique to investigate the local mobility of this molecule: how
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local mobility changes upon formulation as an amorphous solid dispersion with polymer will
provide an interesting study perspective.
1.7.4 Choice of polymer
Polymers are able to stabilise amorphous pharmaceuticals through an anti-plasticizing effect,
ideally raising the Tg value of the amorphous form sufficiently to prevent crystallisation across
the temperature range experienced by the formulation during manufacturing and storage
[177, 178]. Interactions between the drug and polymer and reduction of molecular mobility
of the amorphous form can improve physical stability and product shelf life by preventing
crystallisation [179]. It is therefore important to understand how well the various components
mix, and the types of interactions present within the system [179]. Polyvinylpyrollidone-vinyl
acetate (PVP-VA) was chosen as the polymer to carry forward in the study as studies have
been carried out but it is not overly published in the literature. It has previously been
studied in a solid dispersion with IMC (prepared via solvent evaporation) which used DSC
and FT-IR to look at drug polymer interactions in relation to crystallisation [84] and Sun et
al. [85] found that IMC is actually soluble in this polymer. Zhao et al. [180] also predicted
the miscibility of IMC and PVP-VA using the Flory-Huggins theory and found that PVP-VA
did inhibit the crystallisation of IMC, especially at higher polymer loading levels.
1.8 Aims of the Project
The overall aim of this project was to characterise the local structure and dynamics of three
amorphous solid dispersions (IMC, FFA and TLB; with PVP-VA), and correlate this with
outcomes of physical stability. We focused on exploiting the huge potential of solid-state
NMR as a tool to probe the local molecular environment of such dispersions, aiming to unify
the knowledge gained with other commonly used characterisation techniques.
In order to achieve this goal, we aimed to develop solid-state NMR methodologies to
understand important factors contributing to the successful formulation of solid
dispersions, in terms of being fully amorphous, fully miscible and physically stable
upon storage; and relate them to local structure and dynamics. We focused on using
variable temperature solid-state NMR techniques, as literature investigations are limited in
this area; to enhance understanding of molecular motions on different timescales, aiming to
identify key parameters, methodology and information to aid the prediction of physical
stability. To ultimately use NMR to enable the prediction of crystallisation outcomes from
standard stability studies could pave the way to enable the quicker identification of
potential storage issues, since molecular mobility of amorphous dispersions is a key factor
affecting their physical stability.
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Characterisation of amorphous dispersions using a ’one technique’ approach is limiting:
drug/polymer systems can be very complex, and therefore require a multicomponent
characterisation approach to provide information from a number of different perspectives.
Characterisation was performed on a bulk level using more traditional techniques (DSC
and PXRD), with local molecular level information provided via solid-state NMR and
monitored throughout a 12 week accelerated stability study. We concurrently characterised
the dispersions with a number of variable temperature solid-state NMR techniques, which
provided a sensitive probe of changes in local mobility. By correlating the traditional and
variable temperature characterisation across a range of systems we therefore aimed to
obtain a clearer understanding of the mobility and stability behaviour within these
systems.
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Chapter 2
Characterisation
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This chapter summarises the principles and theory behind the various techniques used to
characterise the three model drug systems of IMC, FFA and TLB; both as amorphous
materials, crystalline polymorphs and amorphous solid dispersions of varying drug loading
levels. The techniques described are common across all results chapters. The experimental
conditions used for each technique are discussed in chapter 3.
2.1 Nuclear Magnetic Resonance (NMR) spectroscopy
2.1.1 Basic NMR principles [1–4]
Nuclear Magnetic Resonance (NMR) spectroscopy relies upon interactions between a nucleus
exhibiting a magnetic moment (−→µ ), and an external magnetic field (−→B ), and is a powerful
analytic technique providing detailed information about chemical structure and dynamics.
Magnetic moment occurs in nuclei which possess the intrinsic property angular momentum,
often referred to as nuclear spin. Nuclei can be thought of small bar magnets, as any charged
body in motion is associated with a magnetic field. The magnetic moment of a nucleus
(equation 2.1) is directly proportional to the spin quantum number (I ) and gyromagnetic
ratio (γ), which is a constant dependent on nucleus type.
−→µ = γh¯I (2.1)
where h¯ is Plank’s constant divided by 2pi. To be magnetically active, a nucleus must have
a spin quantum number (I ) 6= 0, (e.g. I = 12 , 1, 32 , 2, 52 ...).
Angular momentum is a vector quantity, and is related to spin quantum number through
equation 2.2:
−→
I 2 = (I(I + 1)h¯2) (2.2)
Without the presence of an external magnetic field (B0), magnetic moments are orientated
randomly, with all orientations (2I + 1) having the same energy. Upon application of an
external magnetic field, magnetic moments will align at an angle either with (’spin-up’) or
against (’spin-down’) B0. The two spin states are separated by ∆E, as outlined in figure
2.1 (termed the Zeeman effect), which depends on the strength of the interaction between
the nucleus, and the magnetic field.
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Figure 2.1: Relative energy levels of spin 1
2
nucleus, showing the two magnetic spin states (m = magnetic
quantum number) with increasing B0, adapted from [1,5]
In the presence of an external magnetic field, the magnetic moment rotates about B0, at an
angular velocity, known as the Larmor frequency:
ω0 = −γB0 (2.3)
Electromagnetic radiation (radiofrequency (rf ) pulses), oscillating at a specific frequency,
are applied in NMR to measure the energy difference of the Zeeman effect. This frequency,
applied close to the Larmor frequency of the nucleus of interest is therefore dependent on
both the observation nucleus and external magnetic field. At a particular magnetic field
strength, the Larmor frequency occurs in the radiofrequency region of the electromagnetic
spectrum. For example, for a 1H nucleus in a 9.4 T external magnetic field, ∆E between the
two spin states is measured to be 400 MHz, which is the Larmor frequency of protons at this
B0.
2.1.2 Bulk Magnetisation [1, 4]
We have so far discussed the interactions of a single spin, with the external magnetic field.
Analysis of actual sample with NMR spectroscopy involves a much larger number of spins,
which of course must be taken into consideration. If multiple nuclear spins are placed into
an external magnetic field (B0), thermal equilibrium will be established through equation
2.4, the Boltzmann distribution.
n(+12)
n(−12)
= exp(
∆E
kT
) (2.4)
where n represents the population of the spin states, k is Boltzmann’s constant, T is absolute
temperature.
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For example, using equation 2.4 to calculate the population of spin states in an external
magnetic field of 9.4 T, an extremely small excess of ca. 50 α spins in every million spins,
as compared to β spins exists. This excess of α spins leads to a net magnetization in parallel
alignment along the z axis, termed the bulk magnetisation (M0). M0 is represented in figure
2.2, which outlines the ’vector model’ analogy.
Figure 2.2: Vector model of bulk magnetisation (collection of spin- 1
2
nuclei), where the Boltzmann
distribution leads to bulk magnetisation (M0) parallel to M0, adapted from [20,21]
As previously outlined, applying an rf pulse (via a coil) at the Larmor frequency leads to
spin excitation. The magnetic field of the applied rf field is termed B1. For the bulk
magnetisation, the individual magnetisation vectors are still precessing at the Larmor
frequency (around the applied field). To aid understanding, the rotating frame of reference
is used as a simplified descriptive model for pulsed NMR experiments.
Figure 2.3: Representations of the laboratory and rotating frames of reference, adapted from [20,21]
In the laboratory frame, the x, y and z axes are viewed as being static; whereas in the
rotating frame, the whole frame rotates at the rf frequency (ν0), with B1 and M0 stationary,
and perpendicular to each other. The rotating frame model therefore removes the time
dependency.
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2.1.3 Chemical Shift [1–5]
As previously discussed, the resonant frequency of a nucleus is dependent upon both the
gyromagnetic ratio, and the strength of B0. To obtain one single frequency signal for each
particular magnetically active nucleus would not be particularly useful. In reality, the NMR
frequency is sensitive to the environment of a nucleus in a molecule, which arises through
differences in the electron distribution.
This effect occurs because the external magnetic field influences the chemical environment,
causing surrounding electrons to circulate in their atomic orbitals, resulting in small local
magnetic fields (B). I.e. the local field experienced by the nucleus is actually different to
the external magnetic field. The induced motion can be compared to a wire with a current
passing though, which generates a small (local) magnetic field, in the opposite direction
to B0, and shields the nucleus from its surrounding electrons and external magnetic field.
The effect of the local magnetic field gives rise to differences in the frequencies detected,
dependent on chemical environment, hence NMR is particularly useful in the characterisation
and identification of molecules.
The local field (B) is slightly smaller than the the external magnetic field (B0), and is
calculated using equation 2.5:
B = B0 −B′ = B0(1− σ) (2.5)
where σ is the shielding constant. In molecules, as compared to a single atom, the electron
distribution becomes much more complex. The electron distribution depends upon
neighbouring atoms, and can be affected by a number of different factors including
hydrogen bonding, electronegativity and unpaired electrons. The effects of shielding
changes the resonance frequency of the nucleus, resulting in a chemical shift value (δ).
Experimentally, chemical shift is measured in ppm, showing the difference in resonance
frequency between the particular nucleus (ν) and a reference nucleus (νref ), commonly
tetramethylsilane (TMS).
δ = 106(
ν − νref
νref
) (2.6)
2.1.4 Solid-state NMR [4,6, 7]
Solids and liquids show completely different behaviour in terms of their nuclear spin
interactions. In solution-state NMR, fast molecular motions average out the majority of
the nuclear spin interactions, resulting in narrow, isotropic chemical shifts. In solids
however, atoms and molecules are more likely to be rigid, therefore do not experience
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random tumbling. The reduction in molecular mobility leads to additional anisotropic
(orientation dependent) nuclear spin interactions, resulting in broadening of linewidths.
Nuclei in a magnetic field experience many different types of interactions, and can be
described using Hamiltonian operators (Hˆ). Hˆ represents the energy in the system, and
generally provide a quantum mechanical description of the interactions between a nuclear
spin and a local magnetic field.
Hˆ =
−→
I ·A · −→B (2.7)
where A represents the orientation dependence of the interaction (with respect to the x,y,z
axes) and
−→
B is the magnetic field. The spin Hamiltonian (equation 2.8) provides a
quantum mechanical description of all possible interactions between nuclear spins, with
each interaction contributing to the properties of linewidths in NMR.
HˆTOTAL = Hˆz = HˆCSA + HˆD + HˆQ + HˆJ (2.8)
where:
• Hˆz = Zeeman Hamiltonian
• HˆCSA = Chemical Shift Anisotropy Hamiltonian
• HˆD = Dipolar coupling Hamiltonian
• HˆQ = Quadrupolar coupling Hamiltonian
• HˆJ = J-coupling Hamiltonian
For an isotropic liquid, the orientation dependent interactions (HˆCSA, HˆD and HˆQ) are
averaged out through fast molecular motions. However these interactions result in
significant broadening of solid-state NMR linewidths. In order to overcome these
orientation dependent factors, and therefore achieve higher resolution solid-state NMR
spectra, a number of methodologies must be applied. In solids, the HˆJ becomes negligible,
as J-coupling interactions in the solid-state are so small. Additionally, the quadrupolar
coupling Hamiltonian (HˆQ) is only relevant for nuclei with I >
1
2 , which were not observed
in this research. The Zeeman interaction is the strongest, and therefore most important
interaction in NMR. However, this interaction in the solid-state is very similar to the
liquid-state. Therefore, a detailed description of the only the important anisotropic nuclear
spin interactions, (HˆCSA and HˆD) and the methods employed to overcome the resulting
spectral broadening are discussed below.
A summary of the interactions, and relative magnitudes in both the solid and liquid state
can be seen in figure 2.4.
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Figure 2.4: Summary of the organisation of the spin Hamiltonian interactions, with relative magnitudes
represented by circle area, adapted from [7]
2.1.4.1 Chemical Shift Anisotropy (HˆCSA) [4, 6, 7]
Chemical shift describes the change in frequency of a nucleus, arising from the effect of
induced motions of electrons by the external magnetic field (B0) on the local magnetic field
(B). Chemical Shift Anisotropy (CSA) originates from the orientation dependence effect of
a molecule, with respect to external magnetic field (B0). This is due to electron distribution
around a nucleus often being non-spherical, assumed to be an elongated ellipsoid stretched
along bonds. In the liquid-state, anisotropy is averaged out to zero by fast molecular motions,
therefore a single isotropic value of chemical shift is observed for each nuclear environment.
In the solid-state however, the molecule can adopt a range of different orientations (with
respect to B0). The shielding interaction experienced by each orientation is therefore slightly
different as well, resulting in small variations of chemical shift, and therefore and therefore
a much broader peak (figure 2.5).
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Figure 2.5: Orientation dependence of chemical shift of a solid, with respect to the external magnetic
field, adapted from [5,6]
To further understand CSA, the chemical shift Hamiltonian must be analysed (equation 2.9):
HˆCSA = γB0Iz[δiso +
1
2
δCSA(3cos
2θ)− 1)] (2.9)
where θ = angle of the molecular orientation (with respect to external magnetic field). δiso
(equation 2.10) and δCSA (equation 2.11) describe the isotropic chemical shift, and the
magnitude of the CSA respectively.
δiso = (δ11 + δ22 + δ33)/3 (2.10)
δCSA = δiso − δ33 (2.11)
where δ11 is the least shielded (has the largest influence on the chemical shift), and δ33 is
the most shielded (has the smallest influence on the chemical shift) component. In reality in
solids, there are many more possible orientations than the three principle values described
in equation 2.10, which leads to the presence of a broadened powder pattern, as outlined in
figure 2.6.
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Figure 2.6: Powder pattern of a molecule with axial symmetry, adapted from [4]
The anisotropic component of HˆCSA contains a geometric term (3 cos
2θ - 1) which can be
eliminated through Magic Angle Spinning (MAS), described alongside other techniques for
eliminating the effect of CSA in section 2.1.4.3.
2.1.4.2 Dipolar Coupling (HˆD) [3, 4, 7]
Dipolar coupling (often termed dipole-dipole couplings) occurs due to interactions of nuclear
spins with each other. This can occur through interactions between like (homonuclear, I-I)
spins; or unlike (heteronuclear, I-S) nuclei. Dipolar coupling is a through-space interaction,
which leads to significant line broadening in solids. Methods employed in solid-state NMR
to help to reduce broadening though dipolar coupling are outlined in section 2.1.4.3.
2.1.4.2.1 Homonuclear dipolar coupling Homonuclear dipolar coupling arises from
the interaction between two like-spins (for example 1H and 1H), when close enough in space.
The homonuclear dipolar Hamiltonian is described by equation 2.12:
HˆDD = (
µ0
4pi
1
2
γiγj h¯
r3ij
)2Iˆiz Iˆjz − 1
2
[Iˆ1+Iˆ2− + Iˆ1−Iˆ2+](3cos2θij − 1) (2.12)
where Ii and Ij are like-spins, rij is the distance between the two nuclei, µ0 is the permability
of free space, γ is the gyromagnetic ratio of each spin (j and k).
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The dipolar coupling Hamiltonian is extremely complex, and beyond the scope necessary
here. However, to relate the Hamiltonian equation to common nuclei, such as 1H and 13C,
we can split the equation into three main terms. This helps to understand the effect of
dipolar coupling on the resulting NMR spectra (figure 2.7)
Figure 2.7: Demonstration of the three important terms of the dipolar coupling Hamiltonian
From this, it becomes clearer that:
1. Dipolar coupling constant is dependent on gyromagnetic ratio and distance between
spins.
2. Spin term represents the energy conserving ’flip-flop’ transition between two like spins,
commonly referred to as spin diffusion. This term is dependent on the abundance of
the spin.
3. Geometric term describes the orientation dependent broadening effect, and was
previously seen in the HˆCSA. Reduction of the broadening effect will be discussed in
section 2.1.4.3.
The resonance frequency of the two-like spins is similar, therefore they are able to undergo
’flip-flop’ transitions, described by the spin term of the homonuclear dipolar Hamiltonian.
This transition is an energy conserving process where one spin flips to a higher energy
state, whilst the other spin flips to a lower energy state, through a change of spin angular
momentum (figure 2.8). The ’flip-flop’ transition is commonly referred to as spin diffusion,
and will be discussed further in chapter 4.
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Figure 2.8: Diagramatic representation of flip-flop transition between homonuclear spins, adapted from
[5,6]
Therefore, in summary, important properties of the dipolar coupling interaction include:
• Dipolar coupling constant: The magnitude of the interaction is proportional to the
gyromagnetic ratio (γ), therefore higher γ nuclei (e.g. 1H) will display much stronger
homonuclear dipolar coupling as compared to lower gamma nuclei (e.g, 13C or 29Si)
• Dipolar coupling constant: Distance between nuclei determines the strength of
dipolar coupling, (D is inversely proportional to r3), making it highly distance
dependent. Nuclei with higher abundance (e.g. 1H or 19F) are more likely to be close
in space than low abundance nuclei (e.g. 13C or 15N), and have stronger dipolar
coupling interactions
• Geometric term: The dipolar coupling Hamiltonian contains the orientation
dependence term (3cos2θ-1), which leads to broadening of the spectra, and can be
reduced through MAS
Dipolar couplings can be seen in the solid-state spectrum as a ’Pake Doublet’ (figure 2.9).
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Figure 2.9: Powder pattern (Pake doublet) of two spin 1
2
nuclei experiencing homonuclear dipolar
coupling, adapted from [6]
The two sub-spectra arise from the different spin states (α, or β), with molecular orientations
where θ is between 0 and 90 deg. The peak intensities correspond to the number of crystallites
adopting the particular orientation, hence the highest intensity peak is observed when θ is
perpendicular to B0. The splitting of the Pake-doublet is equal to D (dipolar coupling
constant). When the sample is placed at θ = 54.74, ° known in solid-state NMR as the
’magic angle’ the frequency is unaffected by dipolar couplings (see section 2.1.4.3).
2.1.4.2.2 Heteronuclear dipolar coupling Heteronuclear dipolar coupling occurs due
to the interaction between unlike spins that are close in space. Using NMR terminology, the
unlike spins are labelled I (abundant spin, e.g. 1H) and S (rare spin, e.g. 13C). In the presence
of a magnetic field, Zeeman splitting occurs for each spin, resulting in alignment of the I and
S spins either spin-up, or spin-down, with respect to B0). Each spin also experiences a local
magnetic field, which can affect the magnetic field of close proximity neighbouring spins.
The heteronuclear dipolar coupling for unlike (Iˆ,Sˆ) spins is described by the following
Hamiltonian:
HˆDD = (
µ0
8pi
1
2
γIγS h¯
r3IS
)2IˆzSˆz(3cos
2θIS − 1) (2.13)
It has a very similar form to the homonuclear Hamiltonian, but with a reduced spin term.
This is because the energy saving spin-diffusion process can not occur in unlike spins, as the
resonant frequencies are too different (figure 2.8). Again, the coupling strength is dependent
on γ, and distance between spins.
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2.1.4.3 Techniques used in solid-state NMR to improve resolution
A number of clever methodologies have been developed as the field of solid-state NMR study
has progressed, in order to compensate for the strong anisotropic interactions described above
2.8.
2.1.4.3.1 Magic Angle Spinning (MAS) [4, 6] The Hamiltonians describing
homonuclear and heteronuclear dipolar coupling and chemical shift anisotropy all contain
the same geometric component: (3 cos2 θ - 1). This orientation dependent term can be
averaged out in the solid-state, by spinning the sample at an angle of 54.74 ° with respect
to B0. The ’magic angle’ results in the anisotropy of the interaction averaging to zero,
((3cos2θ-1) = 0). This effectively removes the orientation dependence of the Hamiltonians,
giving an isotropic chemical shift in the NMR spectrum.
For MAS to effectively remove interactions, the MAS frequency needs to be at least 3 times
greater than the interaction itself. In the case on strong interactions (for example 1H-1H
dipolar interactions), this can be difficult to achieve. Removal of 1H-1H dipolar interactions
requires extremely fast spinning rates (ca. 80 kHz), which requires extremely specialist fast
MAS probes. However, 1H-13C heteronuclear dipolar interactions can be removed more
easily, with spinning rates of ca. 10 kHz sufficient to remove the spectral broadening of these
interactions.
2.1.4.3.2 Decoupling [3,4,6] For strong interactions, which are not effectively averaged
out through Magic Angle Spinning, decoupling will likely be employed to further improve
spectral resolution.
High power heteronuclear decoupling techniques use multiple high power radiofrequency (rf )
pulse sequences, at the resonant frequency of the I (abundant) spin to further average the
effects of dipolar coupling, during acquisition of the free induction decay (FID) of the S
(less abundant) spin. The rf irradiation results in the I spins rapidly switching between the
α (spin-up) and β (spin-down) states, at a rate determined by the decoupling power. To
fully average the coupling interactions to zero, the rate of transition must be greater than
the heteronuclear decoupling strength. This method, known as continuous radio-frequency
wave (CW) decoupling [181] is not commonly used, as it results in sample heating during
long acquisition times. Higher sophistication decoupling pulse sequences have since been
developed, for example Two Phase Pulse Modulation (TPPM), which employs two high
power pulses which differ in phase (between 10 and 70 °) [182]; and SPINAL-64 [183]. The
effect of molecular mobility on heteronuclear decoupling is discussed in more depth in chapter
4.
The successful application of homonuclear dipolar decoupling is much harder to achieve, due
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to the additional spin term (describing the flip-flop transitions of spin diffusion) present in
the HˆD. Homonuclear decoupling techniques are based upon multiple pulse sequences, which
contain sections where the dipolar coupling Hamiltonian has no effect on the magnetisation.
Acquisition of magnetisation during one of the sections, results in improved resolution in
the NMR spectrum. Commonly used decoupling sequences include Frequency-Switched-Lee-
Goldburg (FSLG) [184] and Decoupling Using Mind Boggling Optimisation (DUMBO) [185].
2.1.4.3.3 Cross-Polarisation [4,8,9] Cross-Polarisation (CP)/MAS NMR experiments
are commonly used to enhance signal-to-noise ratios and reduce the acquisition time of low
γ, low sensitivity nuclei, such as 13C and 15N.
The cross-polarisation pulse sequence is based upon a magnetisation transfer step, which
occurs through the tendency of magnetisation to move from highly polarised spins → less
polarised spins, when the spins are in close contact. This CP step is analogous to the
heat flow associated with thermal transfer from hot to cold objects in thermal contact.
In section 2.1.4.2.1, we discussed the energy conserving ’flip-flop’ transitions of like spins,
and highlighted that such transitions do not occur for heteronuclear spin pairs. However,
the application of rf pulses can essentially bridge the energy gap of the unlike resonance
frequencies, leading to the transfer of magnetisation between the heteronuclear spins. For this
to occur, the contact condition must adhere to the Hartmann-Hahn matching condition [186],
described in equation 2.14:
γIB
I
1 = γSB
S
1 (2.14)
where γI , BI and γS BS are the gyromagnetic ratios and rf pulses applied to the I and S
spins respectively.
To fulfil the Hartmann-Hahn condition, the simultaneous application of two continuous rf
pulses, each one at the resonance frequency of either the I or the S spin must take place.
Application of an rf pulse will result in the precession of magnetisation about the xy-plane,
with the rate of precession dependent on both the frequency, and amplitude of the applied
field. The application of the two fields, results in the precession of the I and the S spins
about a particular axis. When these rotation frame frequencies are equal, the Hartmann-
Hahn condition is said to be met, and an energy conserving dipolar contact occurs between
the I and S spin, which in turn allows the polarisation transfer between the spins.
The pulse sequence of a typical 1H-13C CP/MAS NMR experiment can be seen in figure
2.10. The pulse sequence involves a pi/2 pulse, which flips proton magnetisation into the
xy plane, followed by the application of simultaneous RF fields to the I and S spins, for a
period (τCP ), followed by the detection of S spins, during which the I spins are decoupled,
as described previously.
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Figure 2.10: Pictorial representation of 1H-13C CP/MAS NMR pulse sequence
2.1.5 Probing mobility using solid-state NMR [4,7]
Solid-state NMR provides a number of techniques for characterisation of molecular mobility
characterisation, and is able to probe dynamics on different time and length scales (figure
2.11). The effects of motions on nuclear spins are dependent on the three nuclear spin
timescales: relaxation, spectral and Larmor. All timescales are also dependent on the
sample, and on physical parameters such as temperature and strength of external magnetic
field [7].
The techniques available to probe molecular mobility in solid-state NMR range from cross-
polarisation based experiments, to the measurement of a number of different relaxation times.
Chapter 4 outlines the main applications of solid-state NMR for the detection of different
motional regimes in pharmaceutical solids. To aid understanding of these techniques, nuclear
relaxation will be briefly introduced below.
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Figure 2.11: The motional timescales of NMR: physical processes and NMR relaxation methods, adapted
from [7]
2.1.6 NMR Relaxation [4, 7]
At equilibrium, the populations of energy levels are predicted by the Boltzmann distribution.
Following the application of an rf pulse, equilibrium is disturbed, and the energy level
populations deviate from equilibrium positions, often generating spin coherence. The nature
of the coherence is dependent on the magnitude of the pulse. A pi pulse (180 °) will invert
the spin population along the z-axis; whilst a pi/2 pulse (90 °) will transfer spins into the
observable xy-plane.
Following perturbation from the application of an rf -pulse, magnetisation will re-establish
equilibrium, through the process of nuclear spin relaxation. This occurs via one of two
relaxation pathways: spin-lattice relaxation, or spin-spin relaxation; through interaction of
the spins with the thermal environment (figure 2.12).
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Figure 2.12: NMR relaxation pathways following a pi/2 pulse: magnetisation decay through T2 relaxation
(viewed looking down the z-axis) and re-establishment of magnetisation through T1 relaxation, adapted
from [20,21]
Spin-spin relaxation (also referred to as transverse, or T2 relaxation) occurs through
coherence decay. This occurs through the energy exchange between α and β spin states
(via. through-space dipole-dipole interactions), which results in loss of coherence without
a net change in energy, which eventually, though repetition will drive overall (net)
magnetisation back to zero.
Spin-lattice relaxation (also referred to as longitudinal, or T1 relaxation) involves the
movement of spins back to the Boltzmann distribution, through loss of heat energy from
the spins to the surroundings (or the ’lattice’). The loss of energy is so small, it is
undetectable in the bulk sample. The T1 relaxation mechanism mainly occurs though
dipole-dipole interactions, which are strongly dependent on molecular motion. This occurs
as follows: for example for nuclei with I = 12 , relaxation occurs due to fluctuations in the
local environment, or local magnetic field, which are induced by thermal molecular motion.
These fluctuations are influenced by the surrounding nuclei which are close in space,
through dipolar coupling. However, additional pathways, such as chemical shift anisotropy,
quadrupolar relaxation and spin rotation do exist, but will not be discussed further.
Spin-lattice relaxation was employed in this study as the main technique to explore the
molecular mobility of the three model amorphous systems, therefore spin-spin relaxation
will not be discussed further.
2.1.6.1 Measurement of spin-lattice (T1) relaxation [8]
The recovery of the z-magnetisation (Mz) back to thermal equilibrium (governed by the
Boltzmann distribution) follows an exponential decay, as described by the Bloch equation
(equation 2.15 [8]):
dMz(t)
dt
=
Mz(t)−M0
T1
(2.15)
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where M0 is the magnetisation at thermal equilibrium, and T1 is the time constant. Bloch
theory assumes first order kinetics are followed. Following the application of a pi/2 pulse,
the T1 time, at time t, is described by:
Mz = M0[1− e
t
T1 ] (2.16)
1H T1 relaxation times were measured using an inversion recovery pulse sequence (see chapter
3). In this sequence, a pi pulse is applied to first invert the magnetisation. A delay (τ) is
then allowed, during which magnetisation relaxes, followed by a pi/2 pulse to measure the
remaining z-magnetisation after time, τ . The delay is varied, which allows the peak intensities
to be measured as a function of τ .
2.1.6.2 Spin-lattice relaxation in the rotating frame
T1 relaxation in the rotating frame (T1ρ) is sensitive to slower molecular motions, as
compared to T1. Investigation of T1ρ
H allowed us to probe the motions associated with
backbone polymer chain motions [29,161], thought to reflect the overall ’freeing up’ of local
mobility as temperature conditions change, especially through the Tg [187]. These motions
occur on a kHz timescale (ms – µs) at the frequency of rotating frame, determined by the
B1 field. T1ρ
H relaxation provides a sensitive probe of local mobility, giving a snapshot of
molecular level changes within the systems which is particularly important below, and
around Tg.
The measurement of T1ρ
H involves the use of the spin-locking pulse sequence, first devised
by Schaefer et al. [188], . 1H relaxation times are measured through the acquisition of 13C
spins, following a cross-polarisation transfer step between 1H and 13C nuclei. Using this
method, the 13C magnetisation relaxes in the rotating frame, during the spin-locking time
period (τ). Peak intensities, as a function of spin-lock time are fitted in a similar way to T1
(see chapter 2).
2.2 Other characterisation techniques used in the study of
pharmaceutical compounds
2.2.1 Differential Scanning Calorimetry (DSC) [10,11]
Differential Scanning Calorimetry measures the uptake of thermal energy by a sample during
monitored changes in temperature. The energy uptake of the sample is compared to an empty
reference pan in order to determine and identify thermal transitional events.
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Figure 2.13: Schematic representation of the experimental set-up of Differential Scanning Calorimetry
(DSC), adapted from [22]
The sample and reference pans are separately heated at the same linear rate, within a
specified temperature range. As the reference is an empty pan, the heating rates between
sample and reference will be different, with the difference representing the energy uptake
of the sample. Isothermal conditions are maintained through calculation of the additional
energy absorbed (endothermic) and released (exothermic) by the sample as compared to the
reference. The calculated energy differences provide useful information on specific thermal
events, including glass transitions (Tg), crystallisation (Tc) and melting (Tm) (figure 2.14).
Figure 2.14: Example DSC curve, highlighting the glass transition temperature (Tg), exothermic
crystallisation event (TC) and endothermic melt (Tm), adapted from [23]
A miscible amorphous solid dispersion should have a Tg value which is intermediate between
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the individual components, i.e drug and polymer. This theoretical Tg value of ’ideally
mixed’ amorphous solid dispersions can be predicted using a number of equations, including
the Gordon-Taylor (G-T) [112], Gordon-Taylor/Kelley-Bueche [113] and Couchman-Karasz
[114]. The G-T equation (equation 2.17)) is based upon free volume theory, and assumes
that individual components are miscible, and that their free volumes are additive.
Tgmix =
w1Tg1 + kw2Tg2
w1 + kw2
(2.17)
where w1 and w2 are the weight fractions of the two components, and Tg1 and Tg2 are the
respective Tg values. k is a constant related to the ratio of free volume, and is calculated
using the Simha-Boyer rule (equation 2.18) [189].
k ≈ ρ1Tg2
ρ2Tg1
(2.18)
where ρ1 and ρ2 are the true densities of the individual components.
The Gordon-Taylor/Kelley-Bueche equation (G-T/K-B) is a slight variation on the original
equation, where k represents a measurement of interaction between the components, rather
than ratio of free volume (equation 2.19) and ∆Cp is the change in heat capacity at Tg
[112,113,190].
k ≈ ∆Cp2
∆Cp1
(2.19)
Additionally, the Couchman-Karasz equation (equation 2.20) is also used to predict the Tg
of miscible systems, and is based on a more classical thermodynamic approach, which takes
into account the combined entropy of mixing of the individual components [62,114,179,191].
lnTg =
(w1∆CplnTg)1 + (w2∆CplnTg)2
(w1∆Cp1) + (w2∆Cp2)
(2.20)
For amorphous dispersions, significant deviation of Tg between experimental and predicted
values can potentially indicate differences in intermolecular interactions between components
(both drug/drug and drug/polymer) [190]. Conversely, lack of deviation from predicted
values indicates ’ideal’ mixing with the absence of specific drug/polymer interactions [192].
Molecular interactions can affect the Tg value of the system as follows:
• Negative deviation from predicted value: interactions between like species (e.g
drug/drug interactions) dominate [192–194]
• No deviation from predicted value: indicates ideal mixing between phases, with a lack
of specific drug-polymer interactions [190].
40
• Positive deviation from predicted value: interactions between different species (i.e
drug/polymer interactions) dominate [192–194].
2.2.2 Powder X-ray Diffraction [12–14]
Powder X-ray Diffraction (PXRD) is a technique employed to characterise materials with an
ordered three-dimensional structure, for example crystalline pharmaceutical APIs. A crystal
can be defined as ‘a solid body having a characteristic internal structure and enclosed by
symmetrically arranged plane surfaces, intersecting at definite and characteristic angles’ [60].
The repeating array of atoms in a crystal, or scattering centres, can be detected through
X-Ray Diffraction if the scattering centres are separated by a particular distance (d) which
is comparable to the X-Ray wavelength (λ), giving rise to interference between the scattered
X-rays (figure 2.15. In the case of ordered structures, interference maxima and minima occur,
which results in a diffraction pattern. In a typical X-Ray diffraction experiment:
1. A cathode ray tube is used to generate X-rays
2. The resulting X-rays are then filtered, resulting in a monochromatic beam
3. This beam is directed at the sample of interest
4. Diffraction rays are collected through the detector
5. The basis of the diffraction pattern is formed due to the angle between the incident
and diffraction rays
Figure 2.15: Example of X-ray diffraction, resulting in reflections at angle θ, adapted from [12]
To emerge as a single beam, reflected beams must arrive in phase with one another, known
as constructive interference through satisfaction of Bragg’s Law (equation 2.21).
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nλ = 2dsinθ (2.21)
where n is the order of the beam, λ is the wavelength of the X-ray beam, d is the distance
between adjacent planes (d-spacings) and θ is the angle of incidence of the X-ray beam. d
spacings are calculated using known values of θ and λ.
Characteristic diffraction patterns can be collected for each crystal structure, due to
differences in the arrangement of atoms within the crystal lattice. There are two mains
techniques which employ X-ray diffraction: single crystal X-ray diffraction and powder
X-ray diffraction (PXRD). Single crystal XRD is mainly used for precise determination of
unit cell parameters, to solve crystal structures. It can provide information regarding cell
dimensions, atom positions, bond lengths and bond angles [195]. Powder XRD, which was
the technique employed in this thesis, analyses a solid powder sample to obtain a unique
characteristic ’fingerprint’ X-ray diffraction pattern, where peaks represent constructive
interference by atoms in the crystal lattice. This technique enables the identification of
different crystalline materials, including identification of different polymorphs of crystalline
pharmaceuticals [196].
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Chapter 3
Experimental
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3.1 Materials
Indomethacin (C19H16ClNO4), Flufenamic Acid (C14H10F3NO2), Tolbutamide
(C12H18N2O3S), methanol, ethanol and acetonitrile were purchased from Sigma Aldrich,
UK. PVP-VA (polyvinylpyrollidone-vinylacetate) (Kollidon VA 64) was purchased from
BASF chemicals, Germany.
3.1.1 Amorphous drug preparation
Amorphous IMC was produced via the quench cool method by melting the crystalline drug
in an aluminium pan in an oven to 453 K, holding at this temperature for 5 minutes, followed
by immediate quench-cooling in liquid nitrogen (adapted from [29, 84]). Amorphous FFA
was prepared using the same method carried out in a cold room to minimise crystallisation,
due to the low stability at ambient temperature. Attempts to form amorphous TLB were
unsuccessful, due to the low Tg of ca. 278 K. The fresh samples were lightly ground in a
pestle and mortar and stored at 203 K. Analysis by Differential Scanning Calorimetry (DSC),
Powder X-ray Diffraction (PXRD) and solid-state NMR confirmed the amorphous nature.
3.1.2 Preparation of amorphous solid dispersions
Amorphous Solid Dispersions were prepared using a solvent evaporation technique adapted
from [71, 84]. γ-IMC, form I FFA and form IL TLB were formulated with PVP-VA in the
following drug/polymer wt. ratios: 80/20, 70/30, 60/40, 50/50, 40/60, 30/70, 20/80 and
10/90. This was achieved by dissolving 8 g (total weight) of lightly mixed drug/polymer
in a minimum volume of methanol at ambient temperature. Ethanol and acetonitrile were
additionally used to prepare 80/20 IMC/PVP-VA dispersions to study the effect of solvent on
crystallisation. The solvent was removed under vacuum at 323 K using a rotary evaporator,
rotating at 8 rpm. The resulting powder was lightly ground in a pestle and mortar and
stored at 203 K.
3.1.3 Preparation of crystalline polymorphic forms
The purchased IMC was confirmed to be γ-form through DSC and PXRD [50]. α-IMC was
formed by dissolving ca. 250 mg of γ-IMC in methanol in a round bottom flask. The solvent
was removed under vacuum at 323 K using a rotary evaporator set at 8 rpm. The resulting
powder was lightly ground in a pestle and mortar and stored at 203 K.
The purchased FFA was confirmed to be form I through DSC and PXRD [197]. Form III
was prepared according to the method by Lopez-Mejias et al. [39]: 50 mg was dissolved in
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1 ml of EtOH, and heated to 358 K. The resulting solution was allowed to cool to ambient
temperature, where it was stored until crystals formed.
The purchased TLB was confirmed to be form IL through DSC and PXRD [42, 172]. Form
II was prepared according to the method by Thirunahari et al. [42]: 1.2 g of purchased TLB
was dissolved in 10 g acetonitrile at ambient temperature. 5 ml of water was slowly pipetted
into the solution without stirring, where it was left until crystals formed. Form IH was
prepared in situ in the NMR rotor, by heating the purchased form IL above 311 K [43].
Analysis by DSC, PXRD and solid-state NMR confirmed the successful formation of the
different polymorphic forms.
3.2 Methods
3.2.1 Differential Scanning Calorimetry
All DSC measurements were performed using a Q 2000 MTDSC instrument (TA
Instruments, Newcastle, DE, US). Indium, tin and n-octadecane were used as calibration
standards. Standard TA crimped 100 µL aluminium pans were used for all experiments.
The sample weights were between 2-5 mg (crystalline samples) and 5-10 mg (amorphous
and solid dispersion samples) and a nitrogen purge of 50 mL/min was used for all
experiments.
Experiments for each API were carried out within the following temperature ranges, to cover
all glass transition, crystallisation and melting events for each system: IMC (283 - 493 K);
FFA (253 - 463 K); TLB (243 - 463 K).Standard experiments on all crystalline API were
carried out using a heating rate of 5 K/min. Modulated DSC experiments were carried
out on all amorphous API and amorphous solid dispersions with a heating rate of 2 K/min
with a modulation of ± 0.5 K every 60 seconds. This was repeated three times, using a
heat-cool-reheat cycle, with an isotherm of 1 minute at each temperature extreme. The
initial heating run was not taken into account for Tg calculations, but was performed to
remove thermal history of the materials. Analysis was performed on all samples using TA
Instruments Universal Analysis 2000 software (TA Instruments, Waters LCC).
3.2.2 Powder X-ray Diffraction
PXRD patterns were acquired with an ARLTM XTRA Powder Diffractometer (Thermo
Fisher Scientific Inc., Waltham, MA, US), using Cu Kα radiation (λ = 1.541 A˚) in the 2θ
range between 3 and 60 °. All samples were analysed with a step size of 0.01 ° and a scanning
rate of 1.2 s per step.
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3.2.3 In situ PXRD at variable temperature *
The PXRD experiments at elevated temperature were performed using a Bruker AXS D8
Discover powder diffractometer (Bruker AXS GmbH, Germany) equipped with an MRI
temperature chamber. Copper Kα radiation (λ = 1.5418 A˚) was used in the experiments.
Data were collected using a flat sample (depth of 0.8 mm) holder in the Bragg–Brentano
geometry. The X-ray diffraction measurements were performed at various temperatures
(293, 313, 333, 353, 363, 373 K). Diffraction patterns were recorded with a 0.02 ° step size
and a scan speed of 0.2 s per step in the 2θ range from 3 to 40 ° for FFA samples.
* - VT PXRD run by Inese Sarcevica, Department of Chemistry, University of Riga, Latvia.
The author acknowledges Inese, and thanks her for her invaluable help and advice with these
experiments.
3.2.4 Accelerated stability study
Amorphous dispersions of IMC/PVP-VA and FFA/PVP-VA and TLB/PVP-VA (20/80,
40/60, 50/50, 60/40, 70/30 and 80/20 wt. ratios) were monitored over a period between 8 -
14 weeks under the following storage conditions: room temperature 0% RH; room
temperature 75 % RH; 313 K; 333 K. The high-drug loading dispersions were additionally
stored at extreme temperature conditions (353 - 373 K) to further investigate
crystallisation.
Each sample was monitored for evidence of crystallisation every two weeks using modulated
DSC, PXRD and solid-state NMR.
3.2.5 Solid-state NMR
All solid-state NMR spectra were acquired at 9.4 T using a Bruker AVANCE III WB
solid-state spectrometer operating at 400.23, 376.30 and 100.64 MHz for 1H 19F and 13C
respectively. The chemical shifts of 1H and 13C are referenced with respect to external
TMS, whilst 19F was referenced to external PTFE. Samples were spun at an MAS rate of
10.0 kHz using 4 mm diameter zirconia rotors with a 4 mm 1H/X/Y triple resonance probe.
3.2.5.1 One dimensional magic angle spinning (MAS)
1H and 19F single pulse MAS NMR experiments were acquired using a simple pulse program
shown in figure 3.1. 19F signal was achieved through tuning the 1H channel to the Larmor
frequency of 19F.
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Figure 3.1: Representation of the single pulse MAS NMR experiment
1H MAS NMR spectra were acquired using a pi/2 pulse length of 2.60 µs at an MAS rate of
10.0 kHz and recycle delay of 10 s. 19F MAS NMR (1H coupled) were acquired with a pi/2
pulse length of 3.62 µs at 10.0 kHz and a recycle delay of 6 s.
3.2.5.2 1H-13C Cross Polarisation Magic Angle Spinning NMR (1H-13C
CP/MAS NMR)
All 1H-13C CP/MAS NMR experiments were acquired using a ramp amplitude 1H pulse
shape with SPINAL-64 [183] heteronuclear decoupling applied during the acquisition (figure
3.2).
Figure 3.2: Representation of 1H-13C CP/MAS NMR pulse sequence
All spectra were acquired at a MAS rate of 10.0 kHz, with an optimised 1H pi/2 pulse length
of 3.0 µs, contact time of 2.0 ms and a pulse delay of 10 s for IMC and TLB and 15 s for
FFA. 1H rf decoupling field of 78 kHz was applied during acquisition. The Hartmann-Hahn
matching conditions were set using hexamethylbenzene (HMB). Typically 512 scans were
accumulated for crystalline materials and 1024 scans for amorphous materials.
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3.2.5.3 Dipolar dephasing with Non-Quaternary Suppression (NQS)
The dipolar dephasing 1H-13C CP/MAS NMR pulse sequence is a spectral editing method,
which allows the distinction between protonated and quaternary carbons. This method relies
on differences in the strength of heteronuclear dipolar interactions in different functional
groups. The inclusion of a dephasing delay (τDD) between the CP step and acquisition
allows the 13C magnetisation to evolve under the influence of the dipolar interactions. The
pulse sequence is shown in figure 3.3.
Figure 3.3: Representation of 1H-13C CP/MAS NMR dipolar dephasing (NQS) pulse sequence
We used this pulse sequence for Non-Quaternary suppression (NQS), which allows the
detection of quaternary carbons, whilst excluding -CH and -CH2 functional groups. NQS
was achieved through setting the dephasing delay to 40 µs. All other parameters were the
same as in the standard 1H-13C CP/MAS NMR above.
3.2.5.4 Single pulse 13C with high power 1H decoupling (13C{1H} MAS NMR)
13C{1H} MAS NMR experiments were carried out at using an optimised 13C pi/3 pulse of
2.3 µs and a recycle delay of 30 s. Typically 1024 scans were accumulated.
Figure 3.4: Representation of 13C{1H} MAS NMR pulse sequence
SPINAL-64 heteronuclear decoupling [183] was applied during acquisition, with an 1H rf
decoupling field of 89 kHz. Chemical shift values were referred to that of TMS.
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3.2.5.5 Two dimensional 1H-13C WIdeline SEparation (WISE)
WIdeline SEparation (WISE) experiments in solid-state NMR are used to correlate
information on local mobility with chemical structure [198]. The 2D WISE spectrum
(figure 3.5) combines the 1H wideline spectral patterns with each of the 13C chemical shifts
acquired through 1H-13C CP/MAS NMR, which enhances spectral resolution. The widths
of 1H are indicative of the strength of 1H-1H homonuclear dipolar coupling, which in turn
depends on mobility, with more rigid structures having wider lines.
Figure 3.5: Representation of 1H-13C 2D WISE pulse sequence
1H-13C WISE spectra were acquired for amorphous IMC, IMC/PVP-VA dispersions and
PVP-VA at an MAS rate of 10 kHz, with a 1H pi/2 pulse length of 3.0 µs and a pulse
delay of 10 s. SPINAL-64 heteronuclear decoupling [183] was employed during t2 with an
rf field strength of 83 kHz. 128 - 256 increments were recorded during t1, and 512 scans
were accumulated. A fixed contact time of 200 µs was used to limit 1H spin diffusional
effects, as longer contact times would lead to a lack of distinction between 13C sites through
equilibration of 1H magnetisation.
3.2.5.6 Spin-lattice relaxation
3.2.5.6.1 Spin-lattice relaxation in the laboratory frame (T1) T1 relaxation
experiments were collected using the standard inversion-recovery (IR) pulse sequence for
both 1H and 19F nuclei (figure 3.6).
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Figure 3.6: Representation of inversion recovery (IR) pulse sequence
A pi pulse (5.2 µs for 1H and 7.2 µs for 19F) rotated magnetisation into the -z plane, followed
by an evolution period of time τ , with a final pi/2 pulse to rotate remaining magnetisation
into the - xy plane for acquisition. 15 experiments were carried out with τ set between 0.01
to 20 ms for both 1H and 19F. Peak intensities were plotted as a function of delay time (τ),
and fitted with exponential equation 3.1:
Mz(t) = M0z(1− 2exp(− t
T1
)) (3.1)
where t is the delay time, and Mz(t) is the net magnetisation along z at this time.
3.2.5.6.2 Spin-lattice relaxation in the rotating frame (T1ρ
H : Variable spin-
lock) T1ρ
H relaxation times in the rotating frame were measured using a modified CP
sequence (based on figure 3.2) with an additional spin-locking pulse (figure 3.7).
Figure 3.7: Representation of the T1ρH spin locking pulse sequence
Before the CP step, 1H magnetisation was locked along the y axis for a variable time (τ)
between 0.01 and 30 ms using a spin-locking pulse. During this delay time, the 1H
magnetisation evolves under the effect of the homonuclear dipolar interaction. This results
in a difference in the peak intensity dependent on 1H relaxation efficiency in the rotating
frame. A spin-locking field of 78 kHz was employed during τ . The contact time was fixed
to 2 ms, delay time to 10 s (IMC and TLB) and 15 s for FFA, at an MAS rate of 10 kHz.
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To obtain a T1ρ decay curve, 15 experiments were carried out with τ set between 0.01 and 30
ms. Peak intensities were plotted as a function of spin-lock time, and fitted with exponential
equation 3.2:
M(t) =
∑
M0iexp(− t
T1ρi
) (3.2)
where t is the spin lock time, and M(t) is the peak intensity at this time.
The indirect detection of T1ρ
H via 13C leads to higher resolution 13C spectra compared
to 1H. Measurements also highlight the volume averaged property of T1ρ
H (through spin
diffusion - see chapter 4), allowing detection of homogeneity within a sample.
3.2.6 Data Processing
The NMR spectra were acquired and processed using Bruker Topspin 3.1.7 analysis
software. All spectra were fitted with 60 Hz line broadening, unless otherwise stated.
Further processing was carried out with Origin 9.0, including fitting of T1 decays and
deconvolution. T1ρ fits were achieved with Bruker Dynamics Centre (version)
3.2.7 Variable temperature
Variable temperature measurements were typically performed between 253 K and 373 K at
10 - 20 K intervals. Temperature control was accomplished with a Bruker BCU II chiller
unit, and through heating the bearing gas within the probe via a probe filament. Prior to
acquisition, packed rotors were spun for 30 minutes to equilibrate sample temperature.
3.3 Solution-state NMR
Solution-state NMR experiments were conducted on a Bruker Avance I 500 MHz NMR
spectrometer equipped with a 5 mm TXI actively shielded Z-gradient high resolution probe,
operating at 499.68 MHz for 1H and 125.65 MHz for 13C. 1H, 13C, 2D 1H-1H COSY and 2D
1H-13C HSQC NMR spectra were collected.
To gain further resolution, FFA solution-state 1H, 1H-1H COSY and 2D J-resolved NMR
spectra were acquired using a Bruker Avance III 800 MHz NMR spectrometer, operating at
800.23 MHz for 1H and 201.22 MHz for 13C, equipped with an HCN Inverse triple resonance
z-gradient probe.
Samples were prepared to a final API concentration of 0.05 M in 600 µl aliquots of CD3OD.
For assignment purposes, the following pulse sequences were utilised:
51
• 1H single pi/2 pulse of length 7.87 µs (IMC), 6.71 µs (FFA) and 7.99 µs (TLB), and
delay time of 2.0 s.
• 13C{1H} NMR: pi/2 pulse of length 11.25 µs, delay time of 2.0 s and WALTZ-16
decoupling
• 1H-1H COSY: 1H pulse of length 7.77 µs (at 500 MHz) and 1H pulse of length 9.05 µs
(at 800 MHz)
• 1H-13C HSQC: 1H pulse of length 7.77 µs, and 13C pulse of length 11.25 µs, with GARP
decoupling
• J-resolved: 1H pulse of length 9.05 µs (at 800 MHz)
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Chapter 4
Detection of mobility in solid-state
NMR
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Solid-state NMR provides a number of techniques for characterisation of molecular mobility,
and is able to probe dynamics on different time and length scales (figure 4.1). The effects of
motions on nuclear spins are dependent on the three nuclear spin timescales: relaxation,
spectral and Larmor. All timescales are also dependent on the sample, and on physical
parameters such as temperature and strength of external magnetic field [7].
Figure 4.1: The motional timescales of NMR: physical processes and NMR relaxation methods, adapted
from [7]
The solid-state NMR methods described below are common to all three drug/polymer
systems studied (chapters 5 to 7) across a range of temperatures. For the benefit of the
reader, the main applications of solid-state NMR for the detection of different motional
regimes in pharmaceutical solids are outlined below.
4.1 13C Magic Angle Spinning (MAS) NMR
Both 1H-13C CP/MAS NMR and 13C{1H} MAS NMR (high-power decoupling) techniques
were used to acquire 13C spectra throughout this study, with variable temperature
experiments allowing a further probe of the mobility [199]. This often leads to the detection
of a difference in mobility of individual drug and polymer components within dispersions.
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4.1.1 1H-13C Cross Polarisation(CP)/MAS NMR and mobility
CP/MAS NMR experiments are commonly used to enhance signal-to-noise ratios and reduce
the acquisition time of low sensitivity nuclei, such as 13C and 15N. CP/MAS also provides
a building block for numerous more complex pulse programmes, such as 2D correlation
techniques (HETCOR) [4]. During the contact time period, upon fulfilment of Hartmann-
Hahn conditions, proton magnetisation in the rotating frame relaxes back to the lattice at
a rate of T1ρ
Hs. At the same time, 13C signal is acquired through transfer of magnetisation
from 1H to 13C spins via heteronuclear dipolar couplings, at a rate of TCP s [4,24,199] (figure
4.2). The efficiency of polarisation transfer is therefore highly dependent on the strength of
1H -13C dipolar interactions and the number of protons involved in transfer. The 1H-13C
dipolar interactions depend on the distance between carbon and proton nuclei, orientation
with respect to external magnetic field and local molecular motion [24,25,199].
Figure 4.2: Representation of Cross Polarisation dynamics during contact time, adapted from [24]
In an extreme case, if T1ρ
H is too short, the loss of magnetisation into the lattice can
occur faster than cross-polarisation, leading to absence of signal from the acquired spectrum
altogether [24]. T1ρ
H is temperature dependent (see section 4.4.2) therefore if structural or
motional heterogeneity exists between regions of a sample i.e. between drug and polymer
components within a solid dispersion, T1ρ
H times may change drastically with temperature,
allowing the discrimination between drug and polymer components. This effect can be
observed both directly by calculating T1ρ
H times via spin-locking experiments, and indirectly
through monitoring 13C resonances with CP/MAS NMR.
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4.1.1.1 Detection of mobility through 1H-13C dipolar coupling: intermediate
timescale motions
Intermediate motions can affect the cross-polarisation transfer efficiency via the motional
modulation of 1H-13C dipolar interactions [28, 199] (1H-13C dipolar interactions ca. 20-30
kHz [2]), leading to a reduction in signal intensity [200]. Reduction in signal intensity of
CP/MAS spectra is often seen as a disadvantage of the technique, but this loss of signal
can provide important information about changes in the local dynamics of the sample [28],
which more traditionally have been studied via CP-kinetics build up curves [184].
Two early literature examples of the loss of signal in 1H-13C CP/MAS NMR spectra of
polyethylene, compared with the 13C{1H} MAS NMR spectra are shown in figure 4.3.
For both polyethylene samples, additional 13C resonances are present in the 13C{1H} MAS
NMR as compared to the 1H-13C CP/MAS NMR. This is due to loss of signal in the 1H-
13C CP/MAS NMR spectrum through motional averaging of dipolar interactions, leading to
reduced cross-polarisation efficiency. Fyfe et al. [25] (figure 4.3 A) attributed the additional
peak in the 13C{1H} MAS NMR spectrum to a more mobile amorphous region. Harris [24]
(figure 4.3 B) saw the same effect in end groups of polyethylene chains, with much greater
intensity peaks present in the 13C{1H} MAS spectrum, again attributing the loss of CP
signal to higher mobility of amorphous chain regions.
Figure 4.3: A) CP/MAS (contact time = 1.5 ms; recycle delay = 2 s) and 13C{1H} MAS NMR (SPE)
(delay = 20 s) 13C spectra of semi-crystalline polyethylene [25] and B) CP/MAS (contact time = 1 ms;
recycle delay = 1.25 s) and 13C{1H} MAS NMR SPE (delay = 11 s) 13C spectra of lower molecular weight
polyethylene wax [24]
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4.1.1.2 The effect of 1H-1H spin diffusion on CP/MAS NMR spectra
1H-1H spin diffusion also plays a significant role in the efficiency of 1H-13C CP/MAS NMR,
and can provide information on homogeneity of drug and polymer in solid dispersions. Spin
diffusion is a property of 1H-1H homonuclear dipolar interactions, and involves the
exchange of spin energy between protons via flip-flop transitions (see chapter 3 for further
explanation). Classical CP theory (named the I-S model) assumes that the 1H-1H spin
diffusion is sufficiently rapid to communicate between all protons in the system, which
means all protons will behave in the same manner and will act as the source of
polarisation [8]. Therefore if efficient spin diffusion can take place across the 1H pool, we
will observe homogenous relaxation behaviour across all carbon sites. If the average
domain size of a particular component of a system is below 6 nm, 1H-1H spin diffusion
averages out T1ρ
H differences, and we observe one common relaxation time across all
sites [2,46]; for larger domains, we might observe a difference in cross-polarisation efficiency
due to inefficient spin diffusion, leading to differences in T1ρ
H times between components,
i.e. drug and polymer within a dispersion. The I-S model of CP-kinetics is usually used to
describe functional groups with weaker heteronuclear, and moderate to strong homonuclear
dipolar interactions, for example quaternary carbons [8, 201].
4.1.2 13C{1H} MAS NMR and mobility
13C{1H} MAS NMR, often referred to as SPE (Single Pulse Excitation), or DP (Direct
Polarisation) involves a direct excitation of 13C spins, combined with high power proton
decoupling to remove 1H-13C dipolar interactions. It is mainly used for quantitative
analysis, where the area under each peak represents the number of carbon atoms within
that particular environment, similar to peak integration in solution-state NMR [24]. As the
delay time between pulses must be long enough to allow full relaxation to equilibrium,
13C{1H} MAS NMR experiments are often very time consuming, especially for solids with
long T1
C times [200]. The main effect of mobility on the acquisition of 13C{1H} MAS
NMR spectra is through motional modulation of the heteronuclear decoupling step, which
leads to the reduction of spectral resolution.
4.1.2.1 Detection of mobility through interference with heteronuclear
decoupling: faster intermediate timescale motions
Motions on a similar timescale to the 1H rf decoupling field (usually between 50 - 100 kHz,
and ca. 89 kHz in our 13C{1H} MAS NMR experiments) can reduce the effectiveness of
heteronuclear dipolar decoupling [26, 28, 200]. This manifests as line broadening of carbon
signals within both 1H-13C CP/MAS NMR and 13C{1H}MAS NMR spectra [25]. Reduction
in decoupling efficiency results from molecular motions modulating heteronuclear decoupling
57
through partial uncoupling of protons from the field [202]. Zhang et al. [203] varyied the
decoupling strength to prove the observed broadening was indeed due to the interference of
heteronuclear decoupling. Therefore, if particular motions are site specific within a sample,
this experimental ’flaw’ can be used as an identification and characterisation tool.
4.1.3 Manifestation of faster isotropic motions in solid-state 13C MAS
NMR
Faster motions, an increased motional timescale compared to the previously discussed
intermediate motions (i.e. > 1000 kHz) can also be detected in the solid-state, particularly
with variable temperature 1H-13C CP/MAS and 13C{1H} MAS NMR experiments. With
increasing temperature, line narrowing can be observed due to the presence of faster
motions, which partially average both heteronuclear and homonuclear dipolar interactions
to a value lower than the MAS frequency (10 kHz in our case). This leads to the presence
of narrow isotropic peaks in the solid-state spectrum. This phenomenon has previously
been observed for aliphatic chain motions of poly(vinyl methyl ether) (PVME)
polymers [26] and methyl rotations in amorphous simvastatin [28]. The effect of chain
motion on the linewidth of peaks in the 13C{1H} MAS NMR spectrum of PVME in
PS/PVME blends can be seen in figure 4.4.
Additionally, even faster isotropic motions (i.e. equivalent to a ’liquid-like’ environment,
with τ c < 0.01 µs) can lead to the complete loss of
1H-13C CP/MAS NMR signals, leading
to the complete loss of signal intensity in the spectrum. These faster motions affect 1H-13C
CP/MAS NMR spectra through interference with the cross-polarisation transfer step, and
do not affect signals of 13C{1H} MAS NMR spectra, instead fast motions would lead to the
observation of sharp 13C resonances through direct excitation spectra [24,204].
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Figure 4.4: 13C{1H}MAS NMR spectra for PS/PVME (50/50) polymer blend, at 312 and 372 K, adapted
from [26]
4.1.4 The combined use of 1H-13C CP/MAS NMR and 13C{1H} MAS
NMR for investigation of molecular motion
The combined use of both 13C MAS NMR techniques can result in a greater understanding
of the molecular motion of pharmaceutical solids, through identification of different
mobility regimes across a range of NMR timescales [204]. This approach allows
discrimination between different regions of the sample, for example between drug and
polymer in a solid dispersion. Changes in mobility will manifest themselves in different
ways within the acquired carbon spectra. A variety of molecular motions, including phenyl
ring flips and alkyl chain rotations can affect the 13C linewidth [200], with this method
being particularly sensitive to intermediate motions (10 kHz to 1 MHz), which are on the
timescale of the NMR experiments [28, 184, 199]. Using the combined approach, we were
able to differentiate between the molecular mobility of drug and polymer within solid
dispersions of IMC (chapter 5), FFA (chapter 6) and TLB (chapter 7).
A literature example of the range of motional effects which are possible to observe with
variable temperature 1H-13C CP/MAS NMR is shown in figure 4.5 [27, 205]. Here we see a
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variety of line widths of the methyl resonance (C-3), as it undergoes temperature dependent
rotation:
• Fast mobility: at increased temperature the methyl resonance is sharp, with narrow
linewidth, due to rapid motional averaging of fast isotropic motion
• Intermediate mobility: maximum broadening is seen at 106 K where the methyl
resonance is no longer visible, as the rate of motion equals the 1H decoupling
frequency leading to reduced effectiveness. The methylene and methine carbon
signals remain present.
• Slow mobility: at low temperature, the methyl resonance is present once more, as
the reduced mobility allows the reduction of line width by effective decoupling of C-H
dipolar interactions.
Figure 4.5: Variable temperature CP/MAS spectra of isotactic polypropylene, highlighting the change
in the methyl resonance (red arrows, resonance 3) compared to methylene and methine carbon signals [27]
A number of studies have been reported, where different motional regimes have been
highlighted through VT 1H-13C CP/MAS NMR and 13C{1H} MAS NMR experiments.
Our group reported changes in local motions of drug/PLGA films dependent on drug
loading levels. With increasing temperature, line broadening of carbonyl and aliphatic
resonances was observed in CP/MAS experiments, due to reduced decoupling efficiency
from increased backbone motions in the mid-kHz range (20 % drug loaded dispersion).
Within a more rigid system (10 % film) no change in linewidth with increasing temperature
was observed [202]. Nunes et al. [28] recently undertook a VT 1H-13C CP/MAS study on
amorphous simvastatin and found significant line broadening and loss of signal intensity
with increasing temperature, for the majority of 13C peaks. This was attributed to an
intermediate motional regime interfering with decoupling. Line narrowing of the peak
corresponding to the ester tail, due to faster motions averaging both homonuclear and
heteronuclear dipolar coupling was also highlighted. They found that having multiple
frequency regimes within one system resulted in increased configurational entropy, leading
to increased physical stability (with respect to crystallisation).
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Figure 4.6: Variable temperature 1H-13C CP/MAS NMR spectra of amorphous simvastatin, adapted
from [28]
Carignani et al. [206] also used VT 1H-13C CP/MAS NMR as part of an investigation on
the different motional regimes present in the ibuprofen Na + salt. Again, significant line
broadening of the aromatic carbon peaks upon heating occurred, which was attributed to
interference with the decoupling field from the phenyl-pi ring flip, occurring on the
intermediate timescale. Schantz et al. [159] carried out VT direct polarisation (13C{1H}
MAS NMR) experiments on amorphous blends of paracetamol and citric acid with a
decoupling field strength of 83 kHz (comparable to our own experiments). Here, linewidth
broadening with increasing temperature was observed, due to motional interference with
the decoupling field. They determined that because both components displayed the same
mobility behaviour, this was a miscible system, with the dominant mobility identified as
whole molecule α-relaxation motions. Above a specific temperature, line narrowing (with
’liquid-like’ resolution) of all peaks was identified, due to rapid molecular motions, above
the intermediate regime. Carignani et al. identified methyl and isobutyl motional rotation
as being on a faster (> 1000 kHz) timescale, and investigated through VT T1
H
experiments, which are on the MHz timescale [206].
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4.2 1H MAS NMR
1H MAS NMR is very sensitive to both structure and molecular motions: increased molecular
mobility leads to line narrowing of the 1H resonances. Sufficiently fast molecular motions can
lead to the averaging of strong 1H-1H dipolar interactions, responsible for the characteristic
’broad hump’ appearance of 1H MAS NMR spectra in the solid-state (see chapter 2) [29,30,
59]. Although it is more difficult to distinguish between drug and polymer peaks, especially at
lower temperatures where amorphous materials have extremely broad 1H spectra, increased
molecular motion can become apparent through monitoring the change in linewidth with
increasing temperature. Sharp resonances, more comparable to a solution-state spectrum,
indicate a higher mobility state [59].
Schachter et al. [30] investigated the mobility of ketoprofen/PEO blends by using VT 1H
MAS. They found that with increasing temperature, significant line narrowing occurred
whilst the blend was still in the solid state, before melting (figure 4.7 B). Apperley et
al. [29] carried out static VT 1H experiments on amorphous indomethacin and nifedipine.
They also showed rapid narrowing of the 1H peaks with increasing temperature, attributed
to increased molecular mobility leading to averaging out 1H-1H dipolar interactions (figure
4.7 A). Carpentier et al. [59] used VT 1H MAS NMR to monitor crystallisation and
polymorphism of amorphous IMC. Firstly, when IMC was in the glassy state (T < Tg), a
broad 1H spectrum was seen. With increasing temperature, they observed the metastable
α polymorph (T > Tg) with line narrowing due to fast molecular motion, attributed to a
cooperative motion identified via dielectric relaxation spectroscopy.
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Figure 4.7: A) Static VT 1H NMR spectra of amorphous IMC [29] and B) VT 1H MAS NMR spectra of
ketoprofen/PEO blends [30]
As seen in chapter 2, increased molecular mobility leads to line narrowing within the spectra
due to the partial cancellation of homonuclear dipolar couplings between 1Hs. In the solution
state, interactions average to zero, which leads to the high resolution/narrow linewidth
observed in solution-state 1H spectra. Increased molecular motion in the solid-state can
therefore become very obvious through monitoring the change in linewidth with increasing
temperature.
4.3 19F MAS NMR
19F is a very attractive nucleus in NMR due to its large gyromagnetic ratio and high
natural abundance, and therefore quick experimental time. Linewidth (quantified through
measurement of Full Width Half-Height (FWHH) can be monitored: smaller FWHH values
indicate the increased mobility of an isotropic ’liquid-like’ environment, due to averaging of
homonuclear dipolar interactions, in a similar way to VT 1H MAS NMR. Changes in
mobility can additionally be determined through monitoring the change in the intensity
and distribution of spinning sidebands within the spectra.
Chemical Shift Anisotropy (CSA) originates from the orientation dependence effect of
chemical shift, with respect to external magnetic field (B0) and is determined by
non-spherical electron distribution around a nucleus. In liquids, anisotropy is averaged out
to zero by fast molecular motion, therefore a single isotropic value of chemical shift is
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observed. In solids, molecules orientate in a wide variety of directions, resulting in slight
differences to chemical shift, and therefore a much broader peak. The anisotropic shielding
tensor contains a geometric component (3cos2θ - 1), which is averaged through MAS to
zero, essentially removing the orientation dependence resulting in a narrow isotropic
chemical shift (see chapter 2 for further explanation). However, if the MAS rate is not
sufficient to fully achieve such averaging, spinning sidebands on either side of the main
isotropic peaks are observed, separated by the MAS frequency. The reduction, or
disappearance of spinning sidebands in 19F MAS spectra, as a result of increasing
temperature, would indicates higher molecular mobility within the system.
19F MAS NMR is becoming increasingly important as a characterisation tool of
pharmaceuticals. Currently 20 - 25 % of pipeline active pharmaceutical ingredients (APIs)
contain one or more 19F atoms [207]. Additionally, very few pharmaceutical excipients
contain 19F atoms, therefore 19F MAS NMR becomes a highly sensitive characterisation
tool for solid dispersions, allowing the monitoring of API without the complication of
drug/excipient peak overlap, even for highly diluted systems [207]. Brus et al. [207] used
19F MAS NMR combined with factor analysis to successfully characterise a number of solid
forms of atorvastatin, including polymorphs and amorphous materials, by monitoring
changes in chemical shift values. The same group went on to investigate the changes in the
molecular arrangement of atorvastatin when formulated as a dispersion with PVP using
19F MAS NMR alongside multivariate analysis [208]. Pham et al. [88] studied a number of
pharmaceutical systems using 19F MAS NMR. Firstly, 19F-13C CP/MAS and 1H-19F
HETCOR experiments were used to compare dispersions of diflusinal/PVP and
voriconazole/PVP to show interactions between the drug and polymer. They also
measured 19F detected 1H T1 times for dispersions of voriconazole/PVP to investigate
phase separation. Abraham at al. [209] used 19F-13C 2D HETCOR NMR as a tool for
molecular structure investigation of the crystalline drug avagacestat, and solid dispersions
with HPMC-AS; and were able to determine proximities between fluorine and carbon of up
to 8 A˚. Aso et al. [41] assessed the feasibility of 19F-NMR for the investigation of molecular
mobility within FFA/PVP and FFA/HPMC solid dispersions, using variable temperature
spin-lattice relaxation, and concluded that it was a useful measure for the assessment of
physical stability. 19F MAS NMR has additionally been used to determine the amount of
crystalline content within dispersions of AMG 517/HPMC-AS [210], for polymorph
identification of crystalline casopitant [211], and for the characterisation of amorphous and
crystalline forms of an M3 receptor antagonist with increasing temperature [212].
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4.4 Detection of molecular mobility in the solid-state with
spin-lattice relaxation
It is important to note at this point, that the measurement of molecular mobility and
discussion of relaxation in this thesis will refer to the measurement of spin-lattice
relaxation through solid-state NMR. A discussion of different measures of relaxation,
associated with molecular mobility in the amorphous state above and below Tg was
provided in chapter 1, section 1.3.1.
NMR relaxation time measurements in the solid-state allow motions across a range of
timescales to be investigated, including faster motions on a MHz timescale (i.e. methyl
group rotations), with T1
H/C , and slower backbone motions on a kHz timescale with
T1ρ
H/C times (figure 4.1). We investigated the T1ρ
H , T1
H and T1
F relaxation of various
amorphous systems, which enabled us to probe a range of motions. T1
H was used to probe
faster MHz timescale relaxation of crystalline drugs, and all solid dispersions, with T1
F
providing an additional analysis tool of 19F containing FFA/PVP-VA dispersions.
Investigation of T1ρ
H allowed us to probe the slower motions, namely those associated with
backbone polymer chain motions [29,161], thought to reflect the overall ’freeing up’ of local
mobility as temperature conditions change [187]. These motions occur on a kHz timescale
(ms – µs) at the frequency of rotating frame, determined by the spin-lock field (ω1 = 78 kHz
in this case). T1ρ
H relaxation provides a sensitive probe of local mobility, giving a snapshot
of molecular level changes within the systems which is particularly important below, and
around Tg. The timescale of molecular motions changes dramatically on cooling, with much
slower dynamics occurring near and below Tg.
The T1ρ
H relaxation times give an indication of the molecular motions in the solid state,
and are influenced by dipolar coupled nuclei and therefore structural rigidity [28, 46]. The
spin-lock relaxation pulse sequence enables an estimation of T1ρ
H relaxation time associated
with 13C peaks, allowing us to monitor the mobility of both the drug and the polymer
components of the systems. T1ρ
H is a volume property, averaged over a distance of ca. 2 -
5 nm [8, 46], which allows a tool for the study of miscibility within drug/polymer systems.
Single 1H relaxation times across each chemical site would indicate good miscibility within
the system, due to efficient 1H-1H spin-diffusion occurring in the solid state [46] (see section
4.4.2).
4.4.1 Temperature Dependence
When studying relaxation times, it is important to take into account the temperature
dependence, in order to link relaxation behaviour with the mobility and dynamics of the
system. Relaxation times display a typical dependence on temperature, as shown in figure
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4.8. Spin-lattice relaxation times (T1
H and T1ρ
H) are highly dependent on temperature,
passing through minima as different motional processes lead to relaxation [24]. It is
therefore important to determine the temperature dependence of relaxation times in order
to determine which motional regime the relaxation time belongs.
Figure 4.8: Typical temperature dependence of spin-lattice relaxation time
When studying molecular motions using VT relaxation, we must determine which side of the
minimum the particular relaxation time is placed. On the slower regime side, the relaxation
time will decrease with increasing temperature; on the faster regime side, the relaxation time
will increase with increasing temperature [28,161,202,213].
Activation energies (EA) for the particular motional regime probed on kHz (T1ρ
H) or MHz
(T1
H) timescales can be calculated using a simple Arrhenius expression (equation 4.1),
1
T1(ρ)
∝ exp(EART ) (4.1)
By plotting ln T1(ρ)
H against the reciprocal of temperature, a slope equal to -EA/RT can
be used to calculate activation energy. A positive gradient would indicate the presence of
motions on the slow side of the temperature dependence curve, and a negative gradient a
faster motional regime [213]. To characterise the types of motions further, the correlation
time (τ c) can be calculated from T1ρ/T1
H using equations 4.2 and 4.3. τ c is the average time
it takes for a molecule with random molecular tumbling to progress through one radian [214],
which therefore enables us to calculate the rate of molecular motion [213], by applying
BPP/KT theory, which provides a relationship between τ c and T1ρ
H/T1
H [28, 215–218].
1
T1ρ
=
3
10r6
γ4h¯2[
5
2τc
(1 + ω20τ
2
c )
+
τc
(1 + 4ω20τ
2
c )
+
3
2τc
(1 + 4ω21τ
2
c )
] (4.2)
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1T1
=
3
10r6
γ4h¯2[
τc
(1 + ω20τ
2
c )
+
4τc
(1 + ω20τ
2
c )
] (4.3)
where r is internuclear distance, γ is gyromagnetic ratio, h¯ is reduced Plank’s constant, ω0 is
Larmor frequency and ω1 is frequency of rf pulse. This gives us a way to link relaxation rate,
internuclear distance, resonance frequency and spectral density functions of molecular motion
by taking into account the effect of molecular motion on local field disturbance [214]. Variable
temperature relaxation studies are therefore useful as they can provide both quantitative and
qualitative information, which gives us a measure of changes in local mobility (within the
kHz timescale) for both drug and polymer.
4.4.2 Detecting miscibility with relaxation times
The detection of miscibility through analysis of spin-lattice relaxation times was originally
developed to detect polymer mixing within blends [219, 220] and has been since utilised for
the detection of phase separation between drug and polymer components of amorphous solid
dispersions [46,88,152]. Spin-lattice relaxation is a volume averaged property, due to efficient
spin-diffusion in the solid-state [152]. The length scale of mixing of the components of interest
can therefore be estimated via solid-state NMR. If the individual components (for example
drug and polymer), are closer in space than the length scale of 1H-1H spin diffusion, then the
transfer of magnetisation is highly efficient [46]. This results in one common relaxation time
between components, which is a weighted average of the expected individual values [221].
The length scale of spin diffusion is measured using equation 4.4. Here, the maximum range
of 1H-1H spin diffusion effects can be estimated from the diffusion path length (L) during
the spin-lattice relaxation time period (t), for both T1 and T1ρ times.
L =
√
6Dt (4.4)
where D represents the spin diffusion coefficient (equation 4.5), calculated from the distance
between protons (l0) and the spin-spin relaxation time (T2).
D =
〈l20〉
T2
(4.5)
Typically, D is assumed to be 10−12 cm2 s−1 in studies of polymers [221] and drug/polymer
dispersions [152]. Using this value of D, and assuming typical T1
H (1 - 5 s) and T1ρ
H (5 - 50
ms) relaxation times, the effective spin-diffusion lengths (L) are shown to be approximately 24
- 55 nm (T1
H) and 2 - 6 nm (T1ρ
H). By taking the difference of spin-lattice relaxation times
between the two components of interest (∆T1
H and ∆T1ρ
H) the following three outcomes
are possible [46,62,88]:
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• ∆T1H > 0 indicates domains of > 55 nm
• ∆T1H = 0, but ∆T1ρH > 0 indicates miscibility on the 6 - 24 nm length scale
• ∆T1ρH = 0 indicates miscibility on the 2 - 6 nm length scale (domains of < 2 nm)
Differences in the relaxation times (∆T1ρ
H and ∆T1
H) of drug and polymer components
have been used previously to provide information on miscibility and domain sizes in
nifedipine/PVP dispersions [46,152] and mefenamic acid/EUDRAGIT® dispersions [86].
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Chapter 5
Variable Temperature Studies of
Indomethacin
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IMC has been extensively studied with a range of characterisation methods, and has been
demonstrated to successfully form amorphous solid dispersions with PVP [71, 77] and
PVP-VA [84]. Here we chose to use IMC as a ’proof of concept’ comparison to other less
studied molecules (flufenamic acid and tolbutamide) with lower Tg values, to illustrate the
capabilities of solid-state NMR methods used to characterise dispersions. Although there is
a large volume of literature surrounding IMC, there is still a lack of information regarding
the mobility of IMC formulated as amorphous dispersions at increased temperatures, and
crystallisation from high drug loaded dispersions.
DSC has been previously used to investigate molecular mobility below Tg: a number of
studies found that IMC experienced significant molecular mobility (α and β relaxation)
at temperatures up to 65 K below Tg [69, 222]. The same group also used DSC to find
evidence of nucleation of α IMC at temperatures 55 K below Tg which provides evidence
for nucleation in the β-relaxation region [223]. Matsumoto et al. [84] studied a variety of
weight ratio IMC/PVP and IMC/PVP-VA dispersions, using DSC and FT-IR to investigate
drug polymer interactions in relation to crystallisation from the amorphous state. They
found that both polymers interacted with IMC through hydrogen bonding, eliminating the
carboxylic dimer interaction required for the nucleation and growth of the γ-crystalline form.
They additionally found that 5 % PVP content prevented crystallisation of IMC at 303 K
over the 20 week storage period. Other studies have used dielectric relaxation spectroscopy
to look at the molecular mobility of supercooled IMC, finding that high molecular mobility of
amorphous IMC was observed below Tg, which was linked to reduced physical stability [150].
The amorphous form of IMC has been found to crystallise from the amorphous state under
storage at 303 K within a few weeks, however inhibition of crystallisation was been observed
for over 6 months when the storage temperature was reduced to 277 K [68], although storage
near refrigeration temperatures is not always practical and room temperature storage would
be more desirable [84]. Apperley et al. [29] characterised the amorphous form using variable
temperature relaxation studies (T1ρ
H and T1
H), variable temperature 13C and 1H MAS
NMR. Karmwar et al. [224] also investigated the effect on the stability of amorphous IMC
of the method of manufacture, finding that recrystallisation was different for each method,
with quench cooled samples ranking as most stable. Carpentier et al. [59] combined dielectric
relaxation spectroscopy with 1H NMR spectroscopy to investigate the molecular mobility of
both the amorphous and crystalline forms (γ and α) of IMC [59].
A handful of solid-state NMR studies have also investigated IMC/PVP solid dispersions.
Guilbaud et al. [77] studied the functional group mobility with and without polymer using
13C and 1H relaxation time measurements, at ambient temperature. They found that solid-
state NMR was able to demonstrate the stabilisation of the amorphous drug by reducing guest
mobility. Brettmann et al. [225] used T1
H and T1ρ
H times to detect miscibility of electrospun
IMC/PVP dispersions at two drug loadings, following storage at 313 K for 6 months, finding
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that the dispersions remained homogenous over this time period. Additionally, Pham et
al. [88] used advanced 2D 1H-13C CP MAS HETeronuclear CORrelation (CP-HETCOR)
and 1H double quantum (DQ) correlation experiments to characterise the structures in terms
of drug/polymer intermolecular interactions; and T1
H times to study phase separation of
the solid dispersions. Again, no phase separation was detected in these systems with this
method.
5.1 Crystalline Indomethacin
Indomethacin is known to exhibit polymorphism, with two monotropic forms (γ and α)
most widely studied within the literature. γ-IMC is the most thermodynamically stable
form under ambient conditions, with a melting point of 432 - 434 K and enthalpy of fusion
(∆Hf) of 109.5 J·g−1 [51]. α-IMC is a frequently occurring metastable form, with a melting
point of 426 - 428 K and ∆Hf of 103.5 J·g−1 [51]. The crystallographic information of both
polymorphs is shown in table 5.1.
Table 5.1: Crystallographic data of γ and α-IMC, adapted from [31,49]
γ α
Crystal system triclinic monoclinic
Space group P-1 P21
a (A˚) 9.295(2) 5.4616(16)
b (A˚) 10.969(1) 25.310(9)
c (A˚) 9.742(1) 18.152(7)
α (°) 69.38(1) 90
β (°) 110.79(1) 94.38(3)
γ (°) 92.78(1) 90n
V (A˚3) 869.8 2501.8
Z/Z’ 2/1 6/3
CSD Code INDMET INDMET02
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Figure 5.1: Crystal structures of γ and α-IMC as viewed along the a axis, extracted from the Cambridge
Structural Database (structure references INDMET and INDMET02). The hydrogen-bonding of both
polymorphs is highlighted
γ and α-IMC exhibit differences in hydrogen bonding in their crystal structures (figure
5.1 and 5.2). The lattice of γ-IMC is stabilised through carboxylic acid hydrogen-bonded
dimers of equivalent molecules in the unit cell, with H-bond length of 1.604 A˚ [31]. The three
asymmetric unit molecules of α-IMC exist as trimers, with two molecules (molecules 1 and 2)
forming a hydrogen-bonded carboxylic acid dimer similar to γ-IMC, but with different length
H-bonds; with an additional bonding motif between the amide carbonyl of the carboxylic
acid dimer (molecule 2) and a carboxylic acid group of an additional molecule (molecule
3). [31].
Figure 5.2: Hydrogen bonding in A) γ-IMC and B) α-IMC [31]
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The ambient temperature 1H-13C CP/MAS NMR spectra of γ and α-IMC are shown in
figure 5.3. Peak splitting patterns of solid-state spectra can provide information regarding
the number of crystallographically non-equivalent molecules within the lattice structure.
For example, γ-IMC has one molecule within the asymmetric unit, therefore single, narrow
peaks are seen in the 13C spectrum [29]. α-IMC can be identified from the 13C spectrum
due to the splitting of each resonance into three [226], representing the positions of the three
non-equivalent molecules in the asymmetric unit [31].
Figure 5.3: Experimental 1H-13C CP/MAS NMR spectra of γ and α-IMC, recorded at an MAS rate of
10 kHz
Borka [50] described four forms of IMC, using a different naming system: Form I (γ), form
II (α), form III (β) and form IV (δ), although the β and δ forms were not further studied
until more recently [51, 53]. Despite IMC being so extensively characterised as a model
drug, new polymorphs are still being discovered. Surwase et al. recently reported three new
polymorphic forms of IMC, named ε (found to be the same form as a previously unnamed
polymorph reported by Lin et al. [227]), ζ and η isolated from amorphous suspensions of
IMC and characterised using PXRD, DSC and FT-IR [52]. From solution concentration
profiles at 273 K, they predicted the stability order to be ε < ζ < η < α. A summary of the
melting points of all described polymorphs is shown in table 5.2.
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Table 5.2: Tm values (K) of Indomethacin polymorphs adapted from [50–53]. * Form ε too unstable for
analysis, transforming to α upon drying; ** Formed via desolvation from methanolate form [53]
Form Tm (K)
α (II) 426 - 428
β (III) 421
γ (I) 432 - 434
δ (IV) ** 407
ε N/A *
ζ 415
η 427
5.2 Initial Characterisation of Amorphous IMC, and
IMC/PVP-VA solid dispersions
Amorphous IMC and IMC/PVP-VA solid dispersions were initially characterised using
modulated DSC, PXRD and 1H-13C CP/MAS NMR. The solid dispersions were confirmed
to be amorphous by the single Tg values (figure 5.4), traditionally taken as an indication of
miscible, single phase systems ( [69]), with domain sizes undetectable at less than 30 nm in
size [164, 165]. Tg values of the dispersions were intermediate between those of pure
amorphous IMC and PVP-VA, as expected from the Gordon-Taylor relationship [112], and
increased with increasing polymer content, indicating the anti-plasticising property of
PVP-VA. This relationship has been demonstrated previously for dispersions of
IMC/PVP [29, 77]. Ideal Tg values of the dispersions were calculated using the
Gordon-Taylor/Kelley-Bueche (G-T/K-B) and Couchman-Karasz (C-K) equations
(equations 2.17 with 2.19 and 2.20 - see chapter 3), and can be seen in figure 5.4.
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Figure 5.4: Glass transition temperatures for IMC/PVP-VA dispersions at different drug loadings,
compared to values predicted by the Gordon-Taylor/Kelley-Bueche (G-T/K-B) and Couchman-Karasz (C-K)
equations
A very slight positive deviation from predicted Tg was observed for the IMC/PVP-VA
dispersions, which was greatest for the mid drug loadings between 40 to 60 wt. %. This
indicates the possible dominance of drug/polymer interactions [192–194]. IMC has been
previously shown to interact with PVP via hydrogen bonds between the IMC hydroxyl and
PVP carbonyl groups [71]. However, the maximum deviation (ca. 6 K), is negligible in this
case. In previous studies, deviations of ± 5 K were considered to be good agreement for
’ideal’ mixing [78]. Examples of positive deviation from predicted values have been
encountered in the literature for solid dispersions: Song et al. [62] found large positive
deviations in dispersions of lapatanib/HPMC-P, with intermediate loadings (40 - 60 wt. %
drug) displaying the largest deviation, with experimental Tg values over 40 K higher than
predicted. This was found to be due to specific ionic interactions between drug and
polymer, additionally detected via 15N solid-state NMR. Gupta et al. [190] additionally
found positive deviation in celecoxib/PVP dispersions, which again was most significant for
intermediate loading dispersions. Considerable deviations are more likely at intermediate
content, as these dispersions experience the greatest difference in free volume of each
component upon mixing.
Amorphous indomethacin was produced via the quench cool method [29,70]. Upon heating,
the Tg was observed at ca. 314 K, which is in agreement with literature Tg values [77]. This
was followed by crystallisation (ca. 378 K) and subsequent melting of α-IMC (425 K) and
γ-IMC (433 K) (figure 5.5). This behaviour is in agreement with previous literature DSC
studies on the crystallisation of amorphous IMC [32].
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Figure 5.5: Modulated DSC curve (heat→ cool→ reheat cycle) for amorphous IMC prepared via quench
cooling
The initial DSC heating cycle of the 80/20 and 70/30 IMC/PVP-VA dispersions indicates
that they appear to contain a small amount of crystalline drug (figure 5.6). The melting
endotherms were not preceded by a crystallisation event, indicating the possible presence of
small seeds of crystalline material upon formulation, which melted at high temperatures.
In previous studies of solid dispersions where two melting endotherms have been identifed,
the lower temperature event is attributed to melting of a drug/polymer solid solution,
formed through the dissolution of drug in the polymer upon heating [90, 148]. The higher
temperature endotherm is thought to occur due to the melting of residual crystalline API
formed during manufacture [190]. The presence of single endotherms in DSC curves of
drug/polymer dispersions has been attributed to either solid solution formation, or
dissolution of the drug in polymer upon heating, [228].
Two melting endotherms are present in the DSC curve of the 80/20 IMC/PVP-VA dispersion.
The higher temperature endotherm at ca. 429 K in the 80/20 dispersion likely indicates the
presence of a small amount of residual α-IMC (Tm = 426 – 428 K [31]). The quantity of
crystalline drug can be approximated according to [229]:
%crystallinity = (
∆Hdisp
∆Hα ×W )× 100 (5.1)
where ∆Hdisp is the enthalpy of fusion of the α-IMC in the dispersion, ∆Hα the enthalpy of
fusion for pure α-IMC and W the weight fraction of API in the dispersion. This equation has
previously been used to quantify the % crystallinity of physical mixtures and solid dispersions
of ibuprofen/PVP-CL and ibuprofen/MCC [229,230].
76
The known melting enthalpy (∆Hf ) of pure α-IMC is 91 J·g−1 [59, 231, 232]. Therefore the
residual content of α-IMC in the 80/20 dispersion is calculated to be 2.1 %. For the 70/30
IMC/PVP-VA dispersion, the small single melting endotherm ca. 410 K is likely due to
dissolution of the drug [90] rather than the presence of residual crystalline IMC.
Figure 5.6: Modulated DSC heat capacity curve of IMC/PVP-VA 80/20 (red) and 70/30 (green)
dispersions with melting peaks highlighted inset, for heat → cool → reheat cycles * ∆Hf calculated from
heat flow vs. temperature curves
PXRD patterns indicated that all dispersions were fully amorphous (figure 5.7). The small
amount of crystalline seeds identified in the DSC curves for the 80/20 and 70/30 dispersions
are therefore below the detection limit of PXRD.
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Figure 5.7: PXRD patterns of all IMC/PVP-VA dispersions
The 1H-13C CP/MAS NMR spectra (figure 5.8) confirm that amorphous IMC was obtained
via quench cooling of IMC melt. The amorphous IMC displays broad 13C resonances
compared to narrow peaks of the crystalline IMC spectra. For example the FWHH of the
CH3 (C-11) peak (ca. 56 ppm) are 104.6 and 367.4 Hz for γ-IMC and amorphous IMC
respectively. Broadening of peaks for amorphous materials is due to the lack of long range
order, leading to a wider range of possible orientations of molecules, and an increased
number of magnetically non-equivalent carbon atoms compared to the well defined
repeating unit cell in crystalline structures. The full assignments of the 13C chemical shifts
of amorphous IMC [70, 77], γ-crystalline IMC [29, 130, 233], α-IMC [130, 226] and
PVP-VA [148] have been reported previously. From figure 5.8 it can also be seen that
amorphous IMC has an additional carbonyl peak at ca. 172 ppm, comparable to 13C
spectrum of α-IMC, which is attributed to an additional H-bonding motif between the
amide carbonyl and carboxylic acid groups [31, 130, 226]. This is in agreement with the IR
and Raman spectroscopic data presented by Taylor and Zographi [71], where two hydrogen
bonding mechanisms in amorphous IMC were demonstrated: 1) carboxylic acid
hydrogen-bonded dimers, similar to γ-IMC, were the dominant mechanism; 2) additional
hydrogen bonding between the carbonyl and carboxylic acid groups, similar to the α-IMC
was also observed.
78
Figure 5.8: Experimental 1H-13C CP/MAS NMR spectra of α-IMC, γ-IMC and amorphous IMC, recorded
at an MAS rate of 10 kHz
Figure 5.9 and table 5.3 show the assignment of chemical shifts to IMC, PVP-VA, or both
drug and polymer within the IMC/PVPVA 40/60 dispersion. The main 13C peaks of IMC
affected by overlapping with PVP-VA are the carbonyl resonances (C-10, C-13) masked
by the lines from the carbonyl polymer peaks (C-D, C-I) and the IMC CH2 group (C-
9) masked by aliphatic polymer chain carbons (C-G, C-H). However, all aromatic peaks
of IMC are unaffected by the PVP-VA. This peak separation allowed us to independently
monitor changes to both components of the dispersion during variable temperature NMR
investigations. The carbonyl region also provided additional information about changes in
H-bonding during phase transitions and recrystallization.
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Figure 5.9: 1H-13C CP/MAS NMR spectra with full peak assignments for IMC/PVP-VA 40/60 solid
dispersion compared to amorphous IMC and PVP-VA recorded at an MAS rate of 10 kHz
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Table 5.3: 13C Chemical Shift Assignments of IMC and PVP-VA (based on the 40/60 IMC/PVP-VA
dispersion)
Chemical Shift (ppm) IMC PVP-VA
175.9 10 I
171.3 13 D
156.8 5
131.7 1,3,8, 14-19
115.0 - 107.2 2,6,7
101.5 4
68.0 G
56.2 11
42.9 A,E
36.9 F
32.0 9 G,H
21.4 J
19.2 B
13.8 12
The change in the intensities of the drug/polymer peaks in the 1H-13C CP/MAS NMR
spectra reflect the ratio of the two components within each dispersion (figure 5.10). For the
dispersions with the highest drug loading (80/20 and 70/30) an additional carbonyl shoulder
peak at ca. 172 ppm is present, likely due to hydrogen bonding between the amide carbonyl
and a carboxylic acid, as seen in amorphous and α-IMC [31, 71]. This could be due to the
presence of increased IMC/IMC over IMC/PVP-VA interactions at high drug loading, or
could indicate the presence of a small amount of α-IMC, identified in the 80/20 dispersion
through DSC.
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Figure 5.10: 1H-13C CP/MAS NMR spectra for amorphous dispersions of various drug loadings, recorded
at an MAS rate of 10 kHz
5.2.1 Correlating local mobility with chemical structure using WIdeline
SEparation (WISE) NMR
WIdeline SEparation (WISE) experiments in solid-state NMR are used to correlate
information on local mobility with chemical structure [198, 234]. The 2D 1H-13C WISE
spectrum shows the 1H wideline spectral patterns associated with each of the 13C chemical
shifts. The widths of 1H are indicative of the strength of 1H-1H homonuclear dipolar
coupling, with more rigid structures displaying wider lines in the WISE projections. WISE
NMR was originally developed to correlate structure and mobility during characterisation
of poly(styrene)-poly(siloxane) polymer blends [234] and has since been utilised to
investigate local mobility of a variety of co-block polymers [235,236], biopolymers [198] and
encapulation of an amorphous decapeptide in PLGA [202].
The WISE spectra and measured FWHHs of amorphous IMC, PVP-VA and dispersions
with drug loadings of 20, 40 and 80 wt. % are shown in table 5.4 and figure 5.11. In the
mid-loading dispersion (40/60), the FWHH of IMC and PVP-VA are similar to those
measured for the individual components, suggesting formulation at this drug/polymer ratio
has little effect on the local mobility of amorphous IMC and PVP-VA. The mixing of
similar wt. ratios of drug and polymer therefore does not seem to disrupt the 1H-1H
dipolar coupling network of either component. However, in formulations where the content
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of one component is much greater than the other, we see changes in local mobility. With
excess IMC (80/20 IMC/PVP-VA dispersion), the local mobility of the drug is unaffected,
but narrowing of the polymer peaks is observed, indicating an increased local mobility of
the polymeric matrix. Enhanced local mobility of polymer was previously reported by
Guilbaud et al. [202] with higher drug content of AZD/PLGA formulations. With excess
PVP-VA (20/80 IMC/PVP-VA dispersion), broadening of drug and polymer widelines are
observed, indicating a restriction of overall local mobility and an increase in 1H-1H dipolar
coupling for both components of the dispersion. The carbonyl widelines (13C δ = 176 and
171 ppm) provide information on the overall strength of the dipolar coupling in the system,
as carbonyl functionalities do not have directly attached protons. The broadening of these
widelines in the 20/80 dispersion indicates a change to the local proton population, in
comparison with pure PVP-VA, and could be an indication of interactions between drug
and polymer [237].
Table 5.4: 1H full width half height (FWHH) in Hz of the main 13C chemical shifts of amorphous IMC,
PVP-VA and 20/80, 40/60 and 80/20 IMC/PVP-VA dispersions, extracted from wideline spectral patterns
of WISE spectra at 293 K. Assignment of I = IMC peak; P = PVP-VA peak; – unable to measure FWHH
due to low intensity peak
Assignment 13C (ppm) FWHH (Hz)
Amorphous 80/20 40/60 20/80 PVP-VA
I and P 176 – 627 788 1183 874
I and P 171 – 552 636 1082 633
I 131 679 684 676 1104
I 115 758 762 743 1047
P 43 – 1001 1527 1186
P 32 975 1073 1450 1140
P 21 652 627 1102 879
P 19 663 756 1295 778
I 13 628 629 648 1159
The WISE spectra highlighted differences in local mobility of IMC and PVP-VA dependent
on drug loading levels upon formulation of amorphous solid dispersions. These changes will
be further investigated with variable temperature solid-state NMR techniques.
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Figure 5.11: 1H-13C WISE NMR spectra (1D and 2D projections) for A) Amorphous IMC, B) 20/80
IMC/PVP-VA, C) 40/60 IMC/PVP-VA, D) 80/20 IMC/PVP-VA and E) PVP-VA
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5.3 Variable temperature NMR studies of IMC
1H-13C CP/MAS NMR spectra of amorphous IMC and the IMC/PVPVA dispersions were
acquired across a range of temperatures to probe their stability by monitoring crystallisation
and changes in mobility.
5.3.1 Detection of crystallisation at high temperatures
Crystallisation was investigated by monitoring changes in 13C spectra with increasing
temperature, above and below Tg, as changes in mobility around and below Tg have been
linked with changes in physical stability. It was thought previously that storing an
amorphous material at the Kautzmann temperature (Tg – 50 K) would be sufficient to
indefinitely stabilise it [69]. However, studies have shown that changes in mobility can
occur, leading to instability, even at very low temperatures [123].
When amorphous IMC was heated from 298 to 373 K the 13C CP/MAS NMR spectra
indicated the onset of crystallisation by 353 K, well above the Tg of 315 K (figure 5.12). The
peaks became narrower and more defined with increasing temperature, and with chemical
shifts and splitting characteristic of the α-polymorph [31, 130]. Detailed comparison of the
spectra indicates full crystallisation of the amorphous IMC at temperatures above 353 K.
There were no changes observed in the spectra around and below the Tg. A comparison of
the spectra upon cooling highlights that α-IMC was still present, indicating a permanent
crystallisation event from amorphous to α-IMC occurred.
85
Figure 5.12: 1H-13C CP/MAS NMR spectra of amorphous IMC recorded at different temperatures
between 293 K and 373 K, with comparison spectrum of α-IMC (373 K), at an MAS rate of 10 kHz
This extends work by Apperley et al. [29], who heated amorphous IMC to 353 K under
MAS conditions, but found the results ‘relatively uninformative’ with some line narrowing
around 343 K and increased resolution at 353 K but with no specific polymorph identified
[29, 238]. Upon cooling, their sample appeared more amorphous than crystalline, therefore
line narrowing was attributed to increased molecular mobility rather than recrystallisation
[238].
In our case, the crystallization above Tg is in agreement with previous stability studies of
amorphous IMC. Yoshioka et al. [68] found that crystallisation to the more stable γ-form
occurred at storage temperatures below Tg, but at higher temperatures (above Tg)
crystallisation to the metastable α-form predominated. Andronis and Zographi [32] further
studied the polymorphic phase selectivity of IMC and found that the α-polymorph was
more likely to crystallise at higher temperatures due to a lower free energy difference
between crystalline and amorphous forms (∆Gv), faster nucleation and growth rate, and
lower activation energy of crystallisation compared to the γ-polymorph at elevated
temperatures (figure 5.13). At 353 K, where we observed crystallisation from amorphous
IMC to the α-form, the activation energy of crystallisation for α-IMC is lower than that for
the γ-polymorph. These findings were in agreement with Stranski’s proposal that at a
specific temperature, the nucleated phase will be the phase with the lowest free energy
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barrier of formation. Crystallisation to γ-IMC, occurred at lower temperatures,
particularly around Tg, where γ-IMC has a lower activation energy for recrystallization.
Figure 5.13: Energy-temperature diagram to summarise activation energies for: free energy barrier to
nucleation (∆G) of α and γ-IMC; and viscosity of dry amorphous IMC (dotted line), adapted from [32]
The crystallisation of amorphous IMC (prepared via melt quench) to different polymorphs
has been studied under a variety of conditions. In addition to high temperature heating, the
metastable α-polymorph was found to recrystallise preferentially at high humidity (above 43
% RH) [124], under dissolution conditions (phosphate buffer at 37 ◦C, and a water-ethanol
(50 % w/w) solution) from amorphous IMC moulded into compacts during the melt quench
process [73, 239]; and from amorphous suspensions in 0.1 M aqueous media at 298 K [52].
As discussed above, the room temperature 13C NMR spectra of both amorphous IMC and
α-IMC contained an additional carbonyl shoulder peak, attributed to H-bonding motifs
between -COOH and –N-C=O groups [31]. This could be an indication that the H-bonding
within the amorphous system is similar to the α-polymorph, with an extra H-bond occurring
between amide and carboxyl carbonyl groups.
The variable temperature 1H-13C CP/MAS NMR spectra of PVP-VA (data not shown)
showed no major changes with regards to chemical shifts and line widths, but some loss of
intensity was observed for the peaks at 17, 42 and 19 ppm indicating a slight increase in
mobility leading to loss of CP signal. The carbonyl peak was still present in the spectrum
after heating and cooling, confirming chemical stability.
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5.3.2 Detection of changes in mobility of IMC/PVP-VA dispersions at
high temperatures using 13C VT NMR
The IMC/PVP-VA dispersions proved an excellent system to probe mobility by evaluating
the loss of signal intensity and line broadening with increasing temperature (outlined in
chapter 4), due to separation of drug and polymer peaks.
The VT 13C NMR spectra for IMC/PVP-VA 20/80 dispersion (figure 5.14 A) and 30/70
dispersion (data not shown) illustrate changes in mobility of the dispersions. The CP
spectra show loss of signal intensity of the IMC peaks (especially the aromatic peaks at ca.
131.7 and 115.0 ppm) with increasing temperature up to 373 K. This indicates an increased
mobility of the drug within the dispersion on an intermediate timescale, affecting C-H
dipolar interactions during the CP transfer step. This effect was especially pronounced
above the Tg of 367 K. The mobility on this timescale is likely to be dominated by the
chlorobenzyl aromatic ring of IMC, as a previous study on the motions of amorphous IMC
highlighted this functional group as being crucial for changes in local mobility [59];
although we did see loss of signal intensity across all IMC peaks. The carbonyl resonance
at 171 ppm (IMC: C-13 and PVP-VA: C-D) also showed a loss of signal intensity, likely
from the drug contribution to these overlapping peaks. There was little change in the
polymer peaks on heating, indicating its lower mobility in comparison to the drug on the
observed timescale. There were no significant changes to the 1H-13C CP/MAS spectra
recorded at 293 K before and after heating to 373 K.
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Figure 5.14: A) 1H-13C CP/MAS NMR spectra of IMC/PVP-VA 20/80 dispersions recorded at different
temperatures between 293 and 373 K, and upon cooling back to 293 K (red spectrum); B) 13C{1H} MAS
NMR spectra of IMC/PVP-VA 20/80 dispersions recorded at 293 and 373 K, with FWHH values (Hz) for
the main resonances
There is no significant change to the FWHH or intensity for all resonances in the 13C{1H}
spectra of the 20/80 dispersion with increasing temperature (figure 5.14 B). This indicates
that the observed mobility of IMC is on the intermediate timescale, but is not fast enough
to affect the efficiency of the heteronuclear decoupling of the 1H-13C CP/MAS or 13C{1H}
MAS NMR experiments.
The VT CP/MAS spectra for the IMC/PVP-VA 40/60 dispersion (figure 5.15) showed no
major changes to either the drug or polymer peaks upon heating to 373 K and subsequent
cooling to 293 K. This suggests that both drug and polymer components have similar lower
mobility than that observed for the drug component of the 20/80 dispersion, even above the
Tg of 353 K. This indicates the presence of a homogenous system with restricted mobility
on a kHz timescale. The miscibility of the mid-loaded dispersions is further demonstrated
in section 5.4. The lower mobility of the 40/60 and 50/50 dispersions could possibly be due
to steric hindrance within the system. This has been previously demonstrated in polymer
systems, where Takegoshi et al. [26] found that at ratios of 50/50 PS/PVME copolymer
blends, the freedom of local motion of one component was restricted by steric hindrance of
the other. A previous study by our group also found that at a certain drug/polymer ratio, no
change in line broadening with increasing temperature indicated a more rigid system [202].
The increased number of drug/polymer hydrogen bonding sites within the 40/60 and 50/50
solid dispersions could also contribute to the decreased mobility of the systems, compared
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to the lower concentration solid dispersions [180].
Figure 5.15: 1H-13C CP/MAS NMR spectra of IMC/PVP-VA 40/60 dispersion recorded at different
temperatures between 293 K and 373 K, and upon cooling back to 293 K (red spectrum), at an MAS rate of
10 kHz. Similar results were observed for the 50/50 dispersion (data not shown)
Further analysis of the 1H-13C CP/MAS NMR spectra suggests that for the 20/80 dispersion,
the area of the main drug peak (ca. 131 ppm) at 373 K is 54 % of the same peak at 298 K
for the 20/80 dispersion (figure 5.16); compared to only a 12 % reduction in peak area for
the 40/60 dispersion. For the main polymer peak (ca. 42 - 31 ppm) there is no change in
peak area with increasing temperature across all dispersions.
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Figure 5.16: Changes in peak area of the CP/MAS spectra for A) IMC/PVP-VA 20/80 and 30/70
dispersions with increasing temperature and B) 40/60 and 50/50 dispersions. Integrals of the predominant
drug (ca. 131 ppm) and polymer (ca. 42 - 31 ppm) resonances are shown. Percentages were calculated by
determining the reduction in integral values at each temperature compared to the initial measurement at 293
K, using Topspin analysis software
The VT 1H-13C CP/MAS NMR spectra for IMC/PVP-VA 60/40 dispersion (figure 5.17)
illustrate changes in mobility with increasing temperature. Upon heating from 293 to 353
K, there were no major changes to either the drug or polymer peaks. However at 373 K, we
see significantly broadened 13C signals, which is particularly obvious for the aromatic IMC
signals at ca. 131 and 115 ppm. This indicates a large increase in mobility on the intermediate
timescale, of both drug and polymer in the dispersion, ca. 35 K above the Tg of 339 K. The
drug and polymer signals were all visible in the 13C{1H} spectrum at 373 K (figure 5.17 -
green spectrum), but significant broadening was also observed. This indicates both drug and
polymer are mobile at higher kHz frequencies (ca. 90 kHz) than the 20/80 dispersion at the
same temperature, therefore modulating the heteronuclear decoupling of both the 1H-13C
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CP/MAS and 13C{1H} MAS NMR pulse sequences. There were no significant changes to
the 1H-13C CP/MAS spectra recorded at 293 K before and after heating to 373 K (figure
5.17 - red spectrum).
Figure 5.17: 1H-13C CP/MAS NMR spectra of 60/40 IMC/PVP-VA dispersion recorded at different
temperatures between 293 and 373 K, at an MAS rate of 10 kHz
An increased level of the drug (IMC/PVP-VA 80/20 dispersion) lead to another change
in mobility regime. As the 80/20 dispersion was heated through the Tg (ca. 325 K), two
different motional phenomena were detected (figure 5.18 - 333 K). Significant line broadening
and loss of signal intensity occurred for the main aromatic IMC peaks (ca. 115, 131, 138, 156
ppm), with FWHH at 131 ppm increasing from 470 Hz to 998 Hz, indicating an increase in
molecular motions on the intermediate timescale. Additionally line narrowing of the methyl
groups of both drug and polymer (ca. 13 ppm (IMC: C-12), 19 ppm (PVP-VA: C-B), and 56
ppm (IMC: C-11)) occurred, indicating increased mobility on a faster timescale [26,28]. The
changes in mobility at ca. 333 K are likely due to the reorganisation and phase separation
of the drug molecules within the polymer during the initial stages of IMC crystallisation.
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Figure 5.18: 1H-13C CP/MAS NMR spectra of amorphous IMC recorded at different temperatures
between 293 and 373 K, at an MAS rate of 10 kHz. A comparison of pure α-IMC at 373 K is included for
comparison
At temperatures of 353 K and above, apparent crystallisation to the α-polymorph was
observed, identified in the spectra by the characteristic peak splitting [31, 130], which is in
agreement with DSC results. Increasing temperature resulted in the absence of all PVP-VA
resonances in the spectra, either through loss of signal intensity, or through dramatic line
broadening effects. The higher mobility of the polymer compared to drug at high
temperatures indicates a possible phase separation, which is further explored in section 5.4.
The 1H-13C CP/MAS NMR spectrum of pure α-IMC has been shown to exhibit temperature
dependence: with increasing temperatures (up to 343 K), Masuda et al. reported downfield
shifts of resonances for C-5, C-11 and C-12 due to movement of the methoxy and methyl side
groups [226]. Here we observe the same temperature dependence of α-IMC present within
the 80/20 dispersion (figure 5.19). At 373 K, slight downfield shifts of a number of carbon
resonances occurred, with the spectrum of the 80/20 dispersion comparable to that of pure
α-IMC at the same temperature. This provides strong evidence for the crystallisation of
amorphous IMC to the α-polymorph, which is the expected polymorphic transition from
amorphous IMC above Tg [68]. We also observed one upfield shift of a carbonyl group of
IMC (C-10) in both pure α-IMC and the 80/20 dispersion at 373 K, which was not discussed
in previous literature, and may be due to the presence of hydrogen bonding between drug
and polymer.
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Figure 5.19: 1H-13C CP/MAS NMR spectra for 80/20 dispersion and α-IMC at 373 K: zoomed in on
the C-10 carbonyl (ca. 179.8 - 180.7 ppm), C-5 aromatic (ca. 157.9 - 155.7 ppm), C-11 methoxy (ca. 54.4 -
52.7 ppm) and C-12 methyl (ca. 13.9 - 12.3 ppm) regions, with a comparison to α-IMC at 293 K to highlight
chemical shift differences at high temperatures. Line broadening = 20 Hz
Following heating to 373 K, the 80/20 dispersion was cooled gradually to 293 K within the
rotor (figure 5.20). Slight broadening of the IMC peak at ca. 115 ppm (aromatic C-2,6,7)
was observed but the majority of IMC peaks could still be assigned to α-IMC, suggesting
a permanent crystallisation from amorphous to α-IMC at high temperatures. The polymer
peaks reappeared upon cooling, due to reduction of polymer mobility (figure 5.18).
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Figure 5.20: 1H-13C CP/MAS NMR spectra for 80/20 dispersion before and after heating, compared
to α-IMC. Purple dashed lines indicate the presence of α-IMC, with the orange dashed line ca. 115 ppm
indicating amorphous IMC. Line broadening = 20 Hz
5.3.3 Detection of changes in the mobility of IMC/PVP-VA dispersions
at high temperatures with VT 1H MAS NMR
To investigate the mobility of the IMC/PVPVA dispersions further, variable temperature
1H NMR studies were carried out. 1H solid-state NMR is very sensitive to molecular
motions, where fast molecular mobility leads to line narrowing within the spectra, as
discussed in chapter 4. Although it is harder to distinguish between drug and polymer
peaks, increased mobility can become very obvious through monitoring the change in
linewidth with increasing temperature. The VT 1H MAS NMR spectra show differences in
the mobility of the dispersions dependent on drug content: higher IMC content lead to
narrower resonances with increasing temperature indicating an increase in fast molecular
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motions ca. 373 K (figures 5.21 and 5.22). Only small changes in resolution and chemical
shift values occurred for the 20/80 and 40/60 dispersions with increasing temperature,
indicating a lower mobility. The broad 1H peaks are dominated by the strong 1H-1H
dipolar interactions of drug and polymer. The VT 1H spectra of the 60/40 dispersion
showed some increased mobility by 373 K, which was also seen in the VT 1H-13C CP/MAS
NMR spectrum at the same temperature. For the 80/20 dispersion a dramatic reduction in
linewidth occurred, with peaks of much higher resolution observed ca. 373 K.
Figure 5.21: Variable temperature 1H MAS NMR spectra for A) 20/80, B) 40/60, C) 60/40 and D)
80/20 IMC/PVP-VA dispersions, measured at an MAS rate of 10 kHz, between 293 and 373 K
The 80/20 and 60/40 dispersions at 373 K have comparable chemical shifts values, with
the 80/20 dispersion displaying increased peak resolution (figure 5.22 A)), indicating the
formation of a similar chemical environment ca. 373 K. Resonances for all IMC protons
can be identified in the 80/20 dispersion, indicating the presence of a highly dynamic state.
The broader peaks seen at 373 K in the 60/40 dispersion represent a less mobile state, with
incomplete averaging of homonuclear dipolar interactions between protons.
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Figure 5.22: A) High temperature (373 K) 1H MAS NMR spectra for 80/20 and 60/40 IMC/PVP-VA
dispersions (MAS = 10 kHz) with full chemical shift assignment; B) Solution-state 1H spectra (295 K) for
different IMC/PVP-VA dispersions and IMC alone dissolved in CD3OD (0.05 M)
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Assignment of the 1H peaks was based on the integral and J-coupling values of the solution-
state 1H NMR spectrum (figure 5.22 B), alongside previous literature assignments of IMC
[240,241]. There is an upfield shift (between 0.1 and 0.4 ppm) for the majority of 1H signals
of the 80/20 dispersion at 373 K from the solution to the solid state (table 5.5). In the
solution state, the PVP-VA protons are only visible in a small broad peak at ca. 1.9 ppm,
due to the high molecular weight, but this still allows identification of the polymer within
the dispersion in the solid state at high temperature. The additional 1H peak at ca. 9.6 ppm
(80/20) and 11.3 ppm (60/40) indicates the presence of hydrogen bonding within the system.
The lack of 1H resonances in the hydrogen bonding region of the solution-state spectrum
indicates the absence of bonding interactions in solution.
Table 5.5: Solution and solid-state experimental 1H chemical shifts for IMC and PVP-VA. Solution-
state taken from IMC/PVP-VA 40/60 dissolved in CD3OD at 0.05 M (298 K) and solid-state from 80/20
IMC/PVP-VA dispersion at 373 K, MAS = 10 kHz
1H δ (ppm) Solution at 298 K δ (ppm) MAS at 373 K ∆δ (ppm)
multiplicity J-coupling (Hz)
12,15 7.6 (d) 8.5 7.3 0.3
13,14 7.5 (d) 8.3 7.1 0.4
1 6.9 (d) 2.4 6.8 0.1
3 6.8 (d) 9.1 6.8 0.0
2 6.6 (dd) 2.6, 9.1 6.4 0.2
4,5,6 3.7 (s) – 3.4 0.3
7,8 3.6 (s) – 3.4 0.2
9,10,11 2.2 (s) – 2.0 0.2
PVP-VA 1.9 – 1.7 0.2
Apperley et al. [29] carried out static VT 1H experiments on amorphous indomethacin.
They showed significant narrowing of the 1H peaks with increasing temperature, attributed
to increased molecular mobility averaging out 1H-1H dipolar interactions. At ca. 383 K,
the indomethacin peaks broadened again, due to the reduced molecular mobility associated
with a recrystallisation event [29]. Carpentier et al. [59] studied pure amorphous IMC via
VT 1H MAS NMR. They also observed line narrowing due to fast molecular motion (> 1000
kHz - chapter 4) averaging dipolar interactions at temperatures higher than Tg - this effect
was attributed to a cooperative motion identified with dielectric relaxation spectroscopy. At
ca. 403 K, a broad component to the curve due to recrystallisation to the α-polymorph was
detected. Subsequently, this component disappeared at 420 K, close to the Tm of α-IMC [59].
In contrast to the measurements carried out for pure amorphous IMC, we did not observe a
subsequent broadening in the 1H MAS spectrum for the 80/20 dispersion at 373 K, despite
seeing strong evidence for the crystallisation of α-IMC in the 1H-13C CP/MAS spectra. Our
observations therefore indicate that the 1H MAS NMR spectrum of the dispersions at high
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temperature is dominated by an additional mobile phase, possibly containing amorphous
IMC and polymer, which cannot be detected at high temperature using 1H-13C CP/MAS
NMR. We can postulate that the α-IMC detected at 373 K within the 80/20 dispersion, is
due to small crystallites formed within a mobile polymer environment, which remain in the
dispersion upon cooling.
5.3.4 Effect of solvent on crystallisation of high drug loaded dispersions
The dispersions discussed so far were formulated via solvent evaporation with methanol.
To investigate the effect of solvent on crystallisation behaviour from high drug loaded
dispersions, 80/20 dispersions were additionally formulated using ethanol and acetonitrile.
In section 5.3.2, we demonstrated that amorphous IMC crystalllised to α-IMC in the 80/20
dispersion formulated via solvent evaporation from methanol. Upon preparation from
acetonitrile, the same behaviour was observed, with α-IMC crystallising from amorphous
IMC in the 80/20 dispersion ca. 333 K (figure 5.23 A)). The 80/20 dispersion prepared
from ethanol displayed different crystallisation behaviour: γ-IMC formed from the
amorphous component of the dispersion, again ca. 333 K (figure 5.23 B)). High polymer
mobility was observed at temperatures ≥ 353 K in both dispersions, which is comparable
to the original 80/20 dispersion (formulated from methanol). Upon cooling back to 293 K,
crystalline material was detected in both dispersions (80/20 from acetonitrile and ethanol),
indicating permanent crystallisation of α and γ-IMC respectively.
These results are in agreement with literature surrounding IMC crystal growth in solution,
assuming behaviour from supersaturated solutions. Slavin et al. [33], Okumura et al. [35]
and Lohani et al. [34,242] undertook a number of studies on the crystallisation of IMC from a
wide range of solvents and found that the resulting polymorphic form of IMC was dependent
on the nature of the solvent, degree of supersaturation and temperature. The expected
crystallisation outcomes for IMC in methanol, ethanol and acetonitrile are summarised in
figure 5.24). Additionally, in the solid state, amorphous indomethacin has been found to
recrystallise to the γ polymorph at temperatures below Tg and the α polymorph above
Tg [68].
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Figure 5.23: 1H-13C CP/MAS NMR spectra of IMC/PVPVA 80/20 dispersion prepared via solvent
evaporation of A) acetonitrile (comparison to α-IMC) and B) ethanol (comparison to γ-IMC). Recorded at
temperatures between 293 and 373K and upon subsequent cooling to 293K (MAS = 10 kHz)
α-IMC was the expected polymorph to crystallise from methanol and acetonitrile at high
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supersaturation, with crystallisation of γ-IMC occurring from ethanol solutions at low
supersaturation. However, Okumura et al. found that at room temperature and pressure
(RTP), in supersaturated solutions of IMC dissolved in ethanol, the α polymorph was
formed, but at higher temperatures the γ polymorph was obtained [35].Therefore, if we
assume behaviour from supersaturated solutions, we see the expected outcome from
methanol and acetonitrile of α-IMC. It is possible that the temperature effect is dominant,
therefore γ-IMC is formed, as described by Okumura [35] .
Figure 5.24: Summary of concentration dependent crystallisation outcome from methanol, ethanol and
acetonitrile solutions [33–35]
5.4 Probing miscibility and dynamics of IMC/PVP-VA
dispersions with spin-lattice relaxation
5.4.1 Detection of miscibility at ambient temperatures
The detection of miscibility of solid dispersions is a vital part of formulation development,
as successful production of miscible drug/polymer amorphous dispersions is crucial for
maintaining acceptable physical stability during manufacture and storage of
pharmaceuticals [62,108]. The miscibility of solid dispersions has traditionally been studied
using DSC, where a single Tg value is thought to indicate molecular level
homogeneity [78, 106, 108, 163], with a detection limit of 20-30 nm [46, 164–166], although
this can often be misleading [108]. The use of spin-lattice relaxation times (T1ρ
H and T1
H)
in the solid-state has proven to be extremely useful in providing additional information
about the miscibility and phase separation of solid dispersions, with differences in T1ρ
H
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times allowing estimation of much smaller domains than with DSC; with a demonstrated
detection down to ca. 2 nm in size [46,62,88]
Differences in the relaxation times ((∆T1ρ
H and ∆T1
H)) of drug and polymer components
have been used previously to provide information on miscibility and domain sizes in
nifedipine/PVP dispersions [46] (see chapter 4 for detailed explanation). Domain sizes can
be estimated as follows [46,152]:
• ∆T1H > 0 indicates domains of > 55 nm
• ∆T1H = 0, but ∆T1ρH > 0 indicates miscibility on the 6 - 24 nm length scale
• ∆T1ρH = 0 indicates miscibility on the 2 - 6 nm length scale
This analysis is based upon the process of spin diffusion within a solid-state sample. Within
a homogenous system, common relaxation times will be observed across all sites, due to
efficient magnetization transfer via. 1H-1H spin diffusion [36,46].
Small ∆T1ρ
H values for the 20/80, 40/40 and 60/40 dispersions (figure 5.25) indicate
miscibility on the 2 - 6 nm length scale at 293 K. The 80/20 dispersion showed a larger
∆T1ρ
H , but small ∆T1
H , which indicates immiscibility on the 2 - 6 nm scale, but
miscibility on the 6 - 24 nm length scale. For the investigation of the miscibility of
nifedipine-PVP solid dispersions, Yuan et al. found that dispersions with drug
compositions of 25, 40 and 50 wt. % were miscible on a 2 – 6 nm scale, but that
dispersions with higher drug content (95 and 90 wt. %) were immiscible on this length
scale and borderline miscible on 24 - 55 nm scale [46].
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Figure 5.25: ∆T1ρH between IMC and PVP-VA of 20/80, 40/60 60/40 and 80/20 IMC/PVP-VA
dispersions. T1ρ
H values were averaged out for all the non-overlapping 13C peaks at 168, 156, 131 and
115 ppm of the drug; and at 171, 68, 43, 37 and 21 ppm for the polymer. These chemical shifts correspond
to drug and polymer in the spectra of the amorphous dispersions; and ∆T1
H of 40/60 and 80/20 dispersions
at 293 K, displayed as a function of wt. % drug content
5.4.2 Variable temperature relaxation studies
Investigating the temperature dependence of relaxation times provides invaluable information
about the mobility and dynamics of a system, as outlined in chapter 4. The temperature
dependences of T1ρ
H times for crystalline γ-IMC and α-IMC, amorphous IMC, PVP-VA and
the IMC/PVP-VA dispersions were determined. Activation energies were calculated using
equation 4.1 (chapter 4).
The T1ρ
H measurements of γ-IMC displayed a clear minimum at 293 K with an activation
energy of 42.2 kJ mol−1 (between 293 and 333 K) (figure 5.26). This shows typical Arrhenius
behaviour (analogous with figure 4.8, chapter 4). This was in agreement with the literature
where γ-IMC was found to have a T1ρ
H minimum at 291 K, with an activation energy for
the same regime of 37.7 kJ mol−1 [29], or 42 kJ mol−1 [59]. Carpentier et al. [59] attributed
the T1ρ
H minimum to a relaxation process due to the rotation of the chlorobenzyl group, as
the value of EA was of the same order of magnitude for the similar motions responsible for
other structural transformations in aromatic ring systems of β-estradiol [243].
The T1ρ
H times for the metastable α-polymorph were too long to be measured accurately
(> 70 ms) across the full temperature range. The difference in T1ρ
H times of α and γ-IMC
across a wide temperature range indicates a significant difference in mobility between the
two structures.
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Figure 5.26: Temperature dependence of T1ρH time for γ-IMC (for each 13C site). Activation energy
calculated from average values at each temperature point, between 293 and 333 K
Carpentier et al. [59] also reported a difference in T1ρ relaxation of α and γ polymorphs,
determining that the lack of a minimum in the α-IMC relaxation curve was due to restricted
rotation of the chlorobenzyl ring. This was calculated as being a forbidden motion, which
was attributed to the additional hydrogen bond (between the carboxylic acid hydroxyl and
carbonyl of an amide group) in the more restricted crystal structure (figure 5.27). VT T1
studies additionally highlighted steric hindrance within the α-IMC structure .
Figure 5.27: Crystal structures of γ and α-IMC, highlighting the differences in hydrogen bonding resulting
in the restriction of the chlorbenzoyl ring in the α-IMC crystal structure (yellow box)
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The T1ρ
H times of the dispersions, amorphous IMC and PVP-VA did not display the
expected minima across the studied temperature range. For our systems of study, the
following was generally observed with increasing temperature: Firstly, a slow increase of
T1ρ
H up to a maximum point, TMAX , followed by a change in relaxation behaviour, with a
dramatic decrease in T1ρ
H . TMAX was below Tg for all systems.
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Figure 5.28: Temperature dependence of T1ρH time for different 13C sites for A) IMC PVPVA 20/80
dispersion B) IMC PVPVA 40/60 dispersion, C) IMC PVPVA 60/40 dispersion, D) IMC PVPVA 80/20
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The 40/60 IMC/PVP-VA dispersion was analysed across the widest temperature range.
From this detailed temperature dependence curve (figure 5.28 B)), a number of observations
can be highlighted. Firstly, across all temperature points, T1ρ
H times for both drug and
polymer were similar, and displayed the same temperature dependence. This indicates we
have a homogenous dispersion, due to efficient spin diffusion (see chapter 4 for detailed
explanation), which supports the findings of the VT 1H-13C CP/MAS NMR data (section
5.3.2). There are three main components to the temperature dependence of the T1ρ
H times
of the 40/60 dispersion. Initially, at the lowest temperatures (253 – 283 K), there was little
change in T1ρ
H , which could indicate the presence of a minimum just outside the temperature
range studied. This was followed by an increase in T1ρ
H times with increasing temperature
(283 – 313 K) up to TMAX , with an associated EA of 24.0 kJ mol
−1. This indicates a
motional regime on the fast side of a T1ρ
H minimum. Finally at temperatures above the
TMAX , a marked change of gradient occurred, seen by a rapid decrease in T1ρ
H times with
increasing temperature with an EA of 55.7 kJ mol
−1.
The T1ρ
H times of the 60/40 IMC/PVP-VA dispersion (figure 5.28 C) displayed a very
similar temperature dependence curve. There was little change in T1ρ
H times at the lowest
temperatures, followed by an increase in T1ρ
H times up to TMAX (EA = 26.6 kJ mol
−1),
then a more rapid decrease in T1ρ
H times with increasing temperature EA = 65.9 kJ mol
−1).
The T1ρ
H vs. T curve of the 20/80 dispersion was again similar (figure 5.28 A), but showed
only two components: an initial gradual increase in T1ρ
H up to TMAX (EA = 8.7 kJ mol
−1),
followed by a more dramatic decrease in T1ρ
H times with increasing temperature (EA = 35.3
kJ mol−1). Both the dispersions were homogenous, confirmed by similar T1ρH times across
all carbon sites. At the higher temperatures, the curve for the 20/80 dispersion shows only
the T1ρ
H times of the polymer, due to reduced intensity of drug peaks on the CP/MAS
NMR spectra.
The temperature dependence curve of the highest drug loading dispersion (80/20), provided
additional information regarding crystallisation (figure 5.28 D). A temperature dependence
similar to the lower loaded dispersions was observed until ca. 343 K, but with a larger spread
of T1ρ
H times across all 13C sites. At 343 K, a clear separation of drug and polymer T1ρ
H
times is detected - IMC peaks displaying a marked increase in T1ρ
H times, whilst the T1ρ
H
times of the polymer peaks continued to decrease. The separation of T1ρ
H times occurred
at the point of crystallisation of the amorphous form to α-IMC, which was previously shown
through VT 1H-13C CP/MAS NMR (figure 5.18). At temperatures above 343 K, no T1ρ
H
times could be calculated, as the polymer peaks lost intensity in the CP/MAS spectra due to
increased mobility, whilst the T1ρ
H times of the drug peaks became too long to be measured
accurately. At 343 K, the T1ρ
H times for the drug peaks are much longer than those for
the polymer, but still faster than for pure α-IMC (> 70 ms), indicating the formation of
an intermediate IMC phase, which resembles the α-polymorph, but is still influenced by the
presence of the polymer within the dispersion.
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This can be explained (simply) as follows [36]: Pure α-IMC has very long T1ρ
H times, due
to a lack of mobility to transfer magnetization (as energy) to the surrounding environment.
Within the 80/20 dispersion at high temperatures, the highly mobile regions of PVP-VA
relax quicker than the IMC, seen in the measured short T1ρ
H times, and also through loss
of peak intensity in the VT 1H-13C CP/MAS NMR experiments (section 5.3.2). If a
number of small crystalline domains of α-IMC were formed within the ’sea’ of PVP-VA,
magnetization transfer from the slower (α-IMC) to the quicker (PVP-VA) relaxing domains
would occur through 1H-1H dipolar coupling (spin diffusion). The regions of higher
mobility can act as ’relaxation sinks’ within a sample (figure 5.29), leading to shorter
observed T1ρ
H times of α-IMC within the 80/20 dispersion, as compared to the pure
α-IMC. Therefore, we hypothesise that the 80/20 dispersion at increased temperatures
contains small crystalline ’domains’ present within a ‘liquid-like’ polymer carrier. The
approximate maximum domain size, estimated using equation 4.4 and the longest T1ρ
H
time measured at this temperature for the drug in the dispersions (δ = 131 ppm (31.2 ms)
is ca. 13 nm. This presence of small crystalline domains in polymeric carrier has previously
been reported for paracetamol/Eudragit dispersions, identified through a difference in T1
H
times between crystalline API in the dispersion, and without the presence of polymer [88].
Figure 5.29: Representation of the relaxation time differences between pure α-IMC (A) and crystallisation
of α-IMC within the 80/20 dispersion at high temperature (B). The orange squares represent a slow relaxing
domain; blue squares represents a fast relaxing domain; white arrows represent transfer of magnetization via
spin diffusion from orange to blue. Adapted from [36]
Previous studies on the high temperature crystallisation of pure amorphous IMC only
detected full crystallisation from amorphous to α-IMC at ca. 403 K. Andronis et al. [32]
demonstrated that recrystallisation of amorphous IMC requires a lengthy induction period
. Apperley et al. [29] also showed that during heating, increased mobility of amorphous
IMC occurred around 363 K, and some, but not full, recrystallization occurred at
temperatures up to 403 K. The presence of polymer in our study further complicates the
recrystallisation process.
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We initially hypothesised that the non-typical temperature dependence of T1ρ
H times of the
dispersions was determined mainly by the mobility of the polymer, as T1ρ
H is known to be
sensitive to slower motions associated with backbone polymer motions [161]. However, it
can be seen that the T1ρ
H times of both amorphous IMC and PVP-VA display very similar
temperature dependence (figure 5.30).
Figure 5.30: Temperature dependence of T1ρH times for A) Amorphous IMC and B) PVP-VA
For amorphous IMC, T1ρ
H times were measurable up to 323 K, above which crystallisation
to α-IMC occurred (confirmed by VT 1H-13C CP/MAS NMR), hence corresponding
relaxation times were too long to be measured accurately. Apperley et al. [29] found a
similar temperature dependence of T1ρ
H times of pure amorphous IMC until 333 K, with
TMAX occurring around the Tg value, compared to our measurements, where the change in
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mobility occurred slightly below Tg at Tg – 10 K.
Similar examples of non-typical temperature dependence of T1ρ
H times were observed in a
variety of systems, although the literature has not gone far enough to explain this
behaviour. From extensive literature searches, there appears to be a lack of understanding
regarding the deviation from typical dependence. We therefore constructed a scheme
(figure 5.31) which helped form a clearer understanding of the different components of the
non-typical temperature dependence curve. In summary, the main explanation for
non-typical temperature dependence outlines that TMAX is the result of two different,
overlapping motional regimes within the system, each with an associated minimum, and
therefore correlation time outside of the measured temperature range [244–246].
Figure 5.31: Explanation for the occurrence of a maximum point on the relaxation temperature
dependence curve
The maximum point on the curve (TMAX) can be seen as a crossover point between two
different, but overlapping motional regimes, each following the expected classical temperature
dependence of spin-lattice relaxation times. Each minimum is associated with a different
correlation time, which describes the nature of the motional regime being observed. TMAX
is the point on the curve at which the gradient changes direction, indicating a switch in
the dependence of T1ρ
H times. It seems feasible to calculate apparent activation energies
(EAapp) either side of TMAX , representing the kinetic response of the dispersions under
the influence of each motional regime: named EAapp(Low Temperature) (to the right of
TMAX) and EAapp(High Temperature) (to the left of TMAX). The EAapp represent the
kinetic response of the dispersions, and therefore provide a comparative measure of stability
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between systems. The temperature at which TMAX occurs can be related to Tg, giving
an indication of whether increased mobility occurs above or below Tg. Additionally, the
motional correlation times can be calculated across the temperature range of study, using
equation 4.2 (chapter 4). Analysing these parameters can help to determine the motions
responsible for changes in mobility; and link mobility to physical stability of the dispersions.
The main observations of non-typical dependence from figure 5.31 are summarised as follows:
• To the right of TMAX (blue), motions are in a fast regime (increasing T1H with
increasing temperature) associated with the low temperature (LT) minimum. We
have named the associated activation energy of this curve EAapp(LT).
• To the left of TMAX (green), motions are within a slow regime (decreasing T1ρH with
increasing temperature) associated with the higher temperature (HT) minimum. The
calculated activation energy for this curve is EAapp(HT).
• As mobility always increases with increasing temperature, the mobility of the ’slow
HT’ regime will still be faster than the ’fast LT’ regime within the intermediate kHz
timescale of study.
Non-typical temperature dependence of relaxation times of a variety of amorphous
pharmaceuticals with and without the stabilization of polymers has been described in the
literature [28, 46, 47, 161, 202, 213, 244, 245]. Each study observed the non-typical behaviour
we see here with a slow increase in relaxation times with increasing temperature; followed
by a rapid decrease in relaxation times, indicating the presence of motions on the slow side
of the relaxation minimum above TMAX . Studies included investigation of nifedipine/PVP
dispersions [46,160], AZD/PLGA formulations [202], amorphous simvastatin [28], IMC [29],
nifedipine [29, 161] and phenobarbital [161] and lyophilized PVP and methylcellulose [245].
The majority of studies reported only the mobility above TMAX , where a rapid decrease in
relaxation time occurred, as little change was seen below this point.
The temperature of onset of the change in mobility (our TMAX) was described in relation
to Tg. Change in behaviour at temperature substantially below Tg were linked to reduced
physical stability [46, 161]. Increased mobility below Tg was linked to instability of systems
at these temperatures, indicating that changes in mobility below Tg highlighted by solid-
state NMR can play an important role in the prediction of stability of amorphous systems.
Yoshioka et al. additionally linked the presence of multiple motional regimes to maxima on
relaxation temperature dependence curves [244–246].
Aso, Yoshioka and co-workers have published a number of papers investigating molecular
mobility using variable temperature T1ρ [47, 161, 244, 245]. They initially studied the
temperature dependence of amorphous pharmaceuticals (nifedipine and phenobarbital) and
found strong temperature dependence, with a marked decrease in relaxation time with
increasing temperature, but no relaxation minimum, which was attributed to increasing
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molecular mobility of whole molecule motions on the kHz timescale. Yoshioka et al.
extended their molecular mobility investigations into protein formulations [244] and
polymers [245]. For one formulation (dextran in BGG stored at 60 % RH), they were able
to show both a low temperature minimum followed by a higher temperature maximum on
the T1ρ
H temperature dependence curve, and provided evidence for the presence of at least
two proton motional regimes (one slow and one faster) with different correlation
times [244]. Polymers (PVP and methylcellulose) were also found to follow the same
temperature dependence. MC exhibited both a minimum and maximum within the
temperature range studied, again attributed to multiple motional regimes. If only a
maximum was seen followed by a rapid decrease in T1ρ
C (PVP), it was thought to be
associated with a minimum outside the studied temperature range [245]. More recently, as
described below, investigations of drug/polymer solid dispersions have described
non-typical temperature dependence. Our group previously demonstrated this dependence
with AZD/PLGA formulations [202], and Yuan et al. [46] with nifedipine/PVP dispersions.
In the temperature ranges studied, the room temperature miscible nifedipine/PVP
dispersions (75/25, 60/40 and 50/50) remained homogenous, with relaxation times of drug
and polymer varying with temperature in the same (non-typical) manner [46]. For our
80/20 dispersion, which appeared miscible at lower temperatures, we highlighted a phase
separation at temperatures above 353K, which was clearly seen through the separation of
relaxation times, as the crystalline α-IMC has longer relaxation times than the polymer.
Nunes et al. [28] investigated the effect of temperature on the T1ρ
C of amorphous
simvastatin (without polymer) between 293 and 333 K. They found that the majority of
the carbons studied displayed different relaxation behaviour above and below Tg; at T <
Tg, the
13C showed similar relaxation times, with a maximum T1ρ
C below Tg; at T > Tg,
there was a decrease in T1ρ
C which indicated a liberated molecular motion and possible
cooperative motion, possibly due to torsional ring oscillations. They concluded that the
variation of T1ρ
C with temperature indicated that the motions are on the slow-frequency
side of the T1ρ
C minimum, which indicated amorphous simvastatin was in a rigid state [28].
5.4.2.1 Further analysis of TMAX , activation energies and correlation times for
IMC/PVP-VA dispersions
The calculated activation energies (EAapp (LT)/(HT)) representing the temperature
dependence curves either side of TMAX are shown in table 5.6. EAapp(LT) is particularly
useful, as it provides a measure of the mobility behaviour at temperatures below Tg. The
40/60 and 60/40 IMC/PVP-VA dispersions had high EAapps(LT) of 24.0 and 26.6 kJ mol
−1
respectively. This indicates the systems have a more restricted mobility, and likely suggests
that they are the most stable, homogenous systems studied. This is in agreement with the
room temperature 1H-13C WISE NMR; the VT 1H-13C CP/MAS NMR, which showed no
increase in mobility for drug or polymer for the 40/60 dispersion; and the VT relaxation
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data which highlighted high homogeneity within the 40/60 dispersion. This activation
energy relates to motions occurring well below the Tg of each system and it would be
expected therefore, that the EAapp of a more stable system would be higher, particularly
below the Tg.
From table 5.6 it can be seen that the higher drug loading dispersions (60/40 and 40/60)
again had high EAapp (HT) values. The amorphous IMC and 20/80 dispersion have lower
EAapp(HT), which would indicate that the motion associated with this EAapp is easier to
excite, leading to higher mobility. The EAapp(HT) describes the behaviour of the dispersions
at temperatures around and above Tg.
Table 5.6: Activation energies for amorphous IMC, PVP-VA and IMC/PVP-VA dispersions of different
drug loadings. EAapp(HT) could not be calculated for the 80/20 dispersion due to crystallisation to α-IMC
Formulation EAapp: Fast regime (LT)
(kJ mol−1)
EAapp: Slow regime
(HT) (kJ mol−1)
Amorphous IMC 16.4 42.6
20/80 8.7 35.3
40/60 24.0 55.7
60/40 26.6 65.9
80/20 15.5 –
PVP-VA 11.0 39.7
In previous studies, the temperature at which TMAX occurs has been correlated with the
Tg for amorphous nifedipine, phenobarbital and IMC, to attempt to relate the change in
temperature dependence with stability [29, 46, 161]. The relationship between TMAX and
Tg of all our IMC/PVP-VA systems can be seen in figure 5.32. We found that all TMAX
values occurred at temperatures below Tg.Additionally, with increasing polymer content, the
difference between Tg and TMAX (Tg - TMAX) became larger, with the biggest difference
observed for the 20/80 and 40/60 IMC/PVP-VA dispersions.
Aso et al. [47,161] found that TMAX occurred at 20 K below Tg for amorphous nifedipine and
at a similar temperature to Tg for phenobarbital, indicating amorphous nifedipine had a lower
physical stability than phenobarbital, which was in agreement with theoretical calculations of
mean relaxation rate (via Adam-Gibbs-Vogel (AGV) equation) and crystallisation rate. Yuan
et al. [46] found a dramatic increase in the molecular mobility of nifedipine/PVP dispersions
above temperatures around 20 K below Tg, which was thought to be the underlying reason
for the increased structural relaxation and crystallization of amorphous systems below Tg..
Addtionally, NIF has always been found to be less stable than IMC, identified because
increased mobility occurred ca. 20 K below Tg for NIF [46], compared to temperatures similar
to Tg for IMC [29,46]. However, our findings do not agree with this analysis method. Here,
we have shown that increases in mobility of both amorphous IMC, and dispersions of varying
drug/polymer ratio occurred at temperatures below Tg across all systems studied. We have
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also demonstrated that with increasing polymer content, the change in relaxation times
occurred at temperatures further below Tg, in the dispersions least likely to have reduced
physical stability. The relationship between Tg and TMAX will be further investigated
through VT relaxation studies of FFA/PVP-VA (chapter 6) and TLB/PVP-VA (chapter 7)
systems.
Figure 5.32: TMAX calculated by extrapolating the curve either side of the maximum to calculate the
crossover temperature
Correlation times (τ c) were also calculated for the average T1ρ
H times at each temperature
point, using the relationship with T1ρ
H (shown in equation 4.2, chapter 4) for all dispersions,
amorphous IMC and PVP-VA. As T1ρ
H and τ c have a linear relationship, the dependence of
τ c on temperature is the same as the T1ρ
H for each material of study, and therefore doesn’t
provide much additional information.
5.4.3 Stability studies
Throughout the 14 week stability study, all dispersions were monitored for changes in the
local ordering using PXRD, mDSC and 13C CP/MAS solid-state NMR. No crystallisation
was detected for dispersions with IMC content of lower than 70 wt. % across all temperature
conditions. For the 80/20 dispersion, crystallisation to α-IMC was only detected after 4 days
of storage at high temperature (363 K). Crystallisation was identified by the characteristic
splitting in the 1H-13C CP/MAS NMR spectrum and PXRD pattern (figure 5.33).
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Figure 5.33: A) 1H-13C CP/MAS NMR spectra (MAS = 10 kHz) and B) PXRD patterns of IMC/PVPVA
80/20 dispersion before and after storage at 343 and 363 K, with a comparison to α-IMC
Crystallisation to α-IMC is in agreement with the results seen in the VT CP/MAS NMR
study (section 5.3.2), where crystallisation to α-IMC was seen by 333 K in the 80/20
dispersion under MAS conditions. Hence, information regarding the stability and
crystallisation behaviour of IMC formulations was predicted much more quickly, and at
lower temperatures when compared to the more traditional stability study.
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5.5 Conclusions
IMC was successfully formulated as an amorphous solid dispersion with PVP-VA in a
variety of drug/polymer ratios. Initial characterisation with PXRD and 1H-13C CP/MAS
NMR indicated the fully amorphous nature of all the dispersions, whilst DSC highlighted a
small amount of crystalline IMC in the highest loading dispersions. No deviation from ideal
mixing was found, indicating no strong role of hydrogen-bonding in the stabilisation of the
dispersions.
The differences in local mobility of drug and polymer at high and low IMC content
indicated with 1H-13C WISE spectra at ambient temperature became more apparent at
high temperatures with 1H-13C CP/MAS and 13C{1H} MAS NMR. The mobility on the
intermediate kHz timescale, through interference with either heteronuclear dipolar coupling
during cross-polarisation transfer, or heteronuclear decoupling have been identified. Using
VT 1H-13C CP/MAS NMR we were able to mirror the outcome of the accelerated stability
study, highlighting the fully amorphous nature of the dispersions up to 60 wt % drug
loading, and the crystallisation to α-IMC at 80 wt. % drug loading. The use of VT 1H-13C
CP/MAS NMR as a predictive tool for outcomes of physical stability will be demonstrated
further across the FFA and TLB systems.
A fast mobility regime in the higher drug loading IMC/PVP-VA dispersions, was detected
at high temperature. We postulate the high temperature 1H MAS spectrum of the 80/20
dispersion is dominated by an additional mobile phase, possibly containing amorphous IMC
and polymer, alongside small crystallites of α-IMC, which was not detected through 1H-13C
CP/MAS NMR.
We demonstrated that the mobility on the kHz scale of the IMC/PVP-VA dispersions
followed a distinct ’non-typical’ temperature dependence, due to the presence of at least
two overlapping mobility regimes. We were able to extract two parameters from the
temperature dependence curves: EAapp(HT and LT) and (Tg - TMAX). The calculation of
EAapp shows the most promise in relating the mobility behaviour detected through T1ρ
H to
physical stability of the amorphous dispersions, and this will be further investigated using
the FFA and TLB/PVP-VA systems.
Miscibility between IMC and PVP-VA was probed using ∆T1ρ
H measurements which
enables detection of domains down to ca. 2 nm. This provided a more sensitive analysis
tool as compared to more traditional miscibility studies with DSC, where single Tg values
indicate miscibility on a 20 - 30 nm lengthscale. At ambient temperature, phase separation
in the 80/20 IMC/PVP-VA dispersion was detected: the drug and polymer were found to
be miscible on the T1
H lengthscale (24 - 55 nm), but immiscible on the T1ρ
H lengthscale (2
- 6 nm). With increasing temperature, domains of approximately 13 nm were detected, as
the crystallisation of α-IMC from the amorphous drug content within the dispersion was
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observed.
Crystallisation from amorphous IMC was also investigated at different temperatures. Both
pure amorphous IMC, and the amorphous content of the 80/20 IMC/PVP-VA dispersion
permanently crystallised to the α-polymorph above the Tg, which is the expected transition
based on the thermodynamic stabilities of IMC polymorphs at increased temperature. Both
the local structure and dynamics of these systems were affected by the transition. Solvent
dependent polymorphic transitions were also shown for the 80/20 IMC/PVP-VA dispersions.
γ-IMC crystallised from the dispersion prepared via solvent evaporation with ethanol, as
compared to the α polymorph from methanol and acetonitrile. There was some correlation
of these crystallisation outcomes with previous solvent studies of IMC in solution, although
further investigation to understand the reasons behind the solvent effects is required.
The 40/60 IMC/PVP-VA dispersion was shown to have the lowest drug and polymer
mobility. Additionally, the mid-loaded dispersions (40/60 and 60/40) were found to be fully
miscible across a wide temperature range, and demonstrated the highest activation barrier
(high EAapp). This indicated that the mid-loading dispersions are likely to be the most
physically stable across the range of loading levels investigated. The low local mobility, and
high miscibility explains the high physical stability of these dispersions confirmed through
accelerated stability studies, although further investigation with 2D MAS NMR techniques
will be useful in further probing the underlying mechanism of physical stability.
In summary, the numerous methods for probing structure and dynamics employed using the
well documented model amorphous IMC, show promise in the provision of useful information
regarding local structure and dynamics of amorphous solid dispersions, and will be further
investigated with the two lower stability amorphous systems, FFA and TLB.
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Chapter 6
Variable Temperature Studies of
Flufenamic Acid
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FFA has not been studied widely in the amorphous form, with only three published studies
of FFA amorphous solid dispersions. Aso et al. [41] investigated the mobility of FFA as
a solid dispersion with PVP and HPMC (at 80/20 w/w) using variable temperature low
field 19F spin-lattice relaxation studies. They found that FFA formulated with PVP had
lower molecular mobility compared its formulation with HPMC, and was therefore more
stable when stored at 333 K [41]. Eerdenburgh et al. [247] carried out a stability study with
a number of poorly soluble drugs (including FFA) formulated with a variety of polymers
(including PVP-VA) as solid dispersions and spin coated films. The crystallisation was
monitored using polarized light microscopy over seven days at room temperature. Finally,
Ibolya et al. [248] formulated FFA as solid dispersions with PEG-4000 and PEG-6000 via melt
cooling (1:5 and 1:10 weight ratios) to demonstrate that dissolution rates of FFA improved
as a result of formulating with polymers.
6.1 Crystalline Flufenamic Acid (FFA)
FFA exhibits rich polymorphism, with nine known polymorphic forms, eight of which have
solved crystal structures [39]. The crystal structure of form III was first published in by
McConnell in 1973 [54], followed by form I by Murthy et al. in 1982 [55]. Lopez-Meijas et al.
recently solved the structures of six other polymorphs, meaning FFA has a record number
of structurally characterized polymorphs in the Cambridge Structural Database (CSD) [39].
The crystallographic data for all solved structures can be seen in table 6.1 which highlights
the large range of molecules present in the asymmetric units.
Table 6.1: Crystallographic data for all solved crystal structures of FFA polymorphs, adapted from
[39,54,55]
Form I Form II Form III Form IV Form V Form VI Form VII Form VIII
Crystal
system
monoclinic monoclinic monoclinic triclinic monoclinic triclinic monoclinic triclinic
Morphology needle plate needle prism prism needle plate
Temp (K) 300 95 300 273 95 85 85 85
Space
group
P21/c P21/c C 2/c P21 P21/c P21 P21/c P21
a (A˚) 12.523(4) 10.8813(8) 39.84 8.7589(2) 26.6592(18) 8.6485(2) 14.9687(14) 17.0047(14)
b (A˚) 7.868(6) 10.2374(7) 5.10 11.6629(3) 7.9007(2) 11.5115(2) 20.641(2) 19.1941(5)
c (A˚) 12.87(3) 11.7487(10) 12.24 20.0229(14) 23.2430(5) 38.895(3) 7.9486(8) 19.1941(15)
α (°) 90 90 90 80.632(6) 90 87.914(6) 90 81.321(7)
β (°) 95.2(2) 111.318(8) 92.47 81.041(6) 94.084(7) 85.910(6) 98.316(7) 89.580(6)
γ (°) 90 90 90 73.534(5) 90 72.260(5) 90 78.560(7)
V (A˚3) 1263.27 1219.21 2488.57 1922.33 4883.20 3678.32 2430.10 5655.09
Z/Z’ 4/1 4/1 8/1 6/3 16/4 12/6 8/2 19/9.5
Forms I and III are enantiotropically related (Form III → Form I: transition temperature of
315 K [197]), with form I becoming more stable at higher temperatures [249]. Forms I and III
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are the most extensively studied of the FFA polymorphs. The transition Form III → form I
is particularly important as the temperature of conversion is sufficiently low to occur during
manufacturing and/or storage. Forms II and III are also enantiotropically related, with a
higher transition temperature of 377 K [37]. The energy-temperature diagram of forms I -
III is shown in figure 6.1.
Figure 6.1: Energy-temperature diagram for forms I, II and III of FFA. This shows the enantiotropic
relationship of forms I and III (transition temperature = 315 K) and forms II and III (transition temperature
= 377 K). Adapted from [37]
The crystal structures and hydrogen bonding motifs of the forms I and III FFA can be seen
in figures 6.2 and 6.3.
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Figure 6.2: Unit cell of crystalline structures of form I and form III FFA. Structures extracted from the
Cambridge Structural Database (CSD)
Figure 6.3: Different conformations in the molecular structure of FFA forms I and III, adapted from [38]
Both polymorphs have similar hydrogen bonded dimers, with the same overall number of
hydrogen bonds. Jabeen et al. [250] used Raman and IR spectroscopy alongside density
functional theory (DFT) calculations to study conformational differences between forms
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I and III FFA. They found subtle differences resulting from differences in conformation
from rotation about the N-C bond (figure 6.5) and concluded that the conformation of the
whole molecule is dependent on the rotation of these bonds, rather than through differences
in hydrogen bonding as previously thought. Delaney et al. additionally found that the
position of the -CF3 group plays an important role in the difference in overall stability of
the two polymorphs [38]. FFA contains both a carboxylic acid and amino group, but it
has been suggested that hydrogen bonding interactions can only form with the acid group
as a donor [247]. This is because the FFA structure is an ideal candidate for resonance-
assisted hydrogen bonding (RAHB) [251], resulting in the formation of a six-membered ring
stabilised through intramolecular hydrogen bonding and pi-delocalization [247] (figure 6.4).
RAHB commonly occurs in structures of this type, when distances between the N and O are
between 2.66 - 2.75 A˚ [252]. The distances between these atoms in forms I and III FFA fall
within this range [247].
Figure 6.4: Example of the formation of a six-membered ring through intramolecular resonance assisted
hydrogen-bonding (RAHB) in a FFA molecule
Lopez-Mejias et al. [39] characterised polymorphs I - VIII and found unique PXRD patterns
for each. They identified different conformers in all polymorphic forms, which resulted in
multiple packing modes. Such conformational changes occur around the torsional angles of
the biphenyl amine group, highlighted in figure 6.5.
Figure 6.5: Molecule of FFA, with the biphenyl amine group highlighted, about which conformational
changes between polymorphic forms occur ,adapted from [39]
The melting points and relative stabilities of the polymorphs were also determined (table
6.2). Forms I and II were found to slowly convert to form III at 300 K, in agreement with
the E-T diagram in figure 6.1. Forms V, VIII and IX were found to convert to form III
almost immediately, during sample preparation. Form III was still identified as the most
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stable form of all polymorphs at ambient temperature, through ∆Hfus.
Table 6.2: Melting points and enthalpy of melting for FFA polymorphs I - VII, adapted from [39]
Crystalline Form Tm K ∆H fus (J·g−1)
I 407.5 98.2
II 402.6 87.8
III 400.4 105.6
IV 396.9 80.4
V 397.9 90.7
VI 397.2 87.8
VII 393.7 83.2
6.1.1 Solution-state NMR assignment of Flufenamic acid
Solution state 1H NMR and 13C assignments for FFA have been previously published [40]
(table 6.3, figure 6.6). The reported 13C and 1H spectra were acquired at 300 MHz 1H
frequency, therefore only two of the aromatic protons were identified (A and H), with the
remaining protons (B - G) assigned as an overlapping multiplet. We had spectrometers at
higher fields (500 and 800 MHz) available, therefore we were able to fully assign all aromatic
1H nuclei, using previous assignments as an initial guide.
Table 6.3: 1H and 13C solution-state assignments, as reported by [40]. m = overlapping multiplet
1H δ (ppm) [40] 13C δ (ppm) [40]
A 7.95 C-2 147.73
H 6.90 C-13 111.38
E m C-5 132.84
F m C-10 118.36
D m C-4 135.48
G m C-12 114.20
B m C-3 141.17
C m C-11 118.84
N-H 9.68 C-14 131.96
COOH 13.07 C-9 120.20
C-7 129.98
C-8 125.33
C-1 173.96
C-6 123.92
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Figure 6.6: 1H and 13C assignments of FFA available from literature, [40]
The 1D 1H spectrum acquired at 800 MHz is shown in figure 6.7. Here we observed 5
separate proton signals: three corresponding to single protons: doublet of doublets at 8.02
ppm (proton A), triplet of doublets at 7.32 ppm (assigned to proton E) and a triplet of
doublets at 6.84 ppm (proton H). An additional multiplet (protons B, C and D), possibly
consisting of an overlapping singlet, doublet and triplet; and two overlapping doublets, ca.
7.22 (proton F) and 7.21 (proton G) ppm were also observed.
Figure 6.7: 800 MHz 1D 1H NMR spectrum of FFA (0.05 M dissolved in CD3OD) showing the five
separate proton peaks
The two proton spin systems of the aromatic rings were separated through 1H-1H COSY
(figure 6.8 A) and directly bonded protons were assigned to 13C nuclei with 1H-13C HSQC and
literature 13C assignments [40] (figure 6.8 B). From these 2D spectra, protons E, and F and G
were identified (figure 6.10), but the remaining three protons (B, C and D: multiplet at 7.46
- 7.50 ppm) were too closely overlapped to be distinguished. A 2D J-resolved pulse sequence
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was employed to separate coupling constants and chemical shifts into different dimensions
of the spectrum, essentially gaining a one-dimensional spectrum, without the complicating
presence of multiplets (figure 6.9) [253]. From this spectrum, we were successfully able to
identify protons B, C and D (figure 6.10). The full 1H chemical shift assignments are given
in table 6.4.
Figure 6.8: A) 1H-1H COSY NMR spectrum (800 MHz) of FFA (0.05 M in CD3OD) for the identification
of the two proton spin systems: Ring 1: A, E, F, H and Ring 2: B, C, D, G B) 1H-13C HSQC NMR spectrum
(500 MHz) of FFA (0.05 M in CD3OD for the assignment of
1H-13C connectivities
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Figure 6.9: 2D J-resolved NMR spectrum (800 MHz) of FFA (0.05 M dissolved in CD3OD) with projected
coupling constants from the F1 dimension, which allowed the identification of protons B, C and D
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Table 6.4: 1H chemical shift assignments of FFA from 2D 1H-1H COSY, 1H-13C HSQC and J-resolved
NMR spectra
1H Chemical Shift (ppm)
A 7.94
B 7.41
C 7.39
D 7.37
E 7.32
F 7.22
G 7.21
H 6.76
Figure 6.10: 1H and 13C assignments from 2D 1H-1H COSY, 1H-13C HSQC and J-resolved NMR spectra
6.1.2 Initial solid-state characterisation of forms I, III and amorphous
FFA
Forms I and III FFA were characterised initially using PXRD, DSC and solid-state NMR.
There are currently no reports of the successful preparation of amorphous FFA at ambient
temperatures [131], therefore there is no published Tg for comparison. Here we successfully
formulated amorphous FFA via the quench cool method (figure 6.11 A).
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Figure 6.11: Modulated DSC heat-cool-reheat cycle of A) quench cooled amorphous FFA and B) form I
FFA
A Tg of 286 K was obtained from the initial heating run of the amorphous FFA sample (figure
6.11 A), followed by an exothermic crystallisation event and subsequent melting of form I
FFA ca. 407 K [55]. Upon cooling and reheating, no Tg was observed, but crystallisation at
a higher temperature (359 - 362 K) occurred, followed by melting of both I FFA [54], and
an unidentifed form (Tm = 394 K). The presence of crystallisation endotherms upon cooling
and reheating is consistent with the reversible polymorphic transition between forms I and
III. Amorphous FFA produced in situ in the DSC pan from FFA-I polymorph (figure 6.11
B), showed the Tg temperature of 286 K, making it unstable at ambient conditions.
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When packed in the cold room and cooled to 253 K within the rotor, we were able to
acquire the 1H-13C CP/MAS NMR spectrum of amorphous FFA (figure 6.12). The broad
13C resonances reflect the lack of long range order within the amorphous material, leading
to a wide range of carbon environments [29].
There are also significant differences between the 1H-13C CP/MAS NMR spectra of the two
crystalline polymorphic forms (forms I and III). The assignment of the solid-state NMR
spectra of the different forms of FFA is not straightforward, due to the large number of
aromatic carbons. The 13C spectra of forms I, III and V have been published, but no
chemical shift assignments were made [254,255]. Of the few publications on solid dispersions
of FFA, none included any solid-state NMR data. Fewer 13C resonances are observed in the
solid-state compared with solution-state spectra: 13 for form I, 11 for form III and only 8 for
amorphous FFA. We were able to confirm the resonance positions of the 5 quaternary carbons
within the spectrum of form I, via NQS CP/MAS NMR (figure 6.13). As all remaining non-
quaternary carbons are aromatic, additional 13C NMR spectral editing experiments would
not provide further assignment information [241, 256]. One internet reference describing
the assignments of form I via CSA amplification measurements and CASTEP calculations
was identified, however the assignments of form I were given on the spectrum of form III,
therefore this was not deemed to be a reliable source. No peer reviewed references could be
identified.
Figure 6.12: 1H-13C CP/MAS NMR spectra for forms I, III and amorphous FFA, recorded at an MAS
rate of 10 kHz
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Figure 6.13: 1H-13C NQS CP/MAS NMR spectra for FFA form I, highlighting the assignment of
quaternary carbons, recorded at an MAS rate of 10 kHz
Table 6.5: 13C Chemical Shift Assignments of Form I, III and amorphous FFA
13C Form I Form III Amorphous
1 175.0 174.7 175.0
2 149.3 145.8 146.9
3 140.0 142.0 140.8
136.3 137.1 135.4
132.9 133.2 132.1
14 131.7 130.9 ”
129.3 ”
128.2 ”
121.7 122.2 124.5
119.7 120.1 123.3
117.2 117.8 118.4
111.9 114.0 112.1
13 109.6 108.0
Further work with CASTEP calculations to predict the 13C chemical shifts would be useful
in completing the full assignments of forms I and III FFA. Due to time and computer
constraints, this was not completed. However, this was not critical, as our study did not
depend on the full spectral assignment, with further analysis carried out comparatively
between dispersions of different drug loading levels.
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6.1.3 Initial characterisation of FFA/PVP-VA solid dispersions
In our study, all solid dispersions were initially characterised using modulated DSC, PXRD
and 1H-13C CP/MAS NMR. Each dispersion has a single Tg (figure 6.14), intermediate
between the Tg values of pure amorphous FFA and PVP-VA, as expected from the Gordon-
Taylor relationship [112]. As the amount of polymer increased, the single Tg value increased
in a linear manner, which indicates the anti-plasticising property of PVP-VA [257]. Ideal Tg
values of the dispersions were calculated using the Gordon-Taylor/Kelley-Bueche (G-T/K-B)
and Couchman-Karasz (C-K) equations (equations 2.17 with 2.19 and 2.20 - see chapter 3),
and can be seen in figure 6.14.
Figure 6.14: Glass transition temperatures for FFA/PVP-VA dispersions at different drug loadings,
compared to values predicted by the Gordon-Taylor/Kelley-Bueche (G-T/K-B) and Couchman-Karasz (C-K)
equations
The FFA/PVP-VA dispersions displayed slight negative deviation from predicted Tg values,
especially when compared to the G-T/K-B equation predictions. Negative deviation from
ideal indicates dominance of drug/drug interactions within the system and suggests non-
ideal mixing between drug and polymer components [193]. However, literature studies only
report much larger differences between measured and predicted Tg values as ’deviation’
examples [78, 190]. Shamblin et al. [179] found negative deviation from predicted values
(using the Gordon-Taylor equation) in sucrose/PVP, sucrose/PVP-VA and sucrose/dextran
systems, due to hydrogen bonding between sucrose molecules, with differences of up to 40 K.
Compared to literature, all deviations observed are negligible, and therefore do not provide
information regarding specific interactions in the three systems.
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The 10/90 - 60/40 w/w FFA/PVP-VA dispersions were found to be fully amorphous, and
miscible on the DSC scale up to 20 - 30 nm due to the absence of melting peaks and presence
of a single Tg values. However, the 70/30 and 80/20 dispersions contained both amorphous
and crystalline drug phases, highlighted by the presence of several thermal events on the
DSC curves (figure 6.15).
Figure 6.15: DSC curve (Heat flow vs. temperature) for 70/30 (green) and 80/20 (purple) dispersions
(heat-cool-reheat cycles)
For the 80/20 FFA/PVP-VA dispersion, two broad melting endotherms (Tm = 373 and 402
K) were present in the DSC curve on the initial heating run; upon reheating, a Tg of 294
K was calculated. On the final heating cycle, a crystallisation exotherm was present (Tc=
343 K), followed by a single melting endotherm (Tm = 389 K). The DSC curve of the 70/30
FFA/PVP-VA dispersion displayed two broad melting endotherms (Tm = 381 and 393 K)
upon the initial heating cycle, and only a glass transition (Tg = 300 K) on the subsequent
cooling and reheating cycles. Previous studies of partially crystalline dispersions have also
reported the presence of two broad melting endotherms in DSC curves [148, 190, 228, 258].
The lower temperature endotherm is thought to occur due to the melting of a drug/polymer
solid solution, formed through the dissolution of crystalline drug in the polymer upon heating
[90, 148]. The higher temperature endotherm is thought to occur due to the melting of
residual crystalline API formed during manufacture, and is often been reported at lower
Tm values compared to the melting observed for pure API [190, 228]. Previously reported
high drug loading FFA dispersions (formulated with PVP and HPMC at 80/20 w/w via
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melt-cooling) were confirmed to be fully amorphous with microscopic observations under
polarised light [41]. This difference in stability compared to our dispersions could be due to
either differences in formulation method, or in characterisation technique sensitivity.
The fully amorphous nature of the 10/90 - 60/40 w/w FFA/PVP-VA dispersions was
confirmed with PXRD. The 80/20 and 70/30 dispersions were found to contain form III
FFA at ambient temperatures [255] (figure 6.16). The pale yellow colour of both high drug
loaded dispersions was also an indication of the presence of form III FFA [259]. Using this
information, the % of the residual crystalline content of the 70/30 and 80/20 was
calculated assuming the presence of form III FFA (equation 5.1) as 0.5 % (peak at 393 K)
or 25.2 % (peak at 382 K) for the 70/30 dispersion, and 29.8 % for the 80/20 dispersion.
Figure 6.16: PXRD patterns for FFA/PVP-VA dispersions at different drug loadings, with crystalline
form III for comparison. FFA loadings of below 60 wt. % all displayed broad halo patterns, and were therefore
confirmed to be fully amorphous
Figure 6.17 gives the assignment of chemical shifts to FFA, PVP-VA, or both drug and
polymer in the FFA/PVPVA 50/50 dispersion. The numerous well separated peaks of drug
and polymer enabled us to independently monitor the changes in both components of the
dispersion during variable temperature NMR investigations to obtain independent mobility
information. The carbonyl region provided additional information about changes in
hydrogen-bonding during phase transitions and recrystallisation. There is complete overlap
between the FFA and PVP-VA carbonyl peaks at 175.1 and 175.9 ppm respectively,
resulting in a broader peak at 175.6 ppm in the dispersion. The shift in the FFA carbonyl
peak (of 0.5 ppm for the 50/50 dispersion) indicates a difference in hydrogen-bonding
between pure amorphous FFA and FFA in the presence of polymer, and could indicate
interaction between the drug and polymer through the carboxylic acid group. The shift of
the polymer carbonyl peak is greater with increasing FFA content (figure 6.18).
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Figure 6.17: 1H-13C CP/MAS NMR spectra for FFA/PVP-VA 50/50 solid dispersion compared to
amorphous FFA (at 253 K) and PVP-VA recorded at an MAS rate of 10 kHz. Missing FFA chemical shift
assignments are unavailable due to overlapping peaks, PVP-VA assignments are the same as in chapter 5
There were additionally some subtle changes to the aromatic region of the FFA in dispersion,
compared to amorphous FFA: notably the presence of two peaks at 125.6 and 123.2 ppm;
and a shift in the C-N (C-2 and 3) resonances at 145.8 and 142.0 ppm respectively. This
could indicate a difference in conformation around the biphenyl amine group.
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Figure 6.18: 1H-13C CP/MAS spectra for amorphous dispersions of various drug loadings, recorded at
an MAS rate of 10 kHz
From figure 6.18 it can be seen that the intensity of drug peaks increased proportionally
with drug content. The carbonyl peaks change most dramatically as the amount of drug
increases, with the drug peak becoming apparent from 40 wt. % drug load and above. The
80/20 and 70/30 dispersions contain both amorphous and crystalline phases, with the 80/20
dispersion being more highly crystalline than the 70/30. The crystalline phase was identified
as form III FFA (figure 6.19), in agreement with PXRD.
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Figure 6.19: 1H-13C CP/MAS NMR spectra for 70/30 and 80/20 dispersions with a comparison to form
III, recorded at an MAS rate of 10 kHz
The presence of a CF3 group enabled us to use
19F MAS NMR to probe the mobility and
recrystallisation of the amorphous dispersions at increased temperatures. 19F is a very
attractive nucleus in NMR due to its high natural abundance, and therefore much shorter
experimental time. This technique also allowed us to focus on the behaviour of the drug
alone with increasing temperature.
The values of 19F chemical shift and full width half-heigh (FWHH) for forms I, III and
FFA/PVP-VA dispersions are presented in table 6.6. The amorphous nature of the 40/60 -
60/40 dispersions can be confirmed by the broader isotropic peaks compared to crystalline
FFA, due to the wider range of molecular orientations of the CF3 group. The 70/30 and
80/20 dispersions had chemical shift values comparable to form III FFA, with narrower
linewidths than the other fully amorphous dispersions, which is in good agreement with the
PXRD and 1H-13C CP/MAS NMR results.
Table 6.6: 19F Chemical Shift values and Full Width Half Height (FWHH)at 293 K
Peak FFA 8020 FFA 7030 FFA 6040 FFA5050 FFA 4060 Form I Form III
Main: δ (ppm) -62.2 -62.2 -61.9 -61.8 -61.7 -60.0 -62.0
FWHH (Hz) 980 1102 1347 1335 1334 1038.1 856.9
SS 1 -88.9 -88.9 -88.6 -88.5 -88.4 -86.9 -88.7
The fully amorphous dispersions (below 60 wt. % of FFA) additionally display lower intensity
spinning sidebands (ca. - 88 ppm (figure 6.20) compared with the highest drug loaded
dispersions and pure crystalline FFA, which indicates a reduction in chemical shift anisotropy
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(CSA), due to a combination of the increased local mobility, and reduced structural ordering
of the amorphous form as compared to crystalline [6, 7].
Figure 6.20: 19F MAS NMR spectra of 50/50, 60/40, 70/30 and 80/20 dispersions, with crystalline forms
I and III for comparison, recorded at an MAS rate of 10 kHz. Zoomed insets included of the main 19F peak,
and first spinning sideband
6.2 Crystalline and Amorphous FFA
6.2.1 13C and 19F MAS NMR studies of Crystalline FFA
Upon heating of form I, there were no significant changes to the 13C or 19F NMR spectra
(figure 6.21), indicating no polymorphic transitions occurred. This is the expected result, as
form I is the most stable polymorph at higher temperatures. There was some loss of intensity
in the 1H-13C CP/MAS spectra, indicating increased mobility, and a slight change in chemical
shift value in the 19F MAS spectra (-60.1 to -59.8 ppm) with increasing temperature.
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Figure 6.21: A) 1H-13C CP/MAS NMR spectra of Form I FFA, heated between 293 and 373 K, at an
MAS rate of 10 kHz and B) 19F MAS NMR spectra of Form I FFA, heated between 293 and 373 K, at an
MAS rate of 10 kHz
Upon heating form III FFA, the changes to the 1H-13C CP/MAS NMR and 19F MAS spectra
between 353 and 373 K were consistent with a polymorphic transition to form I FFA (figure
6.22). The 13C chemical shift values and characteristic peak splitting of each form are very
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different (section 6.1.2), therefore it is possible to identify the phase transition temperature
between polymorphs; additionally the 19F chemical shifts of forms I and III differ by ca. 2
ppm. Under MAS conditions, form III converted to form I between 353 and 373 K. Upon
cooling back to 293 K, the crystalline FFA remained as form I.
Form I and III are well known to be enantiotropic, with a reported transition temperature of
315 K [197]. It has been shown that both forms can occur at the same time under ambient
conditions in the solid-state, which is understandable as the free energy and dissolution rate
(in water) are very similar below the transition temperature [37,249].
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Figure 6.22: A) 1H-13C CP/MAS NMR spectra of form III FFA, heated between 293 and 373 K, at an
MAS rate of 10 kHz, with form I (293 K) for comparison and B) 19F MAS NMR spectra of form III FFA,
heated between 293 and 373 K, at an MAS rate of 10 kHz, with form I (293 K) for comparison
The transition between forms I and III of FFA has been studied previously using different
spectroscopic methods. Gilpin et al. [260] applied FT-IR to monitor the conversion of form
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III to I, and observed a transition between 358 and 368 K, with a large activation energy of
thermal conversion of 212.7 kJ mol−1. Hu et al. [249] studied the thermodynamic transition
between the two polymorphs using in situ Raman spectroscopy. The observed transition
temperature at 317 K was very close to the originally reported value [197]. To confirm
the transition temperature, Van’t Hoffs plot of solubility were also constructed, with the
solubities of the forms I and III equal at ca. 312 K [249]. Hu et al. [140] previously studied
the transformation kinetics of forms I and III in solution, again with Raman spectroscopy.
They determined that in a slurry, rapid conversion from form III to I occurred above the
transition temperature, especially at higher temperatures. Upon cooling, the conversion of
form I back to III followed much slower kinetics, with forms III and I coexisting for ca. 16
hours at 311 K, with full conversion at 298 K after 100 minutes. Li et al. [131] further studied
the effect of crystal size on the polymorphic transition, and found that larger crystals of form
I converted faster to form III, as they had a larger number of surface defects. The slower
transformation kinetics of form I → form III upon cooling could explain why we did not
see the reverse transformation at 293 K under MAS conditions. If left for longer within the
rotor, the growth of form III may have become apparent. Additionally, the energy gain from
transformation between the polymorphs is low (figure 6.1), therefore under our experimental
conditions, it may not have been favourable for the reversible transition to occur.
6.2.2 Amorphous Flufenamic Acid
The amorphous drug and amorphous dispersions were analysed using variable temperature
solid-state NMR. As discussed previously, there were practically no changes to the 1H-13C
CP/MAS spectrum of the polymer alone upon heating.
When amorphous FFA was heated between 253 and 373 K the 1H-13C CP/MAS NMR spectra
showed the onset of crystallisation by 273 K, below the Tg of 286 K (figure 6.23). The peaks
became narrower and more defined with increasing temperature, and with chemical shifts and
peak splitting typical of form I FFA [254]. As with the pure form I at high temperatures, the
loss of resolution and signal intensity was observed. This is most probably due to increased
mobility.
141
Figure 6.23: 1H-13C CP/MAS NMR spectra of amorphous FFA, heated between 253 and 373 K, at an
MAS rate of 10 kHz, with Form I (293 K) for comparison
Below the transition temperature, form III would be the expected polymorph to crystallise
from the amorphous form, with conversion to form I expected at higher temperatures [255].
However, the possible presence of residual form I seeds formed upon manufacture, may
have led to preferential crystallisation over form III. Hu et al. [249] demonstrated that rapid
crystallisation of form I occurred in the presence of seeds in solution. Therefore, the presence
of low quantities of form I within the amorphous sample could favour the transition to form
I over form III, as the nucleation sights for crystal growth were already present.
6.3 Variable temperature studies of Amorphous FFA/PVP-
VA Dispersions
6.3.1 Detection of changes in mobility of FFA/PVP-VA dispersions: high
drug loaded dispersions
We have extensively characterised dispersions of FFA and PVP-VA, with varying
drug/polymer ratios (80 wt. % to 20 wt. %) using a number of variable temperature
solid-state NMR techniques, including 1H-13C CP/MAS, 13C{1H} MAS, 1H MAS and
spin-lattice relaxation.
The VT 13C NMR spectra for FFA/PVP-VA 80/20 dispersion (figure 6.24) illustrates changes
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with increasing temperature. At 293 K, the presence of both crystalline (form III) and
amorphous FFA (section 6.1.3) can be detected. The Tg of this dispersion is low (293 K),
so it is feasible that we observe crystalline FFA at ambient temperatures. With increasing
temperature, narrowing of all drug peaks occurred, indicating further crystallisation of the
amorphous FFA component to form III. Above 353 K, no polymorphic transition to form I
FFA occurred, as would be expected for pure crystalline form III. Additionally, a significant
reduction in the intensity of the polymer resonances occurred ca. 333 K, with a complete
loss of CP signal by 373 K, indicating high mobility of both drug and polymer.
Figure 6.24: A) 1H-13C CP/MAS NMR spectra of 80/20 FFA/PVP-VA dispersion (blue) recorded at
different temperatures between 293 K and 373 K (MAS rate 10 kHz) and 13C{1H} NMR spectrum at 373 K
(red) and B) 1H-13C CP/MAS NMR spectra of 80/20 FFA/PVP-VA dispersion at 293 K, before and after
heating to 373 K
The 13C{1H} MAS NMR spectra of FFA/PVP-VA 80/20 at 373 K is completely different
as compared to the 1H-13C CP/MAS NMR. Sharp resonances, with chemical shift values
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and peak splitting which are not possible to attribute to currently studied polymorphic
forms [254, 255], are observed (figure 6.25). Additionally, significantly broadened aliphatic
polymer peaks are present, due to increased polymer mobility on an intermediate timescale.
However the predominant carbonyl peak at 373 K appears to be related to C-D of PVP-VA.
Figure 6.25: 13C{1H} MAS NMR spectra of 80/20 dispersion at 373 K (red), with 1H-13C CP/MAS
NMR spectra of forms I and III FFA, and PVP-VA provided for comparison, recorded at an MAS rate of 10
kHz
Possible explanations for the observation of line narrowing in 13C{1H} MAS NMR spectra
include:
• Line narrowing due to a well defined repeating unit cell as a result of crystallisation to
a polymorph not previously characterised with solid-state NMR;
• OR line narrowing due to fast mobility, on a timescale faster than 1000 kHz, resulting
in the manifestation of isotropic peaks more comparable to a ’liquid-like’ state
The presence of a new polymorphic form of FFA can be ruled out, as we would see narrow
resonances in both the 1H-13C CP/MAS NMR and 13C{1H} MAS NMR spectra
respectively. Therefore, the most likely explanation is related to an increased mobility of
the FFA component, with both the amorphous and form III FFA phases present before
becoming too mobile to detect at high temperatures. The 13C{1H} MAS NMR spectrum
at this point clearly indicates a difference in mobility of drug (fast > 1000 kHz) and
polymer (intermediate ca. 90 kHz).
Upon cooling to 293 K, the presence of drug and polymer was detected with 1H-13C CP/MAS
NMR, which highlighted an increased content of the amorphous phase (figure 6.24 B) as
compared to the initial ambient temperature characterisation. This indicates that the line
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narrowing at high temperatures is a reversible effect. The absence of form III in the dispersion
following heating to 373 K could be attributed to the crystalline phase melting, or dissolving
in the mobile amorphous and polymer phase, resulting in the presence of predominantly
amorphous FFA upon cooling. At high temperature, it is possible we are seeing additional
FFA species which are highly soluble and mobile, alongside dissolved amorphous and form
III FFA in the polymer phase in the 13C{1H} MAS NMR spectrum: likely to be small
aggregates of pre-nucleation FFA within a viscous polymer ’sea.’ These assumptions will be
probed further using additional VT solid-state NMR and PXRD methods.
Upon increasing temperature, the 70/30 FFA/PVP-VA dispersion showed behaviour very
similar to the 80/20 formulation (figure 6.26). Some further crystallisation of form III was
observed at ca. 333 K, with the drug and polymer both displaying increased mobility on the
intermediate timescale by 353 K, as expected at temperature ca. 50 K above the Tg. Again,
full signal loss in the 1H-13C CP/MAS NMR spectra occurred by 373 K, with the 13C{1H}
MAS NMR spectrum closely resembling that of the 80/20 dispersion at 373 K. Again, upon
cooling back to 293 K, the CP/MAS spectrum showed an increased content of amorphous
phase. This indicates the formation of a similar high temperature environment, described
for the 80/20 dispersion above.
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Figure 6.26: A) 1H-13C CP/MAS NMR spectra of 70/30 FFA/PVP-VA dispersion (blue) recorded at
different temperatures between 293 K and 373 K (MAS rate 10 kHz) and 13C{1H} NMR spectrum at 373 K
(red) and B) 1H-13C CP/MAS NMR spectra of 70/30 FFA/PVP-VA dispersion at 293 K, before and after
heating to 373 K
The VT 13C spectra of 60/40, 50/50 and 40/60 FFA/PVP-VA dispersions show similar
trends with increasing temperature (figure 6.27 A, B and C). We observe broadening of FFA
resonances, followed by broadening of PVP-VA resonances, with complete signal loss in the
1H-13C CP/MAS NMR spectra by 373 K.
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Figure 6.27: 1H-13C CP/MAS NMR spectra of A) 60/40, B) 50/50 and C) 40/60 FFA/PVP-VA dispersion
(blue) recorded at different temperatures between 293 K and 373 K (MAS rate 10 kHz) and 13C{1H} MAS
NMR spectrum at 373 K (red)
The high temperature 13C{1H} MAS NMR spectra of the 60/40 and 50/50 dispersions were
similar to the spectra of the 80/20 and 70/30 dispersions, with the decoupled spectrum of
the 40/60 dispersion showing mostly broad lines at 373 K. However, some peaks ca. 131.8,
125.1 and 122.5 ppm were observed, indicating the beginnings of the same high mobility
environment described above. The similarity of the high temperature 13C{1H} MAS NMR
spectra of all five FFA loading levels can be seen in figure 6.28.
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Figure 6.28: 13C{1H} MAS NMR spectra for 40/60, 50/50, 60/40, 70/30 and 80/20 FFA/PVP-VA
dispersions recorded at 373 K, with an MAS rate of 10 kHz
6.3.2 Detection of changes in mobility of FFA/PVP-VA dispersions: low
drug loaded dispersion
The VT 13C NMR spectra for FFA/PVP-VA 20/80 dispersion (figure 6.29) show a loss of
signal intensity of the FFA peaks with increasing temperature up to 373 K. This effect was
especially pronounced above the Tg of 353 K. At 373 K, FFA peaks were broadened
significantly in both the 1H-13C CP/MAS and 13C{1H} MAS NMR spectra indicating
mobility on the intermediate timescale, in comparison to the much faster mobility observed
for dispersions of ≥ 40 wt. % drug loading. There was little change in the polymer peaks
on heating, indicating its lower mobility in comparison to the drug on the observed
timescale.
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Figure 6.29: 1H-13C CP/MAS NMR spectra of 20/80 FFA/PVP-VA dispersion (blue) recorded at
different temperatures between 293 K and 373 K (MAS rate 10 kHz) and 13C{1H} spectrum at 373 K
(red)
6.3.3 Comparison of the high temperature 13C{1H} MAS NMR with
solution-state NMR
To explore the possibility of the presence of a ’liquid-like’ environment at 373 K, the
13C{1H} MAS NMR spectra of the dispersions were compared to the 13C NMR
solution-state spectrum of FFA in CD3OD (figure 6.30 and table 6.7). It can be seen that
the spread of the carbon resonances in the high temperature 13C{1H} spectra for each
dispersion match closely with those in the solution-state, with ∆δ values of less than 1
ppm. This suggests that at high temperature the mobility of the dispersions tends towards
a highly mobile, ’liquid-like’ environment. Although the FWHH of the solid-state
resonances at 373 K are small compared to the lower temperature peaks, they are still
much broader than those observed in solution-state spectra. The ’liquid-like’ environment
described in the solid-state is therefore likely to be of much higher viscosity as compared to
a fully isotropic solution.
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Figure 6.30: 13C{1H} MAS NMR for 40/60, 50/50, 60/40, 70/30 and 80/20 dispersions recorded at 373
K, with an MAS rate of 10 kHz, 400 MHz; compared to the solution-state 13C spectrum of FFA 0.05 M in
CD3OD recorded at 500 MHz
Table 6.7: 13C Chemical Shift Assignment comparison of FFA in CH3OD (0.05 M) at 293 K and 13C{1H}
MAS NMR of the 80/20 dispersion at 373 K [40]
13C Solution-state 80/20 ∆δ (ppm)
1 171.8 171.5 0.3
2 148.0 147.7 0.3
3 143.7 143.1 0.6
4 135.4 134.9 0.5
5 133.6 133.1 0.5
6 133.0 132.1 0.9
14 131.5 130.6 0.9
7 125.3 124.9 0.4
8 124.6 123.7 0.9
9 120.2 119.7 0.7
11 119.8 119.3 0.5
10 118.4 118.4 0
12 115.7 115.2 0.5
13 115.1 114.6 0.5
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6.3.4 Probing the mobility of FFA/PVP-VA dispersions using 1H MAS
NMR Studies
To further investigate the mobility of the FFA/PVPVA dispersions at high temperatures, VT
1H NMR studies were carried out. 1H solid-state NMR is very sensitive to faster molecular
motions, and therefore provides additional understanding of the VT 13C MAS NMR.
At ambient temperature, we can distinguish the drug and polymer components of the
dispersions with more than 40 wt. % drug loading in the 1H MAS NMR spectra, as two
broad peaks are seen with resonances ca. 7.2 ppm (FFA) and ca. 1.5 ppm (PVP-VA). The
1H spectrum of the 20/80 dispersion is dominated by the polymer, with one broad peak at
ca. 2.8 ppm (figure 6.31).
Figure 6.31: 1H MAS NMR spectra for 20/80, 40/60, 60/40 and 80/20 FFA/PVP-VA dispersions at 293
K, measured at an MAS rate of 10 kHz. Highlighted FFA 1H peak = 7.2 ppm; PVP-VA = 1.6 ppm (80/20,
60/40 and 40/60 FFA/PVP-VA dispersions); 20/80, broad peak = 3.1 ppm
The VT 1H MAS spectra (figure 6.32) show differences in line widths as a function of
temperature and drug loading level. With higher FFA content, resonances become
narrower with increasing temperature indicating significantly enhanced mobility, which is
especially pronounced at 373 K.
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Figure 6.32: Variable temperature 1H MAS NMR spectra for A) 20/80, B) 40/60, C) 60/40 and D)
80/20 FFA/PVP-VA dispersions, measured at an MAS rate of 10 kHz, between 293 and 373 K
The sharply resolved peaks of the higher drug loading dispersions at 373 K are comparable
to the solution-state 1H resonances of FFA, shown in figure 6.34. We can just observe
the presence of the polymer in the solid-state at ca. 1.9 ppm. At 373 K, broader peaks
were observed for the 60/40 dispersion, indicating slightly lower mobility in comparison
to the 70/30 and 80/20 dispersions (figure 6.33). Additionally, a peak at ca. 9.7 ppm is
distinguishable in the high temperature spectra of the 70/30 and 80/20 dispersions, which
indicates the presence of hydrogen bonding. The solution state 1H spectra of the dispersions
and FFA alone (dissolved in CD3OD at 0.05 M) allowed full assignment of FFA protons.
There were no downfield peaks (> 10 ppm), so no hydrogen bonding of the carbonyl group
was obvious from our solution-state spectra. Munro et al. also reported the absence of a
hydrogen-bonding resonance for the -COOH proton of FFA dissolved in CDCl3, but observed
a downfield peak at ca. 13 ppm for FFA dissolved in DMSO-d6 [40], indicating a solvent
dependent difference in interactions between FFA molecules in solution.
Figures 6.33 and 6.34 indicate the similarity in peak position for the dispersions at 373 K.
The broader peaks observed at lower drug content indicates slightly lower mobility at high
temperatures.
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Figure 6.33: 1H MAS NMR spectra for different FFA/PVP-VA dispersions, measured at an MAS rate
of 10 kHz at 373 K
In dispersions with the highest drug loading, we observe the same general separation of
five 1H environments as in the solution-state. Assignments of protons ’A’ and ’H’ were
straightforward, with more tentative assignment of ’B,C,D’, ’E’ and ’F,G’ groups made
based on the solution state 1H spectra. Due to the high molecular weight of the polymer, the
solution-state resonances were significantly broadened in comparison to the small molecule
FFA.
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Figure 6.34: A) High temperature (373 K) 1H MAS NMR spectra for 80/20, 70/30 and 60/40 FFA/PVP-
VA dispersions (MAS = 10 kHz) with proton chemical shift assignment, B) Solution-state 1H spectra for
different FFA/PVP-VA dispersions and FFA alone dissolved in CD3OD (0.05 M)
154
Table 6.8: Comparison between 1H chemical shift values measured in solution and solid state
1H δ (ppm) solution-state δ (ppm) solid-state (80/20)
A 7.94 7.78
B 7.41 7.15
C 7.39
D 7.37
E 7.32 7.00
F 7.22 6.90
G 7.21
H 6.76 6.45
Polymer 2.33-1.45 1.7
The VT 1H MAS NMR spectra therefore indicate the presence of a highly mobile ’liquid-like’
state at 373 K. The presence of additional FFA polymorphs would be observed in 1H MAS
spectra as much broader peaks. This provides further evidence to support the hypothesis
that the dispersions form a highly mobile viscous ’paste’ at high temperatures, as discussed
in section 6.3.1.
6.3.5 Probing the mobility of FFA in FFA/PVP-VA dispersions using 19F
MAS NMR Studies
VT 19F MAS NMR was applied to elucidate the high temperature mobility behaviour of the
FFA/PVP-VA dispersions by focusing solely on the drug component without complication
from overlapping polymer signals. Changes to chemical shift, FWHH and spinning sidebands
were analysed for the 80/20 - 40/60 dispersions across a range of temperatures from 293 to
373 K.
From figure 6.35 two main changes to the 19F MAS NMR spectra are apparent with increasing
temperature. We see a reduction in both FWHH, as peaks narrowed dramatically with
increasing temperature; and spinning sideband intensity for all dispersions, both of which
indicate increased mobility within the dispersions.
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Figure 6.35: Variable temperature 19F MAS NMR spectra for A) 40/60, B) 60/40 and C) 80/20
FFA/PVP-VA dispersions, measured at an MAS rate of 10 kHz, between 293 and 373 K. Spectra are displayed
between -20 and -100 ppm to highlight the main isotropic peak, and the two main spinning sidebands
A closer inspection of the 19F MAS NMR spectra (figure 6.36) indicates further changes
to the dispersions dependent on drug loading levels. As with the VT 1H MAS NMR, the
effect was less pronounced with the 40/60 dispersion. Additionally, there was also an upfield
shift of the isotropic peak positions, which again was more pronounced for the higher drug
loading dispersions (figure 6.38), although this could be due to temperature related changes
to chemical shifts, instead of changes to the material properties.
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Figure 6.36: Variable temperature 19F MAS spectra for the A) 40/60, B) 60/40 and C) 80/20 dispersions
recorded between 293 and 373 K at an MAS rate of 10 kHz. Spectra are displayed between -57 and -67 ppm
to highlight the main isotropic peak
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Figure 6.37: FWHH of VT 19F MAS NMR spectra between 293 and 373 K for the 40/60 to 80/20
FFA/PVP-VA dispersions, with form I FFA as a comparison
Figure 6.38: Chemical Shift values (ppm) of VT 19F MAS NMR spectra between 293 and 373 K for the
40/60 to 80/20 FFA/PVP-VA dispersions
For the highest loaded dispersions (70/30 and 80/20 w/w), a low intensity 19F shoulder peak
was observed at 373 K, with chemical shift values of ca. -59.6 ppm (figure 6.39), which are
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comparable to the chemical shift of pure form I at -59.8 ppm. This indicates the presence of
two inequivalent -CF3 environments: 1) the bulk highly mobile phase, consisting of dissolved
FFA in a viscous polymer paste (main isotropic peak); and 2) a small amount of FFA form
I, formed through the conversion of residual form III upon heating (shoulder peak). The
19F T1 relaxation (section 6.5.1 below), show the shoulder peak to have a much longer T1
F
time in both the 70/30 and 80/20 dispersions, which is consistent with these assignments.
Both dispersions were found to contain form III FFA upon initial characterisation, therefore
crystallisation from form III to form I would be thermodynamically favourable, as form I is
the more stable polymorph at higher temperatures.
Figure 6.39: 19F MAS NMR spectra for 80/20 (red), 70/30 (blue) and form I FFA (black) recorded at
373 K (MAS = 10 kHz)
Figure 6.40 shows the 19F MAS NMR spectra for the 80/20 and 70/30 dispersions recorded
at 293 K before and after heating to 373 K. Upon cooling, the asymmetrical peaks indicate
the presence of two inequivalent 19F environments in both dispersions, at similar chemical
shift values to at 373 K (figure 6.41). These two peaks can be assigned to: 1) amorphous
FFA, assigned to the peak at ca. -62 ppm, and 2) form I FFA, assigned to the peak at ca. -60
ppm. The 70/30 dispersion contains a smaller quantity of crystalline form I FFA than the
80/20 dispersion, following heating. This difference is also reiterated in section 6.5.1, where
different relaxation times were calculated for each component of the asymmetrical peaks the
70/30 and 80/20 dispersions, after the heating and cooling cycle. There was no change to
the spectra of the 60/40, 50/50 and 40/60 dispersions recorded at 293 K, before and after
heating.
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Figure 6.40: 19F MAS spectra of A) 80/20 and B) 70/30 dispersions recorded at 293 K, before and after
heating to 373 K, at an MAS rate of 10 kHz
Figure 6.41: Gaussian fit deconvolution of the 19F MAS spectra of A) 80/20 (R2 = 0.957) and B) 70/30
(R2 = 0.954) dispersions recorded at 293 K after heating to 373 K
The VT 19F analysis of the dispersions helped to clarify two main points. Firstly that the
dispersion is highly mobile at high temperatures, which is in agreement with the VT 1H
MAS, and 13C{1H} MAS NMR. Secondly, 19F MAS was sensitive enough to distinguish two
different fluorine environments at 373 K, which remained upon cooling. This likely indicates
the permanent presence of crystalline component following heating and cooling in the 70/30
and 80/20 FFA/PVP-VA dispersions, which was not detectable using VT 13C MAS NMR.
Combined, the VT NMR of the three different nuclei become a powerful ’toolkit’ for further
understanding of the behaviour of the dispersions with increasing temperature.
6.4 Clarification of high temperature crystallisation of FFA
in high drug loading dispersions with VT PXRD
To help further clarify the crystallisation behaviour of the higher drug loaded dispersions at
high temperatures observed in the VT 19F MAS NMR (form III→ form I), the FFA/PVPVA
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dispersions were monitored using VT PXRD between 293 and 373 K, at 20 K intervals.
Both the 70/30 and 80/20 dispersions were found to contain a mixture of form III and
amorphous FFA at ambient temperatures. Figure 6.42 illustrates the PXRD patterns for
the 80/20 dispersion with increasing temperature. After storage at 373 K for ca. 30
minutes, peaks corresponding to form I FFA could be identified, with form III peaks
reducing in intensity, indicating the polymorphic transition between forms III and I. This
occurred at much higher temperatures than the expected literature value of 315 K [197],
but is in agreement with the transition we observed upon heating pure form III FFA in situ
in the NMR rotor, and the temperature of transition determined in the highest loaded
dispersions with VT 19F MAS NMR. Upon cooling back to ambient temperatures, the
enantiotropic mixture of forms I and III remained in the 80/20 dispersion.
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Figure 6.42: A) VT PXRD patterns of 80/20 dispersion, recorded between 293 and 373 K in 20 K
increments, holding each sample at temperature for 114 minutes and B) Zoomed PXRD patterns of 80/20
dispersion at 373 K, with comparison to pure forms I and III. The conversion to form I is highlighted in blue
Figure 6.43 A) shows the PXRD patterns of the 70/30 dispersion with increasing
temperature. When held at 373 K, the growth of new peaks can be clearly seen. After
around 40 minutes at 373 K, three main peaks ca. 6.9, 14.0 and 21.2 °2θ greatly increase in
intensity compared to the remaining peaks, attributed to the growth of form I. When
compared to the 80/20 dispersion after annealing at 373 K (figure 6.43 B), both forms I
and III can also be identified in the 70/30 dispersion, with the patterns of each dispersion
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displaying peaks in similar positions.
Figure 6.43: A) Normalised VT PXRD patterns of 70/30 dispersion, recorded between 293 and 373 K
in 20 K increments, holding each sample at temperature for 114 minutes and B) Comparison between 70/30
and 80/20 dispersions after holding at 373 K for 114 minutes, compared with literature forms I and III FFA
Variation in peak intensity of PXRD patterns can occur due to a number of instrumental,
inherent and sample preparation factors including crystal morphology, particle size, preferred
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orientation, sample homogeneity, size of exposed surface, sample surface characteristics and
sample packing [261–263]. It is likely that preferred orientation in one direction is the cause
of the increased intensity in the form I diffraction peaks at high temperatures. Preferred
orientation is one of the most common causes of changes to peak intensity, especially for
acicular (needle-like) crystal morphologies [262, 263], which is the morphology of form I
FFA [55]. Here we see preferentially increased intensity of just three characteristic peaks
of form I FFA (ca. 6.9, 14.0 and 21.2 °2θ). Larger particle size and excess sample packing
can lead to preferred orientation effects [42,262,263]. Sample preparation/packing may have
lead to preferred orientation in this case, as the same effect was not observed with the
80/20 dispersion, which at high temperatures contained the same FFA polymorphs. Sample
rotation can be carried out to confirm preferred orientation effects [262], and may become
part of further VT PXRD investigations of the high temperature effects on the crystallisation
of FFA within dispersions.
Upon cooling, the 70/30 FFA/PVP-VA dispersion remained crystalline, with a combination
of forms I and III detected at ambient temperatures. Interestingly, when the sample was
removed from the holder, it had a hard, glassy surface. The PXRD pattern after scratching
the surface (black pattern in figure 6.44) shows the reduction in intensity of the ’preferred
orientation’ high intensity peaks, which suggests a preferential surface orientation effect,
reversible through reorientation by mechanical impact.
Figure 6.44: PXRD patterns of 70/30 dispersion, recorded at 293 K after the heat and cool cycle, before
(red) and after (black) scratching the sample surface
The 60/40 dispersion remained amorphous with heating up to 363 K, where some
recrystallisation occurred after ca. 18 minutes, with peaks at positions 8.8, 13.2, 17.6, 22.2
and 26.8 ° 2θ starting to grow (figure 6.45). All peaks completely disappeared again, with
the sample becoming amorphous once more. The crystallisation event was short-lived,
lasting only for ca. 40 minutes. Following this when heated to 373 K and upon subsequent
cooling, the sample remained amorphous.
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Figure 6.45: VT PXRD patterns of 60/40 FFA/PVP-VA dispersion during annealing at 363 K
The peaks observed at 363 K can be attributed to either form I or form III, and are all
present in the 80/20 and 70/30 dispersions after annealing at 373 K. The beginnings of
crystallisation from amorphous FFA therefore likely occurs at 363 K in the 60/40
dispersion as conditions become favourable. However, the higher polymer content in the
60/40 dispersion prevents further crystallisation, instead dissolving the crystallites as
increased drug solubility dominates. This explanation is in agreement with our current
hypothesis, which describes the presence of a viscous ’liquid like’ environment at high
temperatures.
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Figure 6.46: Comparison of high temperature crystallisation in the 80/20, 70/30 and 60/40 FFA/PVP-VA
dispersions, with reference to forms I and III FFA
The 40/60 dispersion remained amorphous throughout the VT PXRD.
The VT PXRD studies therefore confirmed the permanent polymorphic transition from
existing form III to form I at 373 K in the 70/30 and 80/20 FFA/PVP-VA dispersions,
detected with VT 19F MAS NMR, but not VT 13C and 1H MAS NMR. Again this transition
occurred at much higher temperature than expected from previous literature studies [197,
249], although there is some inconsistency in the the literature [260]
6.5 Probing miscibility and dynamics of FFA/PVP-VA
dispersions with spin-lattice relaxation
6.5.1 Variable Temperature T1
F
The investigation of variable temperature 19F spin-lattice relaxation times was used to
further probe the faster motions and crystallisation of the drug detected in the
FFA/PVP-VA dispersions at high temperatures. A difference in the temperature
dependence of the T1
F times with increasing drug content was observed (figure 6.47).
There was little change in the T1
F times of the 40/60 - 60/40 dispersions with increasing
temperature, with slight reduction in T1
F times of the 50/50 and 60/40 dispersions at
the highest temperatures. At lower temperatures, the 70/30 and 80/20 dispersions had
longer relaxation times, due to the presence of form III FFA. With increasing temperature,
a gradual increase in T1
F occurred, followed by a more dramatic reduction in T1
F times,
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Figure 6.47: T1F times (s) for the 80/20, 70/30, 60/40, 50/50 and 40/60 dispersions with increasing
temperature (293 K to 373 K)
with the absence of a T1
F minimum. For the 70/30 dispersion, a further change in T1
F
times at ca. 373 K indicates the possible beginnings of a minimum, which is in agreement
with Aso et al. [41] who detected a T1
F minimum in their FFA/PVP 70/30 dispersion at 363
K. Temperature dependence of this kind can be attributed to the overlapping of multiple
motional regimes within the system. At high temperatures, the FFA/PVP-VA dispersions
have been shown to be complex, with possible melting, liquefaction, crystallisation and high
mobility occurring concurrently; making it difficult to fully interpret the changes in relaxation
times. At temperatures below ca. 333 K, relaxation times are most likely dominated by the
presence of form III crystalline material. However, above this temperature, a more rapid
reduction in T1
F times occurs indicating an increased mobility, as the dispersion begins to
change to a more liquid-like state, identified previously. This correlates with the VT 19F
MAS data, which showed the dramatic reduction of linewidth, occurring at temperatures ca.
343 K (figure 6.37).
To gain additional information about the high-drug loaded dispersions, the apparent
activation energies were calculated above and below TMAX , by assuming τ c follows an
Arrhenius law. The EA values calculated above TMAX were greater by a factor of ten for
both dispersions, therefore different motional process are clearly being represented above
and below 333 K.
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Figure 6.48: Arrhenius plots of ln(T1F ) vs. inverse temperature for the -CF3 functional group of the
70/30 and 80/20 FFA/PVP-VA dispersions. Activation energies are shown, as calculated from the gradient
The T1
F times of the two inequivalent fluorine sites assigned to amorphous FFA (ca. -62
ppm) and form I FFA (ca. -60 ppm) (see section 6.3.5) in the 80/20 and 70/30 dispersions
were calculated at 373 K; and upon cooling back to 293 K (figure 6.49). Two distinct T1
F
times were calculated for each 19F environment, which indicates the presence of two different
FFA phases, both at 373 K, which remain present upon cooling to 293 K. At 373 K, there was
a large difference in T1
F between the two sites in both dispersions: the shoulder peak had a
much longer T1
F time than the main peak, which provides further evidence for the presence
of crystalline FFA at high temperature. Upon cooling, we continue to see separation of the
two components within the dispersions via T1
F times: the peak ca. - 60 ppm (corresponding
to the crystalline component) has a longer T1
F than the amorphous peak ca. - 62 ppm.
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Figure 6.49: Arrhenius plots outlining the temperature dependence of T1F times of A) 80/20 and B)
70/30 dispersions, heated between 293 K and 373 K, then cooled back to 293 K. Relevant 19F MAS NMR
spectra for 373 K and upon cooling back to 293 K are shown to highlight the origins of phase separation
There are very few studies in the literature which use 19F MAS NMR to assess the mobility
of drug/polymer dispersions. Aso et al. [41] used variable temperature low field 19F NMR
to assess the mobility of FFA/PVP and FFA/HPMC dispersions at 70 and 80 wt. % drug
loading, by determining T1
F and T1ρ
F times. For T1
F , they observed a minimum for the
FFA/PVP 70/30 dispersion ca. 363 K, but no minimum for the 80/20 dispersion due to
rapid crystallisation above 343 K, where no T1 times could be calculated (figure 6.50).
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Figure 6.50: Temperature dependence of T1F and T1ρF for FFA/PVP and FFA/HPMC 70/30 and 80/20
dispersions [41]
No information was provided to identify the polymorphic form of the crystalline FFA [41].
It is therefore highly likely that the minimum for the mobile phase in our experiments is just
outside the covered temperature range.
6.5.2 Variable Temperature T1ρ
H
The temperature dependence of T1ρ
H times of the FFA/PVP-VA dispersions (40/60 -
80/20), amorphous FFA and forms I and III FFA were investigated. The relaxation times
of form I FFA were too long to be determined accurately (longer than 70 ms) across the
full temperature range. T1ρ
H times of amorphous FFA could only be recorded below 273
K, as following crystallisation to form I (detected via VT 1H-13C CP/MAS NMR at ca.
273 K), relaxation times were also too long for accurate determination.
The 40/60, 50/50 and 60/40 FFA/PVP-VA dispersions were found to be homogenous
across the full temperature range, as indicated by the very similar T1ρ
H times measured for
both drug and polymer, due to efficient spin diffusion (figure 6.51). For the 40/60
FFA/PVP-VA dispersion, the non-typical temperature dependence described in chapter 5,
was observed. Firstly an initial increase in T1ρ
H times with increasing temperature was
identified, indicating a fast motional regime with EA of 12.87 kJ mol
−1 up to a TMAX at
(Tg - 19 K). Following TMAX , a marked change in temperature dependence occurred, seen
by a rapid decrease in T1ρ
H times with increasing temperature (EA = 61.7 kJ mol
−1). The
difference in activation energies above and below TMAX indicates the presence of two
different motions, likely associated with two different T1ρ
H minima, at opposite
temperature extremes outside the studied temperature range. No TMAX was observed for
the 50/50 and 60/40 FFA/PVP-VA dispersions, with T1ρ
H times decreasing with
increasing temperature across the full range, indicating a motional regime on the slow side
of a T1ρ
H minimum. A change in gradient occurred again ca. 19 K below Tg, representing
an increased mobility, with an EA of 55.4 kJ mol
−1.
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The similarity of the high temperature apparent activation energies between the
dispersions indicates the same motional environment with increasing temperature, likely to
be a combination of a number of overlapping motional regimes. The nature of the
FFA/PVP-VA dispersions at high temperatures has been shown to be complex, with
possible overlapping melting, liquefaction, crystallisation and high mobility occurring
concurrently, as highlighted with VT 1H, 19F and 13C MAS NMR experiments.
An increased molecular mobility ca. 19 K below Tg has been observed in the literature with
amorphous nifedipine and nifedipine/PVP dispersions, with a number of separate studies
showing that T1ρ times were dramatically reduced ca. 20 K below Tg, which was linked to
instability due to increased molecular mobility [46,47].
A difference in the relaxation behaviour of drug and polymer indicative of phase separation
can be seen across the whole temperature range for the 70/30 and 80/20 FFA/PVP-VA
dispersions; and was especially pronounced for the 80/20 dispersion (figure 6.52). At 70 wt.
% drug loading, the T1ρ
H temperature dependence was comparable to that seen for the 60/40
and 50/50 FFA/PVP-VA dispersions. Both drug and polymer components displayed similar
temperature dependence, with very little change below Tg, followed by a more dramatic
increase in T1ρ
H above Tg, until the point where signal disappeared from the CP/MAS
spectra. The T1ρ
H times of FFA in the dispersion were consistently longer than for PVP-VA
throughout, however still shorter than pure crystalline FFA. This behaviour is comparable
to the 80/20 IMC/PVP-VA dispersion at temperatures prior to full crystallisation to the
α-polymorph, where regions of higher mobility polymer act as ’relaxation sinks’ for small
crystalline ’domains’. This leads to shorter observed T1ρ
H times of crystalline material
within the dispersion, as compared to pure crystalline material. By 80 wt. % drug loading,
we can clearly see a greater separation of drug and polymer, despite very few points on the
temperature dependence curve, with T1ρ
H times of FFA consistently longer than 70 ms,
indicating the presence of a high level of crystalline FFA.
The relaxation curves of the highest drug loading dispersions are extremely useful visual
tools to identify phase separation and homogeneity in solid dispersions. At high drug loading
levels, the phase separation is obvious, even without further calculation of differences between
T1ρ
H times, often employed as a technique to determine miscibility in solid dispersions [90].
This could become an important technique to initially determine miscibility limits when first
investigating drug loading levels within a formulation.
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Figure 6.51: Temperature dependence of T1ρH times for different 13C sites for A) 40/60 and B) 60/40
FFA/PVP-VA dispersions. The 50/50 dispersion displayed a similar temperature dependence to the 60/40
dispersion
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Figure 6.52: Temperature dependence of T1ρH times for different 13C sites for A) 70/30 and B) 80/20
FFA/PVP-VA dispersions
6.5.2.1 Detection of miscibility on the T1ρ
H timescale
The ∆T1ρ
H (between FFA and PVP-VA) of each dispersion at 293 K can be seen in figure
6.53. As demonstrated in the previous temperature dependence curves, there were no
differences in T1ρ
H times for 20 - 60 wt. % FFA/PVP-VA dispersions, indicating
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miscibility on the 2 - 6 nm length scale. The 70/30 and 80/20 dispersions displayed a large
∆T1ρ
H well above the zero line, indicating the presence of obvious domains larger than 6
nm in size. Due to time constraints, we were unable to carry out VT T1
H time
measurements to further investigate the larger domains present in the 70/30 and 80/20
dispersions.
Figure 6.53: ∆T1ρH (ms) between FFA and PVP-VA in the solid dispersions, at 293 K, displayed as a
function of wt. % drug content
6.6 Stability Studies
Throughout the 8 week stability study, all dispersions were monitored for changes in the local
ordering using PXRD, mDSC and 13C CP/MAS solid-state NMR. FFA/PVP-VA dispersions
with drug content ≤ 50 wt. % remained amorphous in each storage condition throughout,
indicating high physical stability (figure 6.54).
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Figure 6.54: PXRD pattern recorded before (red) and after (blue) 8 weeks storage at 343 K for the 20/80
and 40/60 FFA/PVP-VA dispersions
The 60/40 FFA/PVP-VA dispersion remained amorphous throughout the study at room
temperature (0 % RH), with some crystallisation to form III detected after 6 weeks storage
at all other conditions (figure 6.55). Unusually, no endothermic melting was observed in the
DSC curves in any 60/40 stability study samples, despite form III being identified with both
PXRD and 1H-13C CP/MAS NMR. This may be linked to the higher solubility of the small
crystallites of form III at increased temperature in the polymer which was thought to be
the reason for the lack of crystallisation observed via. VT PXRD. No crystallisation was
identified in the previously discussed 13C, 19F or 1H MAS NMR studies.
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Figure 6.55: A) PXRD patterns recorded before (red) and after 8 weeks storage at room temperature (0
and 75 % RH), 313K and 343 K for the 60/40 FFA/PVP-VA dispersions, with a comparison to form III FFA
and B) 1H-13C CP/MAS NMR spectra acquired before (red) and after storage at 343 K, with a comparison
to form III FFA
No further polymorphic transitions were observed in the 70/30 and 80/20 FFA/PVP-VA
dispersions stored up to temperatures of 343 K, with only form III FFA detected throughout
the 8 week stability study (figure 6.56). This is in agreement with the crystallisation observed
via VT PXRD, as the transition from form III → form I only occurred at 373 K, ca. 60 K
above the reported transition temperature [197].
The three highest loading dispersions were stored at in the oven at 373 K for 2 weeks, to
investigate the high temperature transition from form III→ form I detected through VT 19F
MAS NMR and VT PXRD studies. Unfortunately, under these conditions, the dispersions
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formed hard glass melts, which proved unsuitable for further analysis.
Figure 6.56: PXRD pattern recorded before (red) and after 8 weeks storage at room temperature (0 and
75 % RH), 313K and 343 K for the A) 70/30 and B) 80/20 FFA/PVP-VA dispersions
Aso et al. [41] stored 80/20 FFA/PVP and FFA/HPMC dispersions at 333 K for 10 hours.
They found crystallisation in both samples within this time, with faster crystallisation in
the HPMC dispersion compared to the PVP, which was linked to the higher local mobility
of the sample, confirmed through VT τ c calculations from T1
F and T1ρ
F studies. The
polymorphic form of FFA was not identified. Van Eerdenbrugh and Taylor [247] studied
the ability of a number of polymers to inhibit crystallisation in 8 model drug compounds,
including FFA and PVP-VA. Spin coated samples with drug content between 10 - 95 wt.
% were monitored over 7 days storage under dry conditions at ambient temperature. For
FFA/PVP-VA, crystallisation only occurred in the 75/25 and 90/10 dispersions over the 7
day period, in agreement with our stability study results.
6.7 Conclusions
FFA was successfully formulated as an amorphous solid dispersion with PVP-VA in a variety
of drug/polymer ratios. Initial characterisation indicated the fully amorphous nature of the
dispersions up to the maximum drug loading of 60 wt. %, above which varying levels of form
III, alongside amorphous FFA were detected. The previously unreported full 1H assignment
of FFA and solid-state characterisation of amorphous FFA was presented, with the Tg was
calculated to be 286 K.
In comparison to IMC, the local mobility of the FFA/PVP-VA dispersions proved more
complex. The 40/60 - 80/20 FFA/PVP-VA dispersions showed a similar mobility behaviour
at high temperatures, which was more pronounced with increasing drug loading. Upon
cooling back to 293 K, broad amorphous FFA peaks were detected in all dispersions. We
postulate that at high temperatures, a highly mobile, ’liquid-like’ environment exists in these
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dispersions, described as consisting of an amorphous (or ’melted’) FFA component, dissolved
in a viscous polymer ’paste.’ The timescale of dominant processes in FFA molecular mobility
is likely to be ca. 1000 kHz. At the highest drug loadings, an additional crystalline phase is
likely present, which was further probed using VT 19F MAS and PXRD techniques.
The fully amorphous FFA/PVP-VA dispersions followed the ’non-typical’ temperature
dependence observed with IMC/PVP-VA, due to the presence of at least two overlapping
mobility regimes, although the loss of CP signal hindered the measurements at high
temperatures. EAapp(LT) and (Tg - TMAX) measurements extracted from the temperature
dependence curves provided further data to relate the mobility behaviour detected through
T1ρ
H to physical stability, which is further discussed in chapter 8.
Miscibility between FFA and PVP-VA was additionally probed, with ∆T1ρ
H measurements
allowing the investigation of domains down to ca. 2 nm. Phase separation was shown
across all temperatures for the 70/80 and 80/20 dispersions. These curves are extremely
useful visual tools for the identification of phase separation in solid dispersions. This could
become an important technique to initially determine miscibility limits during initial drug
formulation.
Crystallisation from amorphous FFA, and polymorphic transitions of forms I and III FFA,
were also studied. FFA is known to exhibit complex polymorphism [39], having the highest
number of solved polymorphic structures in the Cambridge Structural Database. Pure
amorphous FFA was shown to crystallise to form I FFA; and Form III was shown to
undergo an enantiomeric polymorphic transition to form I, at ca. 373 K, with both 1H-13C
CP/MAS NMR and 19F MAS NMR. Monitoring the crystallisation behaviour of the high
drug loaded dispersions was hampered due to the high mobility at high temperatures.
However, 19F provided an alternative way to detect and characterise the drug via 19F MAS
NMR and T1
F . This method clearly highlighted two distinct fluorine environments,
corresponding to crystalline (form I) and amorphous FFA, both at 373 K, and upon cooling
to ambient temperatures. There are no previously reported examples of the detection of
phase separated drug phases with T1
F .
The enantiomeric transition from form III → form I in the 70/30 and 80/20 dispersions was
confirmed using VT PXRD studies. This enantiomeric polymorphic transition (form III →
I) was found to occur at a much higher temperature than the expected literature transition
temperature.
In summary, the numerous solid-state NMR techniques employed have provided a large
amount of information regarding the local structure and dynamics of FFA solid dispersions,
which have not previously been reported. We have shown that FFA dispersed in PVP-VA
displays complex high temperature mobility behaviour, which therefore proved to be a
difficult system to investigate. However the presence of a 19F nucleus extended the NMR
analysis options, with the combination of numerous techniques allowing further
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understanding of these systems.
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Chapter 7
Variable Temperature Studies of
Tolbutamide
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Previous literature studies of TLB have focussed mainly on studying polymorphism and
the crystalline form [42–44, 264]. Amorphous TLB has been shown to have low stability
- Graeser et al. [100] found it to be stable at 258 K after 30 days storage, but unstable at
ambient temperatures. There have been some studies of TLB solid dispersions: TLB has been
most widely studied as a cyclodextrin (CD) inclusion complex, using a variety of techniques
including PXRD, DSC and IR-spectroscopy [265] and molecular dynamics simulations [266];
with only one study applying solid-state NMR to investigate crystallisation behaviour [264].
TLB has also been shown to form amorphous solid dispersions with PVP: characterised using
PXRD and dissolution [267], DSC [175] and as part of the same solid-state NMR study to
investigate crystallisation behaviour [264]; and PEG-4000 [176]. Additionally, TLB solid
dispersions (formulated with a number of polymers) were included in a small scale stability
study, which used polarized light microscopy to monitor physical stability [247].
7.1 Crystalline Tolbutamide
Tolbutamide has six reported polymorphic forms (forms IL, IH , II-V) [42–44,172–174], with
its ability to crystallize into different forms due to the flexibility of rotatable alkyl bonds [42].
Form IH has the highest melting point, and is the most stable form at high temperatures:
forms II and III are known to undergo a transition to form I upon heating [58,171]. Form V
was most recently formed by Nath et al. [44], through the crystallisation of TLB in methanol
with a trace of HNO3. Following slow evaporation over 48 hours, single crystals of form V
were isolated, which were found to be unstable with conversion to form I occurring within
2 hours at room temperature [44]. The published crystal packing data of forms I-V can be
seen in table 7.1.
Table 7.1: Crystallographic data on forms I-V tolbutamide [42–44,56]
Form IL Form IH Form II Form III Form IV Form V
Crystal habit Prism Plate Needle Needle Plate
Colour Colourless Colourless Colourless White Colourless
Crystal system Orthorhombic Orthorhombic Monoclinic Monoclinic Monoclinic Orthorhombic
Temp. of structure
determination (K)
153 363 153 153 298 298
Space group Pna21 Pna21 Pc P21/n P21/c Pbcn
a (A˚) 20.223(1) 20.8095(4) 9.087(8) 11.735(2) 10.091 15.851(6)
b (A˚) 7.831(9) 7.9323(2) 17.228(3) 9.052(8) 15.646 9.288(4)
c (A˚) 9.090(10) 9.0610(2) 17.951(4) 13.732(3) 9.261 19.691(8)
α (°) 90 90 90 90 90 90
β (°) 90 90 95.01(3) 103.57(3) 100.49 90
γ (°) 90 90 90 90 90 90
V (A˚3) 1439.55(11) 1494.67(5) 2799.8(10) 1416.4(5) 1438.9 2899.2(19)
Z/Z’ 4/1 4/1 8/4 4/1 4/1 8/1
CSD Code ZZZPUS02 ZZZPUS05 ZZZPUS06 ZZZPUS07 ZZZPUS10
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Due to the conformational flexibility of TLB, the effect of low temperature on crystal
structure was investigated (simultaneously by Drebushchak et al. [57] and Nath et al. [44])
in 2011, as torsional rotations of flexible molecules are known to become frozen at low
temperatures [268]. There were no changes to forms I and II upon cooling, (to 100 K) [57],
but changes to the unit cell structure of form III were determined (table 7.2) [44, 57]. At
100 K, a high Z’ form III was described (named form III2), with 3 molecules in the
asymmetric unit, and elongation of the b axis, which was fully reversible upon heating.
The higher temperature form III was found to have disorder in the butyl chain [57]. There
is discrepancy between the two groups regarding the volume of form III2, with
Drebushchak et al. reporting no change as compared to form III [57], and Nath et al.
reporting a much larger volume [44]. Nath et al. additionally attempted to investigate the
effect of reduced temperature on form V, but found it immediately converted to form I
upon cooling, due to rapid uptake of moisture [44].
Table 7.2: Crystallographic data at different temperatures for form III and III2 tolbutamide [42,44,57]
Form III Form III Form III Form III2 Form III2
Reference [42] [57] [44] [57] [44]
Temp. of structure
determination (K)
153 295 298 100 100
Space group P21/n P21/n P21/n P21/n P21/n
a (A˚) 11.735(2) 11.8100(6) 11.787(5) 11.5671(1) 11.5613(17)
b (A˚) 9.052(8) 9.0587(3) 9.043(4) 27.1703(3) 27.189(4)
c (A˚) 13.732(3) 13.9713(6) 13.955(6) 13.5558(2) 13.556(2)
α (°) 90 90 90 90 90
β (°) 103.57(3) 104.491(5) 104.644(7) 102.746(1) 102.803(2)
γ (°) 90 90 90 90 90
V (A˚3) 1438.9 1447.12(3) 1439.2(10) 1385.1169(7) 4155.2(11)
Z/Z’ 4/1 4/1 4/1 12/4 12/4
CSD Code ZZZPUS06 ZZZPUS13 ZZZPUS08 ZZZPUS11 ZZZPUS09
The thermal behaviour of form I crystalline tolbutamide is illustrated in figure 7.1. On the
initial heating run (green), the conversion of form IL to IH at 313.3 K is observed, followed
by the melting of form IH at 401.8 K. Upon cooling, we observe the Tg of amorphous TLB
at 278.0 K. Upon subsequent reheating, a number of polymorphic transitions occur due to
the crystallisation of form IV, form III and form II to form IH at 358.7, 377.8 and 391.3
K respectively, which indicates an enantiotropic relationship between each polymorph and
form IH . All thermal events observed agree with the literature values, shown in table 7.3.
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Figure 7.1: DSC trace of form I tolbutamide, heated between 253 and 408 K. The initial heat and cool
cycles are displayed in green, with the subsequent reheat cycle in purple
Table 7.3: DSC data of TLB polymorphs, adapted from [42,44,56]
TLB Polymorph Tm (K) Transition Point (K) ∆Htrs J · g−1 ∆Hfus J · g−1
Form IH 401 88.0
Form IL 313 +7.0 (IL to IH) 95.1
Form II 390 +8.1 (II to IH) 97.2
Form III 379 +6.4 (III to IH) 94.7
Form IV 361 -4.8 (IV to IH) 73.2
Form V Unknown
There is some discrepancy in the literature around the correct order of thermodynamic
stability of the TLB polymorphs. Kimura et al. [58] initially reported the thermodynamic
order at room temperature as form III < form II < form I. However, this was disputed by
Hasegawa et al. [43], when they determined that form I displayed enantiotropic behaviour,
with a transition temperature of 311 K; and named the two polymorphs form IL and form
IH . They additionally disputed Kimura’s stability order, as the solubility of form III at
room temperature was found to be higher than that of form I. The revised thermodynamic
stability was published as Form III < Form IL < Form II below the IL → IH transition
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temperature of 311 K; and Form IH < Form III < Form II above the transition temperature.
Therefore form II was determined to be the most stable polymorph, via investigations of
heat of solution (∆H) and solubility [43].
Thirunahari et al. [42] revisited the crystal structures of forms I-IV, providing refined single
crystal structures (forms I-III) and updated information on packing, molecular
conformation and thermodynamic stability. They extensively characterised the polymorphs
using solid-state NMR, FT-IR, DSC, hot stage microscopy and SEM and found that below
ca. 353 K, form II was indeed the most thermodynamically stable polymorph, but above
353 K, form IH was more stable [42]. Thirunahari constructed an E-T diagram of the
tolbutamide polymorphs, based on the DSC data collected (melting point, transition point,
heat of transition, heat of fusion) (figure 7.2). This indicates that at an increased
temperature, all polymorphs undergo a transition to the most stable high temperature
form IH . They showed that forms III/IH and II/IH are enantiotropically related; and
IV/IH monotropically related. Additionally, from the E-T diagram, form IV was suggested
to be monotropically related to all other polymorphic forms, and the transition from form
III to IL was enantiotropic below 311 K [42]. Form V was only isolated recently, so was not
included in the energy-temperature diagram. It is known to be metastable, converting to
form I within two hours at room temperature [44].
Figure 7.2: Schematic energy-temperature diagram of TLB polymorphs, adapted from [42]
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In each polymorphic form, different conformations of TLB molecules are present, divided
into two types of conformational polymorphs: U (same side) and chair (opposite sides), with
reference to the position of the tolyl and butyl groups either side of the central S-N-C-N
plane (figure 7.3) [42]. Forms IL and III follow packing scheme A (U-type), form II has
a combination of schemes C and D (chair-type) and forms IV and V follow scheme B (U-
type) [42,44]. The main hydrogen bonding within each polymorph occurs via the ’urea tape’
motif between N-H donor and C=O acceptor groups (figure 7.3) [42,44].
Figure 7.3: Types of packing schemes around the central S-N-C-N plane in TLB polymorphs, as described
by [42]
Additional information about the enantiotropic transition of forms IL and IH was
published by Hasegawa et al. in 2009 [43]. Using the DSC data, they demonstrated that
the transition was reversible. Changes to the crystal structure were observed above and
below the enantiotropic transition temperature, using both PXRD and solid-state NMR.
Form IL was found to convert to form IH upon heating over 311 K, with an enthalpy of 2
kJ mol−1. Both polymorphs had the same space group, with isomorphic molecular packing.
The structural difference between forms IL and IH was shown to be small: a conformational
change of the terminal butyl group (figure 7.4), with additional movement of the S-N bond
(figure 7.5).
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Figure 7.4: Molecular structure of form IL and form IH TLB, adapted from [43]
Figure 7.5: Torsion angles (degrees) in tolbutamide for A) form IL and B) form IH , adapted from [43]
The solid-state 1H-13C CP/MAS NMR spectra of forms IL and IH can be seen in figure
7.6. The chemical shift assignments of each form are detailed in table 7.4, which are in
agreement with literature values [43]. The main changes to the 13C chemical shifts upon
heating form IL occur within the aliphatic region, due to the rearrangement of the butyl
chain (figure 7.6). Further downfield, the only significant change occurs to C-8 (C=0), which
is positioned between the S-N bond and butyl chain, and undergoes a change in torsion
angle. All differences observed upon conversion of form IL to form IH agree with those found
by Thirunahari at al. [42].
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Figure 7.6: A) 1H-13C CP/MAS NMR spectra of form I TLB at 293 and 313 K, recorded with an MAS
rate of 10 kHz. 13C chemical shift assignments are indicated alongside the molecular structure of TLB. B)
Zoomed aliphatic region, to highlight the temperature dependent enantiotropic transition between form IL
and form IH (* denotes spinning sideband peaks)
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Table 7.4: 13C NMR chemical shifts (δ) of forms IL and IH tolbutamide, compared to literature values
[43,58]
Carbon Measured Literature [43]
Form IL Form IH ∆δ (ppm) ∆δ (ppm)
12 13.4 14.3 0.9 0.8
11 19.3 19.8 0.5 0.4
1 21.9 21.4 0.5 0.5
10 31.6 32.5 0.9 1.0
9 40.1 40.3 0.2 0.2
3,7 125.6 125.5 0.1 0
4,6 131.3 131.2 0.1 0.1
5 138.0 138.2 0.2 0.3
2 145.4 145.6 0.2 0.2
8 155.1 154.5 0.4 0.4
Although the 1H-13C CP/MAS NMR spectra of forms II-IV have been reported (figure
7.7 [42, 58]), their quality is not sufficient to use as a reliable comparison. The spectra can
at best be used as a visual qualitative reference for polymorph identification.
Figure 7.7: 1H-13C CP/MAS NMR spectra of forms I-IV TLB polymorphs, recorded at 400 MHz, as
reported by [42]
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7.2 Initial Characterisation of Amorphous TLB, and
TLB/PVP-VA solid dispersions
All solid dispersions were characterised using modulated DSC, PXRD and 1H-13C CP/MAS
NMR. Each dispersion has a single Tg (figure 7.8), intermediate between the Tg values of
pure amorphous TLB and PVP-VA, as expected from the Gordon-Taylor relationship [112].
The value of Tg increases with increasing polymer content for all dispersions. Ideal Tg values
of the dispersions were calculated using the Gordon-Taylor/Kelley-Bueche (G-T/K-B) and
Couchman-Karasz (C-K) equations (equations 2.17 with 2.19 and 2.20 - see chapter 3), and
can be seen in figure 7.8.
Figure 7.8: Glass transition temperatures for TLB/PVP-VA dispersions at different drug loadings,
compared to values predicted by the Gordon-Taylor/Kelley-Bueche (G-T/K-B) and Couchman-Karasz (C-K)
equations
The Tg values of the TLB/PVP-VA dispersions showed very little deviation from predictions,
indicating relatively ideal mixing between the drug and polymer, with the absence of strong
intermolecular interactions. The experimental values were closer to predictions by the G-
T/K-B over the C-K equation. In previous studies, deviations of ± 5 K were considered to
be good agreement for ’ideal’ mixing [78,190]
The initial heating run for the highest drug loaded dispersions (60/40 - 80/20 TLB/PVP-
VA) showed both endothermic melting peaks, and a glass transition event, highlighting
the presence of both crystalline and amorphous TLB (figure 7.9). For the 70/30 and 80/20
dispersions, the transition of form IL to IH can be observed at 313 K [42]. Additional melting
endotherms were also observed: at 80 wt. % drug loading, a small endothermic transition
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peak at 370 K followed by a large, broad endothermic melt at 396 K (∆Hf = 35.8 J·g−1); and
for 70 wt. % drug loading, a broad endothermic peak at 389 K (∆Hf = 23.4 J·g−1). There
were also very slight exothermic transition points observed in both dispersions at 340 and
346 K for 80/20 and 70/30 respectively, which could indicate crystallisation from amorphous
TLB upon heating. The DSC curve for the 60/40 dispersion showed a small endothermic
peak at ca.380 K. As discussed in chapter 6, the presence of broad melting endotherms in
DSC curves is attributed to either 1) the melting of a drug/polymer solid solution, formed
through the dissolution of crystalline drug in the polymer upon heating [90, 148]; or 2) the
melting of residual crystalline API formed during manufacture, which is often reported at
lower Tm values compared to the pure drug in the absence of polymer [148,190,228]. As we
observe the transition of form IL to IH in the DSC curve of the 70/30 and 80/20 dispersions,
let us assume that they contain residual form IL, formed during manufacture. In this case,
the melting endotherms at 389 and 396 K respectively can be assumed to be due to the
melting of form IH , which has a lower than expected Tm value. The content of residual
crystalline material can therefore be calculated with equation 5.1 (see chapter 5) using ∆Hf
for form IH (88.5 J·g−1 - figure 7.3) as 37.8 % and 50.6 % for the 70/30 and 80/20 dispersions
respectively. If we calculate assuming the presence of form I TLB for the 60/40 dispersion
in the same way, the crystalline content is much lower: only 5.7 % of the TLB content.
Figure 7.9: DSC data for 60/40, 70/30 and 80/20 dispersions (initial heat run only). Tg events are shown
inset (Rev. Cp vs. temperature curves)
PXRD analysis at ambient temperature (figure 7.10) also indicated the presence of crystalline
material in the highest drug loading dispersions. The dispersions with drug loadings lower
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than 50 wt. % were fully amorphous.
Figure 7.10: PXRD patterns of TLB/PVP-VA dispersions at different drug loadings. TLB loadings of
greater than 50 wt. % all displayed broad halo patterns, and were therefore confirmed to be fully amorphous
Here we see the presence of multiple polymorphs of TLB in the 80/20 dispersion, which can
be identified as mainly form IL (dashed black lines), alongside some form II (green lines)
and V (blue lines) ((figure 7.11)) [42, 44]. The crystalline TLB in the 70/30 dispersion was
confirmed to be form IL ((figure 7.11)). There are some slight peaks in the PXRD pattern
of the 60/40 dispersion, which could indicate form IL, although the amount is very low.
Figure 7.11: PXRD patterns of 70/30 and 80/20 dispersions at ambient temperature, compared to form
IL (Sigma Aldrich, UK), form II [42] and form V [44] TLB polymorphs.
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1H-13C CP/MAS NMR confirmed the amorphous nature of dispersions up to 50 % drug
loading (figure 7.12), which was in agreement with DSC and PXRD analysis. Crystalline
TLB was not detected in the 1H-13C CP/MAS NMR spectrum for the 60/40 dispersion, in
comparison to DSC and PXRD. The change in intensity of the drug/polymer peaks reflects
the ratio of the two components within each dispersion. 13C chemical shift assignments of
the amorphous TLB can be seen in table 7.5, with the additional peaks assigned to the
polymer.
Figure 7.12: 1H-13C CP/MAS NMR spectra for all amorphous dispersions: TLB/PVP-VA 10/90 - 60/40
compared to PVP-VA, recorded at an MAS rate of 10 kHz, with the molecular structure of TLB and PVP-VA
to indicate chemical shift assignment
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Table 7.5: 13C NMR chemical shifts (δ) of amorphous TLB and and PVP-VA for dispersions of drug
content between 10 and 60 %
13C assignment Amorphous TLB 13C assignment PVP-VA
C-12 14.4
C-B 19.3
C-1, C-11 21.5 C-J 21.5
C-10 32.1 C-C, C-H 32.1
C-F 36.5
C-9 40.4
C-A, C-E 42.6
C-G 68
C-3,4,6,7 129.9
C-5 138.0
C-2 144.5
C-8 152.7
C-D 171.0
C-I 175.7 (10/90) - 176.9 (60/40)
Figure 7.13 shows the ambient temperature 1H-13C CP/MAS NMR spectra for the 70/30
and 80/20 dispersions. The narrower resonances, with broadening around the base indicate
the presence of both crystalline and amorphous TLB. The crystalline component of the
70/30 dispersion can clearly be identified as form IL, in agreement with PXRD. The 80/20
dispersion contains a more complex mixture of polymorphs. Using the CP/MAS spectrum,
we confirmed the presence of forms IL, II and V in the 80/20 dispersion, in agreement with
PXRD. The assignments of resonances to each polymorph within the dispersion can be seen
in table 7.6. Form V was concurrently obtained in our research group through encapsulation
of TLB within mesoporous silica at 50 % drug loading (which was confirmed by comparison
with the literature PXRD pattern for form V [44]), hence the unreported 13C NMR spectrum
was used here for identification purposes. Following PXRD and 1H-13C CP/MAS NMR
analysis, the calculation of residual crystalline content from the DSC curve can be considered
a good estimation for the 70/30 dispersion, but most likely an underestimate for the 80/20
dispersion. The broad endotherm observed for the 80/20 dispersion at 396 K, is likely due
to the combined melting of forms IH , II and V, which were not fully accounted for in the
calculation. The constituent parts of the high drug loading dispersions have been further
clarified through variable temperature experiments (see section 7.3.2).
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Figure 7.13: 1H-13C CP/MAS NMR spectra for 70/30 and 80/20 dispersions compared to forms IL II
and V, recorded at an MAS rate of 10 kHz at 293 K. Splitting of the peaks at ca. 145.4 and 138.1 ppm for
form II TLB may be due to the increased Z’ value of this polymorph (Z’ = 4, see table 7.1). Unfortunately,
due to time constraints, this was not investigated further
Table 7.6: 13C NMR chemical shifts (δ, ppm) of forms IL, form II and form V tolbutamide, and PVP-VA
within the 80/20 dispersion, recorded at ambient temperature. Note, the level of amorphous TLB in this
dispersion was too low to detect specific chemical shift values
13C assignment Form IL Form II Form V 13C assignment PVP-VA
C-12 13.4 13.4, 15.9 13.4, 15.9
C-11 19.5 19.5 20.6 C-B 19.5
C-1 21.9 20.3 21.9 C-J 21.9
C-10 31.7 32.9 33.9 C-H 31.7
C-C, 32.8
C-9 40.2 39.6 41.5
C-A, C-E 43.4
C-G 68.0
C-3,7 125.6 125.6 127.1
C-4,6 131.5 131.5 130.2
C-5 138.1 140.0 138.1
C-2 145.5 145.5
C-8 155.0 155.0 153.9
C-D 170.9
C-I 176.2
We were able to deconvolute the C-8 peak for the 70/30 dispersion to estimate the relative
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contribution of form IL and amorphous TLB (figure 7.14). Unfortunately, the level of
amorphous TLB in the 80/20 dispersion was too low for accurate deconvolution of this
spectrum.
Figure 7.14: 1H-13C CP/MAS NMR spectrum of the C-8 peak for the 70/30 dispersion. Peak integrals
obtained from Gaussian dseconvolution are shown, alongside the calculated % contribution to the peak from
form IL (δ = 155.0 ppm) and amorphous TLB (δ = 152.7 ppm)
This estimation of 67 % form IL at 293 K is much higher than the value calculated using
the melting enthalpies detected in the DSC curve (37.8 %), although this technique may
underestimate the amorphous form due to the broadening effect.
Changes to the chemical shift of one carbonyl for PVP-VA (C-I) were observed across all
dispersions (figure 7.15). The gradual downfield shift of the carbonyl peak from 175.4 ppm
in pure PVP-VA to 176.9 ppm in the 60/40 dispersion indicates a change in drug-polymer
hydrogen bonding within the fully amorphous dispersions with increasing drug content [30].
The 70/30 and 80/20 dispersions show a change in hydrogen bonding behaviour compared
to the 60/40 dispersion, indicating that the amorphous TLB content in the 60/40 dispersion
is dominant over the small amount of crystalline material present.
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Figure 7.15: Changes to the polymer carbonyl group chemical shift values for C-I across all TLB/PVP-VA
dispersions
From the initial characterisation, we have determined that the dispersions with drug
content up to 50 % are fully amorphous, the 60/40 and 70/30 dispersions contain a mixture
of amorphous and form IL TLB, and the 80/20 dispersion is a more complex mixture of
amorphous, form IL, form II and form V TLB.
7.3 Variable temperature NMR studies of TLB
The VT 1H-13C CP/MAS NMR acquisition for crystalline TLB, and TLB/PVP-VA solid
dispersions followed the temperature cycle as follows:
1. Cooling from room temperature to 253 K over ca. 30 minutes
2. Samples were equilibrated at the target temperature for 15 minutes prior to acquisition
3. Heating, in 20 K intervals, with temperature equilibration prior to acquisition
4. Step 3 was repeated up to the maximum temperature of 373 K
5. Following acquisition at 373 K, samples were cooled back to 293 K, followed by
equilibration and acquisition
Spectra acquired at 293 K during the initial characterisation (section 7.2) were used as a
comparison to determine changes upon cooling to 253 K, and following heating to 373 K.
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7.3.1 Polymorphic transitions of form I TLB
The polymorphic transition of form I TLB (form IL → IH) at ca. 311 K was shown in
section 7.1. Here we investigated the variable temperature behaviour of form I TLB further
by cooling to 253 K (figure 7.16). At lower temperatures, the resonances for aromatic carbons
C-4,6 and C-3,7 are broadened significantly, and appear not to be present within the spectra.
Similar effects have been shown in the spectra for form II TLB at ambient temperature by
Thirunahari et al. (figure 7.7), although an explanation for the broadening of the resonances
was not provided [42].
Figure 7.16: 1H-13C CP/MAS NMR spectra of form I TLB, recorded at different temperatures between
253 K and 373 K, at an MAS rate of 10 kHz. The polymorphic transition between form IL and IH is
highlighted by dashed lines
There is no evidence of disorder around the aromatic ring of TLB form I from
crystallographic structural information. Low temperature crystallographic investigations
show no significant changes in the crystal structure of form IL upon temperature, with
good overlap between aromatic ring positions at 295 and 153 K [57]. Additionally, the
ORTEP (Oak Ridge Thermal-Ellipsoid Plot) diagram of the aromatic ring thermal
197
ellipsoids also shows very low disorder for form IL, as compared to form III, which is known
to undergo temperature dependent disorder effects (figure 7.17) [42].
Figure 7.17: ORTEP diagrams of forms IL and III TLB, adapted from the supporting information of [42]
Disorder in the crystal structure does not explain the broadening of the resonances in the
CP/MAS spectra. The broadening is therefore likely due to a motional freezing of the
aromatic ring, observable on the kHz timescale at low temperature.
At ambient temperatures, the effect of aromatic ring oscillations are averaged between the
carbon positions, leading to two distinct 13C peaks at 125.6 and 131.3 ppm for carbons C-3,7
and C-4,6 respectively. Upon cooling, slightly slower mobility could lead to an increase in
the number of aromatic ring positions. This would result in the loss of chemical equivalence
of the four aromatic carbons (C-4,6 and C-3,7). The broadening effect in the spectra can
be thought of in terms of chemical exchange between a two symmetrical 13C environments,
in dynamic equilibrium [1]. In this case, dynamic equilibria between carbons 4 ⇀↽ 6 and
carbons 3 ⇀↽ 7 must be imagined (figure 7.18 B)). These effects could be further investigated
using other methods, for example 2H NMR, which has been shown to be sensitive to the
identification of mobility of similar systems [269].
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Figure 7.18: A) Representation of the possible oscillation of TLB aromatic ring and B) Example of the
effect of chemical exchange in a NMR spectrum with increasing temperature adapted from [45]
7.3.2 Detection of changes in mobility and polymorphic transitions in high
drug loading TLB/PVP-VA dispersions
The focus of literature on TLB in recent years has been the characterisation of pure
polymorphic forms. There is little evidence of NMR studies of TLB amorphous dispersions,
especially regarding mobility and crystallisation behaviour so far. Here we have extensively
characterised dispersions of TLB and PVP-VA, with varying drug/polymer ratios (80 % to
20 %) using a number of variable temperature solid-state NMR techniques, including
1H-13C CP/MAS, 13C{1H} MAS, 1H MAS and spin-lattice relaxation.
Across a range of temperatures, we were able to observe a number of polymorphic transitions
in the 1H-13C CP/MAS NMR spectra of the 80/20 dispersion (figure 7.19). From the initial
characterisation, the 80/20 dispersion was found to contain a polymorphic mixture of forms
IL, II and V at ambient temperature. There is considerable overlap of peaks between the
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three polymorphs (and polymer), especially within the aliphatic region of the spectrum.
To monitor the changes in polymorphic composition with increasing temperature, the non-
overlapping peaks at 140.0 ppm (C-5: form II) and 127.1 and 130.2 ppm (C-3,7 and C-4,6:
form V) will be used.
Figure 7.19: 1H-13C CP/MAS NMR spectra of 80/20 dispersion recorded at different temperatures
between 253 K and 373 K, at an MAS rate of 10 kHz (* denotes spinning sideband peaks)
Upon cooling from 293 to 253 K, an increased presence of form V is observed, through the
growth of the resonances at 127.1 (C-3,7) and 130.2 (C-4,6) ppm, and the shoulder peak
at 153.9 ppm (C-8), consistent with an enantiotropic transition. All three polymorphs can
still be identified at 253 K, although forms V and II appear to dominate over the form IL
(figure 7.20). The broadening of the C-3,7: C-4,6 resonances observed for pure form IL did
not occur in the dispersion, hence uncertainty of assignment of these resonances to form IL,
form II, or a combination of both at low temperatures remains.
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Figure 7.20: Aromatic region of the 1H-13C CP/MAS NMR spectra of 80/20 dispersion, form IL and
form V recorded at 253 K, with a comparison to form II recorded at 293 K, at an MAS rate of 10 kHz
It is difficult to determine which polymorph converts to form V, although it is likely to be
form IL, as we observe a reduction in the intensity of the peaks attributable to form IL at
253 K. Additionally, in the published characterisation study of form V, Nath et al. [44] found
form V crystallised to form IL within two hours at room temperature, demonstrating the
presence of an enantiotropic relationship. Here we observe this transition in the opposite
direction at lower temperatures, indicating this relationship is reversible and that form V is
the more stable polymorph at low temperatures.
Despite the 80/20 dispersion containing a complex mixture of polymorphs, we were able to
observe a number of interesting polymorphic transitions with increasing temperature, seen
in more detail in figure 7.21.
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Figure 7.21: Aromatic region of the 1H-13C CP/MAS NMR spectra of 80/20 dispersion recorded at
different temperatures between 253 K and 373 K, at an MAS rate of 10 kHz
• 253 - 313 K: The conversion of form V to form I occurs, observed through the reduction
of the resonance intensity for form V, and the increase of the resonance intensity of
form I for carbons C-4,6 and C-3,7.
• 293 - 313 K: Spectral changes in the aromatic (figure 7.22) and aliphatic (figure 7.21)
regions are attributed to the polymorphic transition from form IL to form IH (figure
7.22), which is in agreement with the known transition temperature of 311 K [43].
• Above 333 K: The presence of form II TLB (C-5: 140 ppm) can be observed until 333
K. At 353 K and above the 1H-13C CP/MAS spectrum shows only the presence of one
phase: form IH , as form II becomes metastable and undergoes crystallisation to the
more stable form (figures 7.21 and 7.23).
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Figure 7.22: Aliphatic region of the 1H-13C CP/MAS NMR spectra of 80/20 TLB/PVP-VA dispersion
at 293 (red) and 313 K (blue), with a comparison to forms IL (pink) and IH (green), recorded at an MAS
rate of 10 kHz
These observations agree well with the trend of thermodynamic stabilities of the polymorphs,
as form IH is the most stable polymorph at temperatures above 353 K, with form II being
the most stable at temperatures below 353 K [42]. The thermodynamic stability of form V
is currently unknown, but from this work we can suggest it has a higher stability than form
IL at low temperatures, with an enantiotropic relationship existing between form V/IL.
By 353 K and above, we additionally observe the complete disappearance of all polymer
peaks, and the loss of broadening around the peak base due to amorphous TMB (figures
7.19 and 7.23). This is likely due to the increased mobility of this phase, indicating a degree
of phase separation between crystalline drug and polymer/remaining amorphous TLB at
high temperatures.
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Figure 7.23: Aliphatic region of the 1H-13C CP/MAS NMR spectra of 80/20 TLB/PVP-VA dispersion
at 353 K (blue), with a comparison to form IH (green) and PVP-VA (pink), recorded at an MAS rate of 10
kHz. Spinning sidebands are denoted by asterisks
Figure 7.24 provides a schematic representation of the crystallisation behaviour of TLB in
the 80/20 dispersion with increasing temperature. Although important observations have
been made through the VT 1H-13C CP/MAS NMR spectra of the 80/20 dispersion, future
work should focus on variable temperature PXRD analysis to provide confirmation of the
exact transition temperatures between each polymorph.
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Figure 7.24: Schematic representation of the polymorphic changes within the 80/20 TLB/PVP-VA
dispersion with increasing temperature
Reducing the drug loading of the dispersion to 70 % simplified the polymorphic behaviour.
Initial DSC characterisation of the 70/30 dispersion indicated the presence of amorphous
material (Tg = 299 K), which was also seen through broadening around the base of the
ambient temperature 1H-13C CP/MAS NMR spectrum.
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Figure 7.25: 1H-13C CP/MAS NMR spectra of 70/30 dispersion recorded at different temperatures
between 253 K and 373 K, at an MAS rate of 10 kHz. Spinning sidebands are denoted by asterisks
Upon cooling from 293K to 253 K (figures 7.25 and 7.26), the presence of amorphous TLB
within the dispersion becomes more visible in the spectra for the resonances of carbons C-
3,4,6,7 (132 - 124 ppm), due to the significant broadening of the aromatic ring signals of the
crystalline form IL TLB component, which was observed at lower temperatures in the pure
form IL (figure 7.6). There is some additional broadening around the base of the central
aromatic peaks (138 and 145.5 ppm) (figure 7.26), with a broad shoulder peak apparent ca.
155 ppm (C-8), both also highlighting the amorphous component. When heated from 253 to
above the Tg of 299 K (figure 7.25), the broadening reduced as the amorphous component
crystallised to form I, with the most significant difference being to the peak for C 3-7, which
clearly resolved into two separate peaks, as would be expected for form IL upon heating.
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Figure 7.26: Aromatic region of the 1H-13C CP/MAS NMR spectra of the 70/30 dispersion, compared
to form IL and amorphous TLB, all recorded at 253 K, at an MAS rate of 10 kHz
Above 293 K, the expected polymorphic transition between form IL and IH occurs close
to the known transition temperature of the two polymorphs (311 K [42]) (figure 7.27). As
with the 80/20 dispersion, the polymer peaks, and amorphous TLB peaks, disappear by
353 K, again due to increased mobility leading to phase separation of crystalline drug and
polymer/amorphous drug (figure 7.25).
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Figure 7.27: Aliphatic region of the 1H-13C CP/MAS NMR spectra of 70/30 dispersion at 293 and 313
K compared to form IL and form IH TLB, at an MAS rate of 10 kHz. Spinning sidebands are denoted by
asterisks
The 60/40 dispersion was found to contain a small amount of crystalline TLB, (alongside
mainly amorphous TLB) upon formulation, which was below the detection limit of 1H-13C
CP/MAS NMR. The TLB in the dispersion remained predominantly in the amorphous form
with increasing temperature up to the Tg value of 309 K (figure 7.28). Partial crystallisation
to form IH around 313 K was observed, with form IH identified though the appearance of
resonances at 131 and 125 ppm, for carbons C-4,6 and C-3,7 respectively.
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Figure 7.28: 1H-13C CP/MAS NMR spectra of 60/40 dispersion recorded at different temperatures
between 253 K and 373 K, at an MAS rate of 10 kHz. Spinning sidebands are denoted by asterisks
Between 313 K and 353 K, we see an increase in the content of form IH TLB as amorphous
TLB continues to crystallise. As with the 80/20 and 70/30 TLB/PVP-VA dispersions, the
intensity of the PVP-VA and amorphous TLB peaks reduced considerably by 353 K,
indicating higher amorphous TLB/polymer mobility. By 373 K, complete loss of CP signal
indicates the presence of a highly mobile ’liquid-like’ state, seen for many of the
FFA/PVP-VA dispersions at high temperatures, but which did not occur for the 80/20 or
70/30 TLB dispersions. This indicates that the solubility of the crystalline TLB at this
temperature favours it’s dissolution in the mobile phase, which is thought to consist of
remaining amorphous TLB, plus polymer.
All high drug loading dispersions were therefore found to crystallise to form IH at high
temperatures through a variety of polymorphic ’routes.’ The current proven stability order
of the tolbutamide polymorphs is as follows:
• Between absolute zero and 311 K: Form IV < Form III < Form IL < Form II [42,43]
• 311 - 353 K: Form IV < Form IH < Form III < Form II [43]
• Above 353 K: Form IV <Form III < Form II < Form IH [42]
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There are a number of enantiotropic relationships between the polymorphic forms of TLB.
Alongside forms IL/IH , forms III/IL, III/IH and II/IH have also been shown to be
enantiotropically related. All polymorphs have been shown to undergo transitions to form
IH , as outlined in table 7.3, apart from form V, which has not been published. The
tolbutamide polymorphs are therefore a complex system to study, as transitions between
forms can easily occur, due to the low energy barriers and abundance of enantiotropic
relationships.
Through VT analysis of the higher drug loading solid dispersions using solid-state NMR, we
were able to closely monitor the crystallisation behaviour of TLB. For the 60/40 and 70/30
dispersions, we observed crystallisation of amorphous TLB to form I (IL: 70/30 and IH :
60/40) at temperatures above the Tg values. For both the 70/30 and 80/20 dispersions, form
IL crystallised to form IH above the transition temperature of 311 K. The 80/20 dispersion
contained a complex mixture of forms I, II and V which allowed the observation of a number of
additional polymorphic transitions and highlighted the reversible enantiotropic relationship
of forms IL and V at lower temperatures, and the conversion of form II to IH at high
temperatures, as form IH became the most stable thermodynamic form. Ultimately, at
temperatures above 353 K, all three dispersions showed crystallisation to form IH .
These results indicate that the presence of polymer (up to 40 %) did not affect either the
polymorphic stability order, or polymorphic transitions between forms. The transition
between IL and IH occurred within the expected temperature range, and as expected, the
most stable form of tolbutamide (form IH) was the only form present at high temperatures.
This indicates that drug-drug interactions (urea tape hydrogen bonding motif - see figure
7.3) were not hindered by the presence of polymer; and that the thermodynamic stability
order of the different polymorphs of TLB is the same both in the presence and absence of
polymer. Formulating solid dispersions at high concentrations therefore widens the field of
crystallisation study, with us being able to predict the crystalline behaviour of the drug
once in formulation, clarifying whether transitions between polymorphs occur in the same
way in presence of excipients. Being able to predict the recrystallisation behaviour of
pharmaceutical APIs from amorphous dispersions accurately is of paramount importance,
as this affects the long term efficacy of the formulation. The more information and
understanding we have about polymorphic changes and recrystallisation behaviour, the
more robust and predictable the long term stability of the formulation.
Following heating to 373 K, all three high drug loaded dispersions were cooled to 293 K
within the rotor. After the cooling and reheating cycle was complete, the three resulting
dispersions (80/20, 70/30 and 60/40) had a similar composition: form IL and amorphous
TLB; alongside PVP-VA (figure 7.29). The polymorphic transition between forms IL and
IH is reversible [43], and is again seen here upon cooling past the transition temperature of
311 K.
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Figure 7.29: 1H-13C CP/MAS NMR spectra of 80/20, 70/30 and 60/40 dispersions measured at 293
K following cooling from 373 K, at an MAS rate of 10 kHz. Inset provides a comparison of Form IL and
amorphous tolbutamide
Although the 1H-13C CP/MAS spectra are not strictly quantitative, Gaussian
deconvolution of the peaks upon cooling to 293 K allowed the approximation of the ratios
of form IL:amorphous TLB as 25:75 (80/20), 19:81 (70/30) and 10:90 (60/40).
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Figure 7.30: 1H-13C CP/MAS NMR spectrum of the C-3,7 and C-4,6 resonances for the 60/40, 70/30 and
80/20 dispersion following cooling from 373 K to 283 K. Peak integrals obtained from Gaussian deconvolution
are shown
Table 7.7: Summary of the % integrals for amorphous TLB and form IL TLB in the 60/40, 70/30 and
80/20 dispersions following the heating and cooling cycle. Calculated through Gaussian deconvolution peak
fitting. Standard error is included in brackets after each integral (I) value
Dispersion I for δ = 125.6 ppm I for δ = 129.9 ppm I for δ = 131.3 ppm % Amorphous % Form IL
60/40 0.268 (0.01163) 2.756 (0.02794) 0.040 (0.00982) 89.9 10.1
70/30 0.475 (0.02043) 2.372 (0.02984) 0.085 (0.02654) 80.9 19.1
80/20 0.609 (0.02646) 2.603 (0.06127) 0.272 (0.02453) 74.7 25.3
The additional polymorphic forms present in the 80/20 dispersion throughout the VT study
(forms II and V) were not recrystallised upon cooling to 293 K, indicating the transitions
of form IH to II, or IL to V were not reversible under the conditions employed. The 80/20
dispersion was further cooled to 253 K, where the amorphous TLB content became more
visible in the 1H-13C CP/MAS spectrum (figure 7.31). This is due to the loss of signal
through broadening of form IL 13C resonances (C-3,4,6,7) at low temperature, as previously
discussed.
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Figure 7.31: 1H-13C CP/MAS NMR spectra of 80/20 dispersion measured at 293 K and 253 K following
cooling from 373 K, at an MAS rate of 10 kHz. Orange arrows - form IL peaks; Green arrows - amorphous
peaks
These results indicate that at 373 K, the remaining amorphous content of the 60/40, 70/30
and 80/20 dispersions must be contained in the highly mobile phase, alongside the PVP-VA.
In the VT 1H-13C CP/MAS NMR spectra, this phase is ’invisible’ due to increased mobility.
Therefore, at high temperatures, it is likely that phase separation occurs for high drug loaded
dispersions, with one phase consisting of of form IH crystalline material, which has lower
mobility and is therefore detectable via. CP/MAS NMR; and a second more mobile phase
consisting of amorphous TLB and PVP-VA, which only becomes visible in the spectra upon
cooling back to 293 K. The phase separation behaviour of these dispersions has been probed
further using variable temperature measurements of T1ρ
H and T1
H relaxation times (see
section 7.5).
7.3.3 Detection of changes in mobility of TLB/PVP-VA dispersion: mid
to low drug loading
At drug content below 50 wt. %, no crystallisation of amorphous TLB was detected at high
temperatures. However, the VT 13C NMR spectra for TLB/PVP-VA 40/60 and 20/80
dispersions (figure 7.32) enabled us to detect changes in mobility with increasing
temperature. The drug was monitored using the non-overlapping peaks (with polymer) of
carbons C-2, C-5, C-4,6 C-3,7 and C-12 (152.5, 144.2, 138.5, 129.8 and 14.8 ppm), as the
increased polymer content dominated the aliphatic region.
For both dispersions, the VT CP spectra showed a loss of signal intensity of the aromatic and
carbonyl TLB peaks with increasing temperature and was especially pronounced above the
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Tg: 326 K for 40/60 and 349 K for 20/80. This indicates an increased mobility of carbons 2-7
of tolbutamide within the dispersion on an intermediate timescale at higher temperatures.
At 373 K, the 40/60 dispersion showed similar behaviour to the 60/40 dispersion, with high
mobility of drug and polymer within a ’liquid-like’ state consisting of highly mobily drug
and polymer, leading to loss of signal across the spectrum. Slight line narrowing across all
visible peaks of the 20/80 showed increased mobility of drug and polymer components.
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Figure 7.32: 1H-13C CP/MAS NMR spectra of A) 40/60 and B) 20/80 dispersions recorded at increasing
temperatures between 253 K and 373 K, at an MAS rate of 10 kHz
Following heating to 373 K, both dispersions were cooled gradually to 293 K within the
rotor. Upon cooling, they appeared fully amorphous, with no evidence of crystallisation, or
other significant changes to the 1H-13C CP/MAS spectra (figure 7.33).
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Figure 7.33: 1H-13C CP/MAS NMR spectra of 40/60 and 20/80 dispersions before and after heating to
373 K, recorded at 293 K, at an MAS rate of 10 kHz
To further explore the loss of signal at 373 K for the 40/60 TLB/PVP-VA dispersion,
13C{1H} MAS NMR spectra were acquired. Although some significantly broadened peaks
were just about visible, these spectra largely showed the same mobility behaviour as the
1H-13C CP/MAS NMR spectra between 353 and 373 K, (figure 7.34).
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Figure 7.34: Comparison of 1H-13C CP/MAS and 13C{1H} MAS NMR spectra of 40/60 dispersion
recorded at 353 K and 373 K, at an MAS rate of 10 kHz
7.4 Detection of changes in mobility and crystallisation of
TLB/PVP-VA dispersions with VT 1H NMR MAS
Studies
The enantiomeric transition between form IL and IH TLB was detectable in the VT 1H
MAS NMR spectra, although the changes were more subtle as compared to the 1H-13C
CP/MAS NMR spectra (figure 7.35). Form IL has a broad aliphatic resonance at ca. 1.9
ppm, which reduced in intensity with increasing temperature, eventually disappearing above
the transition temperature of 311 K. The one aliphatic resonance observed for form IH TLB
is seen at ca. 0.6 ppm. There is little change in the aromatic 1H peak between the two forms.
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Figure 7.35: Variable temperature 1H MAS NMR spectra for forms IL and IH enantiomeric polymorphs
measured at an MAS rate of 10 kHz, between 253 and 333 K
To further investigate the mobility of the TLB/PVPVA dispersions at high temperatures,
variable temperature 1H NMR studies were carried out. Figure 7.36 shows the change in 1H
resonances and line widths as a function of temperature, highlighting the mobility differences
dependent on drug loading. With higher TLB content, resonances become narrower with
increasing temperature indicating a significantly enhanced mobility at 373 K.
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Figure 7.36: Variable temperature 1H MAS NMR spectra for A) 20/80, B) 40/60, C) 60/40, D) 80/20
TLB/PVPVA dispersions, measured at an MAS rate of 10 kHz, between 253 and 373 K
The sharply resolved peaks of the higher drug loading dispersions (60/40 - 80/20 TLB/PVP-
VA) at 373 K are comparable to the solution-state 1H resonances of TLB, shown in figure
7.37, indicating a highly mobile ’liquid-like’ environment. We can just observe the presence
of the polymer in the solid-state at ca. 1.8 ppm. Broader peaks were observed for the
60/40 dispersion, indicating slightly lower mobility in comparison to the 70/30 and 80/20
dispersions. The solution state 1H spectra of the dispersions and TLB alone (dissolved in
CD3OD at 0.05 M) allowed full assignment of TLB protons.
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Figure 7.37: A) High temperature (373 K) 1H MAS NMR spectra for 80/20, 70/30 and 60/40 TLB/PVP-
VA dispersions (MAS = 10 kHz) with full chemical shift assignment; B) Solution-state 1H spectra for different
TLB/PVP-VA dispersions and TLB alone dissolved in CD3OD (0.05 M)
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7.5 Probing miscibility and dynamics of TLB/PVP-VA
dispersions with spin-lattice relaxation
7.5.1 The mobility regimes of form I TLB
NMR relaxation behaviour, for any TLB systems has not been previously reported in the
literature. Here we report the variable temperature spin-lattice relaxation of crystalline
form I TLB. We observed changes to the mobility of forms IL and IH across a range of
NMR timescales, with increasing temperature. For the T1ρ
H measurements (figure 7.38) a
clear T1ρ
H minimum at ca. 263 K is observed, with a calculated τ c of 5.6 x 10
−4 s. The
slope above the minimum (263 - 303 K) gave an activation energy of 56.6 kJ mol−1, which
reflects the mobility of form IL TLB. This is most likely associated with the slow oscillation
of the aromatic ring, as changes in this temperature region were additionally highlighted
with VT 1H-13C CP/MAS (see section 7.3.1). This type of aromatic ring motion is expected
to be observable on the kHz timescale [269]. The increase in T1ρ
H times with increasing
temperature above the minimum indicates that we are observing the high-temperature side
of the minimum (associated with a faster regime). Upon crystallisation to form IH above
303 K, T1ρ
H times became too long to accurately measure (longer than 70 ms); indicating
forms IL and IH have very different spin-lattice relaxation behaviour, which is unexpected,
as structurally these forms are very similar [43].
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Figure 7.38: Temperature dependence of T1ρH time for different 13C sites for form I TLB
The T1
H measurements for form I TLB (figure 7.39) also showed a clear minimum, this time
at a higher temperature of 313 K, with an EAapp of 6.77 kJ mol
−1 calculated between 253
and 313 K. The minimum occurs at a similar temperature to the transition between forms
IL and IH (311 K) [43], and likely describes mobility of the butyl chain, which should be
observable on the MHz timescale. The significant difference in activation energies calculated
for T1ρ
H and T1
H times for form I TLB is consistent with different motional processes being
observed via each technique.
Combining the two analysis methods indicates that:
• At low temperatures, form IL TLB undergoes a slower kHz timescale motion, likely
due to the oscillation of the aromatic ring comparable to the frozen (solid II) rotational
motion of benzene 7.3.1. This motion is described by the T1ρ
H minimum at ca. 263 K
• At higher temperatures, a faster MHz timescale motion is observed as form IL converts
to IH . This motion is described by the T1
H minimum at ca. 313 K, likely due to the
conformational change of the terminal butyl group associated with the transition [43].
Isobutyl rotations have previously been shown to be observable on the MHz timescale
in other systems [206].
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By extending the temperature range to 253 K, we observed previously unreported changes
to the 13C spectrum, attributed to a low temperature motional freezing of the aromatic
ring resulting in the loss of chemical equivalence of carbons C-4,6 and C-3,7. We further
investigated both the kHz and MHz motional regimes of form I TLB with VT spin-lattice
relaxation studies. Minima were observed for both the T1
H and T1ρ
H temperature
dependence curves, associated with motions on two different timescales. Additionally,
forms IL and IH were found to have very different T1ρ
H times, which is unexpected as
structurally the forms are extremely similar. The combination of variable temperature
T1ρ
H and T1
H relaxation alongside 1H-13C CP/MAS NMR highlighted the different
motional regimes experienced across the full temperature range for form I TLB.
Figure 7.39: Temperature dependence of T1H times for different 1H sites of form I TLB
7.5.2 Variable temperature relaxation studies of TLB/PVP-VA
dispersions
The TLB/PVP-VA dispersions display two distinct types of relaxation behaviour, dependent
on drug loading. The lower drug loaded dispersions (20 - 40 wt. %) remained amorphous
and miscible throughout, displaying non-typical temperature dependence comparable to the
fully amorphous IMC and FFA/PVP-VA dispersions. For the higher drug loaded dispersions
(60 - 80 wt. % drug loading) we were able to detect and monitor phase separation and
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crystallisation with increasing temperature.
7.5.2.1 Detection of polymorphic transitions and phase separation using VT
relaxation studies: high drug loaded dispersions
Figure 7.40 shows that for the 60/40 dispersion, we observed similar relaxation across all
13C sites until ca. 303 K, indicating homogeneity between drug and polymer. Above this
temperature, a wider spread of T1ρ
H times was measured. Differences in relaxation times
show heterogeneity within the system, due to the presence of processes with different 1H-1H
spin diffusion rates. At 313 K, above the Tg of 309 K, the amorphous TLB within the
dispersion began to crystallise to form IH , with full crystallisation by ca. 333 K (section
7.3.2). These changes are reflected in the T1ρ
H times. The TLB protons show a difference
in relaxation behaviour in two steps. Firstly, at 313 K, longer T1ρ
H times are associated
with the aromatic ring and carbonyl group of tolbutamide (δ = 153, 138 and 130 ppm).
Secondly, above 333 K, the T1ρ
H times of the remaining aliphatic drug peaks (40, 32, 21 and
15 ppm) also increase. Above 333 K, the T1ρ
H times of the drug resonances were too long
to be measured accurately (greater than 70 ms), which indicates crystallisation to form IH
TLB. The phase separation of drug and polymer is therefore mapped by the changing T1ρ
H
times with increasing temperature: homogenous relaxation of the whole dispersion occurs at
lower temperatures, with drug and polymer displaying completely different relaxation times
above Tg. This clearly indicates phase separation of the dispersion, with a different mobility
behaviour seen for the crystalline TLB compared to PVP-VA.
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Figure 7.40: Temperature dependence of T1ρH time for different 13C sites for TLB PVPVA 60/40
dispersion
The VT T1ρ
H relaxation curve of the 70/30 dispersion can be seen in figure 7.41. A difference
in T1ρ
H times of TLB and PVP-VA occurs across the whole temperature range. A T1ρ
H
minimum was observed at ca. 263 K for the TLB peaks, which is associated with a τ c of 5.48
x 10−4 s. Above the minimum, the slope gave an activation energy of 46.05 kJ mol−1 (273 -
303 K). The temperature and τ c of this minimum is comparable to that seen for pure form
IL (figure 7.38), associated with the oscillation of the aromatic ring. Again, we can clearly
see the polymorphic transition between form IL and IH within the dispersion. A difference
in the relaxation behaviour of drug and polymer can be seen across all temperatures, which
agrees with the phase separation observed in the VT 1H-13C CP/MAS NMR (section 7.3.2).
Due to the dominance of the crystalline TLB in the 1H-13C CP/MAS NMR spectrum, we
were unable to calculate T1ρ
H times for the amorphous component of the dispersion.
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Figure 7.41: Temperature dependence of T1ρH time for different 13C sites for TLB PVPVA 70/30
dispersion
The T1
H temperature dependence curve for the 70/30 dispersion (figure 7.42) shows a T1
H
minimum at ca. 313 K, at the same temperature as for pure form I TLB, with a marked
change in relaxation behaviour occurring either side. Above 313 K, the motion has an
activation energy of 12.88 kJ mol−1. The increase in T1H with increasing temperature
indicates we are on the high-mobility side of the minimum. At temperatures below the
minimum, there was little change in T1
H times with increasing temperature, indicating a
difference in mobility between the TLB in the dispersion, and pure form I. It is likely the
dispersion is dominated by the polymer presence at this point.
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Figure 7.42: Temperature dependence of T1H time for different 1H sites for TLB PVPVA 70/30 dispersion
The VT T1ρ
H relaxation curve for the 80/20 dispersion reflects the more complex mixture
of polymorphs, amorphous TLB and polymer present, displaying a wide range of relaxation
times across the different chemical shift sites. Unfortunately, this curve was too complex
to analyse. The variable temperature T1
H dependence of the 80/20 dispersion can be seen
in figure 7.43. Unlike the 70/30 dispersion, the T1
H minimum is outside of the measured
temperature range. An increase in T1 times for all protons is observed with increasing
temperature, indicating the presence of a fast regime. At low temperatures, the relaxation
dependence describes the cumulative behaviour of the three polymorphs, amorphous TLB
and PVP-VA. We do however observe a change in the gradient of the T1
H behaviour at
313 K, which indicates the crystallisation of forms IL and V to the more thermodynamically
stable form IH .
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Figure 7.43: Temperature dependence of T1H time for different 1H sites for TLB PVPVA 80/20 dispersion
7.5.2.2 A non-typical temperature dependence: 20/80 and 40/60 dispersions
The T1ρ
H times of the 20/80 and 40/60 dispersions displayed non-typical temperature
dependence, comparable to the lower loaded IMC and FFA dispersions (figure 7.44). We
observed homogenous relaxation behaviour across all carbon sites for both dispersions.
Initially, between 253 and 333 K, there was a slight but steady increase in T1ρ
H time with
increasing temperature, with similar EAapp(LT) of 8.0 and 6.8 kJ mol
−1 for 20/80 and
40/60 respectively. Above TMAX , a more marked change of T1ρ
H times occurred, with
EAapp(HT) values of 54.7 and 22.2 kJ mol
−1 for 20/80 and 40/60 respectively. TMAX
occurred the same point with respect to Tg for each dispersion: 311 K (Tg - 15 K) for
40/60 and 349 K (Tg - 16 K) for 20/80. No phase separation or crystallisation was
observed in these dispersion across the measured temperature range.
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Figure 7.44: Temperature dependence of T1ρH time for different 13C sites for TLB/PVPVA A) 20/80
and B) 40/60 dispersions
7.5.2.3 Miscibility of dispersions, determined through spin-lattice relaxation
times
Differences in the relaxation time of drug and polymer components within a dispersion
have been used previously to assess miscibility of drug/polymer dispersions (see chapters 4
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and 5 for detailed explanation). To calculate the difference in T1ρ
H for the TLB/PVP-VA
dispersions, the peaks at 177, 171 and 68 ppm were chosen for PVP-VA, as these were the
only non-overlapping polymer peaks. For the drug component, the four peaks between 160
and 120 ppm were used.
The differences in relaxation time (∆T1ρ
H) at 293 K can be seen in figure 7.45. At 293 K,
∆T1ρ
H was 0 for all dispersions except the 80/20 TLB/PVP-VA, indicating miscibility on
the 2 - 6 nm length scale. The 80/20 dispersion showed a large ∆T1ρ
H well above the zero
line, indicating the presence of domains larger than 6 nm in size.
Figure 7.45: ∆T1ρH (ms) between tolbutamide and PVP-VA in the solid dispersions, at 293 K, displayed
as a function of wt. % drug content. Error bars represent 95 wt. % confidence intervals of the difference
between means
The temperature dependence of the ∆T1ρ
H for the 60/40 and 70/30 dispersions were
investigated further (figure 7.46). It was not possible to include the 80/20 dispersion, due
to the complexity of the temperature dependence curve. Both dispersions show no
difference in relaxation between drug and polymer at the lower temperatures, indicating
miscibility on the 2 - 6 nm length scale. However, above 293 K, we see a substantial
increase in ∆T1ρ
H , indicating phase separation of drug and polymer, and the formation of
domains greater than 6 nm. The difference between form I and polymer becomes much
greater above 303 K, where we observed the polymorphic transition between form IL and
IH .
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Figure 7.46: ∆T1ρH (ms) between TLB and PVP-VA in the 60/40 and 70/30 solid dispersions, between
253 and 333 K. Error bars represent 95 % confidence intervals of the difference between means
To further investigate the miscibility of the highest loaded dispersions on a faster timescale,
the differences in T1
H times between the two 1H peaks of the 70/30 and 80/20 dispersions
with increasing temperature were calculated. Although there were some slight differences
in T1
H times at the lower temperatures for both dispersions, these are considered to be
negligible (δT1
H ≈ 0), indicating miscibility on the 6 - 24 nm length scale. Previous studies
found ∆T1
H of > 0.5 s to be indicative of phase separation on the 24 - 55 nm scale [46].
7.6 Stability Studies
Throughout the 8 week stability study, all dispersions were monitored for changes in the
local ordering using PXRD, mDSC and 13C CP/MAS solid-state NMR. The TLB/PVP-
VA dispersions behaved in two ways: dispersions with drug content ≤ 50 wt. % remained
amorphous in each storage condition throughout; dispersions with drug content ≥ 60 wt.
% crystallised to various TLB polymorphs at certain storage conditions, as detailed below.
Unfortunately, upon storage above 333 K, the majority of the higher drug loading dispersions
formed hard glass melts, which proved unsuitable for further analysis.
The small amount of crystalline TLB in the 60/40 dispersion did not increase throughout
the study at room temperature (0 % RH) (figure 7.47). With increased humidity (75 %
RH), further crystallisation to form IL TLB occurred by week 4, indicating that the rate of
crystallisation of amorphous TLB to form I is increased by the presence of moisture, due to
the plasticizing effect of water [122]. Above 313 K, crystallisation to form I occurred more
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quickly, by week 2. The PXRD and solid-state NMR results were carried out at ambient
temperature following removal from storage, hence all form I material is identified as form
IL. Above 311 K, we expect crystallisation to form IH occurred within storage, as seen in
the VT 1H-13C CP/MAS NMR spectra, only converting to form IL upon removal. This
crystallisation behaviour is in agreement with the results seen in the VT CP/MAS, where
amorphous TLB converted to form IH at temperatures ≥ 313 K under MAS conditions.
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Figure 7.47: A) PXRD patterns and B) 1H-13C CP/MAS NMR spectra (MAS = 10 kHz) of TLB/PVP-
VA 60/40 dispersion, before and after storage at RT (0 and 75 % RH), 313, 323 and 333 K
No further polymorphic changes were observed for the 70/30 dispersion, which was found
to contain form I TLB throughout the stability study (figure 7.48). Upon storage at higher
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temperatures, the content of amorphous TLB was reduced, identified with the 1H-13C
CP/MAS NMR spectra, due to the reduction in intensity of the shoulder peak at ca. 153
ppm. This behaviour is in agreement with the results seen in the VT CP/MAS, where the
amount of amorphous TLB reduced at temperatures greater than 313 K, with form I being
the only detected crystalline material.
Figure 7.48: A) PXRD patterns and B) 1H-13C CP/MAS NMR spectra (MAS = 10 kHz) of TLB/PVP-
VA 70/30 dispersion, before and after storage at RT (0 % RH), 313 and 333 K
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Figure 7.49: A) 1H-13C CP/MAS NMR spectra (MAS = 10 kHz) and B) PXRD patterns of TLB/PVP-
VA 80/20 dispersion, before and after storage at RT (0 % RH), 313 333 K and 353 K, with identification of
forms IL, II and V TLB 235
The 80/20 dispersion was initially characterised as containing a mixture of forms IL, II and
V TLB, as well as some amorphous material. The polymorphic mixture makes it difficult
to study, but some changes to the composition were observed over the 8 week period (figure
7.49)). Stored under dry conditions at room temperature, a reduction in the content of
form V was observed, with the presence of forms IL and II remaining constant. At higher
temperatures (313 K and above) no form V was detectable by after 2 weeks of storage, with
the presence of form I greater than form II, see by the changing C-11 resonances ca. 20
ppm. It is difficult to detect changes in the PXRD traces due to overlapping peaks, but
forms I and II can be detected after storage at 313 K and above, with the majority of peaks
corresponding to those of form I. Additionally, we were able to analyse the 80/20 dispersion
following 2 weeks storage at 353 K, where the presence of only form I TLB was detected.
This indicates the transition of form II to form I, and is in agreement with the polymorphic
transitions mapped with VT 1H-13C CP/MAS NMR studies (section 7.3.2).
Figure 7.50 shows the effect of moisture on the composition of the 80/20 dispersion when
stored at room temperature. As highlighted, we observed an increase in presence of form II
(peak = 10.5 °2θ), and a decrease in form V (peaks = 10.2 and 18.8 °2θ). This indicates a
polymorphic transition between form V and II, accelerated by the presence of moisture.
Figure 7.50: PXRD patterns of the TLB/PVP-VA 80/20 dispersion before and after storage at 75 % RH
over the 8 week period
The advantage of using VT 1H-13C CP/MAS NMR to predict crystallisation behaviour is
time constraints, as we were able to observe the same crystallisation behaviour in a much
shorter time period, as compared to the conventional stability study.
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7.7 Conclusions
TLB was successfully formulated as an amorphous solid dispersion with PVP-VA in a variety
of drug/polymer ratios. The fully amorphous nature of the dispersions was confirmed up to a
maximum drug loading level of 50 wt. %, above which varying levels of a number of different
polymorphic forms of TLB were identified. The 70/30 dispersion contained amorphous form,
alongside form IL TLB; with the 80/20 dispersion containing a small amount of amorphous
TLB, alongside three different crystalline polymorphs: forms IL, II and V.
The combined use of different spectroscopic, structural and thermal methods, allowed
successful investigation of the local mobility of the TLB/PVP-VA dispersions across a
range of timescales. Crystallisation from amorphous TLB; and various polymorphic
transitions dominated the analysis of the higher drug loading dispersions, providing an
interesting, if slightly deviated study of the crystallisation behaviour of TLB in polymeric
carriers.
As with IMC and FFA, solid-state 1H MAS NMR highlighted the presence of a fast
mobility regime in the higher drug loading TLB/PVP-VA dispersions, which was able to
more effectively average out strong 1H-1H dipolar couplings. This technique provides
further insight into the mobility behaviour of the amorphous drug content, as the high
temperature 1H spectra are likely dominated by a mobile amorphous TLB phase, alongside
PVP-VA, which was not detected through 1H-13C CP/MAS NMR.
We demonstrated that the T1ρ
H times of the fully amorphous (20/80 and 40/60 TLB/PVP-
VA dispersions) followed the same ’non-typical’ temperature dependence as IMC and FFA,
allowing the extraction of EAapp. This provided further data to relate the mobility behaviour
detected through T1ρ
H to physical stability, which is further discussed in chapter 8.
Miscibility between TLB and PVP-VA was additionally probed, with ∆T1ρ
H measurements
allowing the investigation of domains down to ca. 2 nm. A change in miscibility behaviour
was only observed at temperatures above 303 K for the 60/40 and 70/30 dispersions, which
highlights the important role of studying miscibility at a variety of temperatures. Throughout
formulation and storage, components of solid dispersions can be exposed to a variety of
different temperature conditions, which need to be fully understood in the development
process. Although a dispersion may appear to be intimately mixed at ambient temperature,
a small change can lead to phase separation, and ultimately changes in properties affecting
dissolution rate and physical stability.
Using VT 1H-13C CP/MAS NMR we were able to accurately predict the crystallisation
outcome of the TLB/PVP-VA dispersions occurring during the stability study, including
highlighting the physically stable dispersions which remained amorphous (greater than 50
wt. % TLB content); the lower stability dispersions which showed crystallisation at increased
temperature (60/40 TLB/PVP-VA); and the complex polymorphic transitions occurring
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in the partially crystalline dispersions. VT 1H-13C CP/MAS NMR therefore shows great
promise as a tool for the prediction of stability study outcome of solid dispersions, achieving
reliable results in around 8 hours in situ, compared to up to 8 - 12 weeks in the oven.
Due to the high crystalline content in the 70/30 and 80/20 TLB/PVP-VA dispersions, this
system provided a useful probe of polymorphic behaviour, allowing the mapping of numerous
enantiomeric transitions of crystalline drug in the presence of polymer, which has not
previously been demonstrated with solid-state NMR. Using VT 1H-13C CP/MAS NMR we
were able to monitor the complex polymorphic transitions between forms I, II and V in
the 80/20 TLB/PVP-VA dispersion (figure 7.24). Temperature dependent enantiotropic
transitions of TLB polymorphs were detected in the 80/20 dispersion: form IL → V upon
cooling below 293 K; which indicated form V has higher stability at low temperatures; form
IL → IH at the expected transition temperature; and form II → IH above 353 K.
The presence of different motional regimes across a range of timescales, associated with
transitions between forms IL and IH were demonstrated: 1) A low temperature kHz timescale
motion ca.263 K (kHz timescale), thought to be associated with slow oscillations of the
aromatic ring; and 2) A higher temperature MHz timescale motion at ca. 313 K, associated
with the butyl chain rotation of the form IL→ IH transition. The same motional regimes were
clearly observed in both the pure crystalline form I, and the 70/30 and 80/20 TLB/PVP-VA
dispersion which contained both form I and amorphous TLB alongside PVP-VA.
In summary, the numerous solid-state NMR techniques employed have provided a large
amount of information regarding the local structure and dynamics of TLB solid dispersions,
which have not previously been reported. The inclusion of high drug dispersions in the study,
led to a number of interesting findings surrounding the polymorphic behaviour of TLB at
different temperatures, which are previously not reported in the literature.
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Chapter 8
General Discussion and Conclusions
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In formulating solid dispersions of amorphous drugs with polymers, the ultimate aim is to
prepare a fully amorphous, fully miscible drug/polymer system which remains
physically stable upon storage for the full shelf-life duration.
Here we describe our investigation of these factors using three different drug systems: IMC,
FFA and TLB, formulated at a variety of drug loadings with PVP-VA via solvent evaporation
to investigate the terms:
• Fully amorphous
• Fully miscible
• Physically stable upon storage
We explored a number of different solid-state NMR methodologies to provide local
molecular level information, comparing them to standard bulk characterisation techniques.
We especially focussed on stressing the systems with variable temperature studies, in order
to achieve a more comprehensive understanding of the structural organisation and mobility
behaviour of amorphous solid dispersions, in relation to physical stability. We formulated a
large number of dispersions, encompassing three different drugs, and eight different
drug/polymer loading levels ranging from 10/90 - 80/20 w/w. This is the first time such a
study across different drug systems has focussed on utilising variable temperature
solid-state NMR to study local mobility, in combination with more commonly used bulk
characterisation techniques.
8.1 Deducing properties of formulations based on different
drug content
8.1.1 Determination of maximum drug loading level of amorphous solid
dispersions
During initial formulation development processes, it is crucial for the maximum drug
loading level of the API in the chosen polymeric carrier to be determined in order to
consistently formulate physically stable dispersions. The maximum drug loading for a
stable amorphous dispersion is dependent on properties of both the drug and
polymer [147]. Inadvertently manufacturing a solid dispersion at drug loadings close to the
maximum loading level would be detrimental to the physical stability of the system, as
slight changes in storage temperatures could drive nucleation, leading to crystallisation.
One difficulty of this is to identify techniques with sufficient sensitivity to reliably identify
the successful formulation of fully amorphous dispersions, which are also able to detect,
identify and quantify the presence of coexisting crystalline phases in lower stability
dispersions. Identification of such techniques is integral to the successful design of
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amorphous pharmaceutical dispersions [69, 192]. Understanding the possible polymorphic
crystallisation behaviour around and above the maximum drug loading level in dispersions
is additionally important, as polymorphic behaviour may not necessarily be predictable
from available resources describing the pure crystalline materials [270], especially in drugs
with complex polymorphism. Investigation of crystallisation behaviour in high drug loaded
dispersions is often neglected in literature studies [41,147].
Initial characterisation demonstrated that dispersions formulated at 60 wt. % (IMC and
FFA) and 50 wt. % (TLB) drug content and below were found to be fully amorphous
by all three characterisation methods employed: DSC, PXRD and solid-state NMR. Fully
amorphous dispersions were identified through the concomitant presence of a broad halo
in PXRD, broad peaks in 1H-13C CP/MAS NMR spectra, and absence of crystallisation
and melting events in DSC curves. This initially suggests the suitability of PVP-VA as a
polymeric carrier for formulating solid dispersions with IMC, FFA and TLB, as ca. 60 wt.
% is an extremely high drug loading as compared to the majority of commercially available
amorphous formulations, which tend to contain much lower drug loading levels.
Of the higher drug loading level dispersions (60/40, 70/30 and 80/20 w/w) varying levels
of crystalline drug were detected, highlighting the difference in maximum drug loading level
for each drug/polymer system. Additionally, the three techniques differed in their ability to
identify, characterise and quantify the presence of crystalline API.
In partially crystalline/amorphous dispersions, two different thermodynamic states exist,
which can lead to both structural inhomogeneities, and variation in physical properties
between batches [192], creating difficulties with reproducibility. The presence of crystalline
seeds in a dispersion can act as an initial point for nucleation, in turn leading to
crystallisation [271–273]. Additionally, depending on the level of miscibility between the
phases, the behaviour of one phase may influence the other [192]. Partially ordered systems
have been described by two models [192,271,274]:
• ”One-state” - domains of partial crystalline phase with a semi-ordered structure are
present in the amorphous carrier. This occurs due to motional restriction during
crystallisation
• ”Two-state” - domains of fully amorphous or crystalline phases exist next to each other
in a molecularly mixed state
The ”one-state” model is thought to provide a more realistic model of partially crystalline
dispersions [192].
Using PXRD and 1H-13C CP/MAS NMR, IMC/PVP-VA dispersions were found to be fully
amorphous up to the highest drug loading of 80 %. In contrast, some crystalline drug was
detected in the 70/30 and 80/20 FFA/PVP-VA and 60/40, 70/30 and 80/20 TLB/PVP-
VA dispersions, with the techniques allowing the identification of the particular polymorphs
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present (table 8.1). One very low intensity peak was identified in the PXRD pattern of
the 60/40 TLB/PVP-VA dispersion, Crystalline FFA was identified as form III in both the
70/30 and 80/20 dispersions; and TLB as form IL in the 70/30 and forms IL, II and V in the
80/20 dispersion. The percentage of crystalline content increased as follows: TLB/PVP-VA
60/40 < FFA/PVP-VA 70/30 < FFA/PVP-VA 80/20 ≈ TLB/PVP-VA 70/30 < TLB/PVP-
VA 80/20. The TLB/PVP-VA 80/20 dispersion was found to be highly crystalline, with the
presence of three polymorphs identified upon formulation. The ability of PVP-VA to prevent
crystallisation in these systems appears to follow their physical stability order as predicted
by the Tg values of the amorphous drugs, with IMC being the most stable (Tg = 315 K)
and TLB the least stable (Tg = 278).
Table 8.1: Composition of IMC/PVP-VA, FFA/PVP-VA and TLB/PVP-VA dispersions upon initial
characterisation at ambient temperatures by PXRD and solid-state NMR Amorphous → Crystalline, with
darker colour representing higher crystalline content
10/90 20/80 30/70 40/60 50/50 60/40 70/30 80/20
IMC A A A A A A A A
FFA A A A A A A A + C (form III) A + C (form III)
TLB A A A A A A + C A + C (form IL) A + C (forms IL, II, V)
Therefore in using PXRD and solid-state NMR, the maximum drug loading levels for the
formulation of fully amorphous dispersions for our three drug systems were determined to
be > 80 % for IMC; 60 % for FFA and 50 % for TLB.
DSC was the final technique employed in the initial characterisation of the dispersions.
In previous studies of pharmaceutical dispersions, DSC curves tend to be interpreted to
determine maximum drug loading for amorphous dispersion formation in two ways:
1. Presence of an exothermic crystallisation event indicates spontaneous
crystallisation of the amorphous drug. This indicates the mobility of the drug in the
dispersion is not completely restricted by the polymer, allowing nucleation to occur,
which has increased likelihood in partially crystalline dispersions with higher initial
crystalline content [190,275].
2. Presence of an endothermic melting peak indicating presence of residual crystalline
drug formed during manufacture [276,277]. Melting endotherms in partially crystalline
dispersions are reported as being broad, with lower Tm values than for pure crystalline
drug [148,190,258].
Table 8.2 indicates the dispersions with an exothermic crystallisation event (Tc) detected
in the DSC curve (method 1), where the absence of a crystallisation exotherms indicates
the formation of a fully amorphous dispersion [190]. Tc values were identified for the 80/20
FFA/PVP-VA and 70/30 and 80/20 TLB/PVP-VA dispersions, with the exotherms having
lower ∆HC values compared to amorphous drug without polymer, demonstrating the
ability of PVP-VA to inhibit some but not all crystallisation of the amorphous
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content [190]. Therefore with this analysis method, the maximum drug loading levels for
the formulation of fully amorphous dispersions for our three drug systems were above 80 %
for IMC; ca. 70 % for FFA and ca. 60 % for TLB.
Table 8.2: Presence of Tc in the DSC curve of IMC, FFA and TLB/PVP-VA dispersions with increasing
drug loading level. * ∆Hc values scaled to account for the presence of polymer. ∆Hc of pure amorphous FFA
and TLB = 27.78 and 51.10 J·g−1 respectively
50/50 60/40 70/30 80/20
IMC N N N N
FFA N N N Y (∆Hc = 17.47 J·g−1)
TLB N N Y (∆Hc = 3.13 J·g−1) Y ((∆Hc = 11.36 J·g−1))
Method 2 identified the presence of melting endotherms of all three systems in the 70/30 and
80/20 dispersions, alongside the 60/40 for TLB/PVP-VA; indicating the presence residual
crystalline drug formed during manufacture (table 8.3). The presence of crystalline drug in
formulations can affect the physical stability, therefore this is important to identify. The
quantification of the crystalline content of the IMC/PVP-VA high loaded dispersions; and
60/40 TLB/PVP-VA dispersion highlighted a very low level of crystalline API, with the
majority of the drug in the amorphous form. In this case, the absence of an exothermic
crystallisation peak indicates PVP-VA was able to stabilise the remaining amorphous drug.
Such a low content of crystalline material was below the detection limit for PXRD and/or
1H-13C CP/MAS NMR.
Table 8.3: Presence of melting endotherms in the DSC curve of IMC, FFA and TLB/PVP-VA dispersions
with increasing drug loading level
50/50 60/40 70/30 80/20
IMC N N Y Y
FFA N N Y Y
TLB N Y Y Y
Much broader endotherms, with higher ∆Hf were identified in DSC curves of the
FFA/PVP-VA and TLB/PVP-VA 70/30 and 80/20 dispersions. All endotherms occurred
at lower temperatures than the known Tm of pure crystalline drug, which indicates 1) the
melting of a drug/polymer solid solution formed of crystalline API dissolved in the
polymeric carrier upon heating [148,190] and 2) melting of residual crystalline drug formed
during manufacturing [276,277]. These two melting events can be observed as two separate
endotherms [90], which can merge into one broad peak. Similar broad melting endotherms
have been previously reported in high drug loaded celecoxib/PVP dispersions [190],
phenobarbitone/PVP dispersions [258] and ebselen/PVP-VA dispersions [148]. We were
unable to identify the specific polymorph formed via DSC, as broad endotherms were
present with decreased Tm values. With this analysis method, the maximum drug loading
levels for the formulation of fully amorphous dispersions for our three drug systems were
243
larger than 60 % for IMC/PVP-VA and FFA/PVP-VA and 50 % for TLB/PVP-VA
dispersions.
All dispersions which were partially crystalline had Tg values around or below ambient
temperature; with the lowest Tg dispersions containing the highest levels of crystalline drug.
The presence of residual crystalline drug upon formulation and characterisation at ambient
conditions in these dispersions is therefore not surprising.
Table 8.4: Experimental Tg values of partially crystalline dispersions of IMC, FFA and TLB with PVP-VA
IMC Tg (K) FFA Tg (K) TLB Tg (K)
60/40 309
70/30 335 300 298
80/20 325 294 287
Van Eerdenbrugh and Taylor [247] formulated a number of different solid dispersions with
model compounds and PVP-VA, at a variety of drug loadings. The FFA/PVP-VA
dispersions, formulated at drug loading levels between 10 - 90 wt. % via spin coating with
EtOH, provide a direct comparison to our dispersions. Crystalline FFA was only detected
in the 90/10 dispersion, as compared to the 70/30 dispersion in our study. The likelihood
of nucleation during formulation leading to a partially crystalline dispersion is formulation
method specific. Van Eerdenbrugh’s dispersions were formulated via spin coating, which
employs faster evaporation kinetics as compared to standard solvent evaporation. The
slower evaporation allows more time for nucleation and growth to occur in solution,
increasing the likelihood of the presence of crystalline drug upon formulation. Tobyn et
al. [78] compared BMS-488043/PVP dispersions prepared via solvent evaporation and
spray drying, and found a much higher maximum drug loading in spray dried dispersions
(80 % as compared to 50 %), indicating this was a more effective method of stabilising the
amorphous drug. Formulating fully amorphous dispersions is therefore dependent on a
combination of factors, including the ability of the polymer to stabilise the amorphous
drug, drug loading level and formulation method [78,247].
In summary, the maximum drug loading level identified in the three different drug/
polymer systems differed slightly depending on the characterisation technique employed.
Additionally, we were only able to identify the different polymorphic forms of the partially
crystalline dispersions using PXRD and solid-state NMR. Whilst DSC could highlight the
presence of both amorphous and crystalline phases, we could not extend to the
identification of polymorphs.
The partially crystalline dispersions can be further categorised into:
• Those with low crystalline content, with properties likely to be dominated by the
amorphous phase and behave as more standard amorphous solid dispersions
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• Those with high crystalline content, with properties likely to be dominated by further
crystallisation and polymorphic transitions
The range of crystalline content dispersions allowed us an additional opportunity for the
investigation of polymorphic transitions in solid dispersions with variable temperature,
alongside the standard fully amorphous solid dispersions.
8.1.2 Detection of changes in local mobility in dispersions upon changes
in temperature
Increased knowledge of molecular mobility is fundamental to the understanding of
stabilisation mechanisms of amorphous APIs, both alone and in drug/polymer
dispersions [69, 187]. Considerable studies have focussed on improving research and
understanding in this area. Traditionally, Tg, as measured with DSC is used as an indicator
for changes in molecular mobility of amorphous systems and correlated with amorphous
stability, with research particularly focusing on changes around and below the Tg. Higher
Tg values should indicate increased physical stability [187] although literature examples do
exist where Tg has not proven to be an accurate indicator of amorphous stability [67].
There are an increasing number of literature examples where solid-state NMR has been
used to study molecular mobility [59,278–280], using variable temperature MAS techniques
focusing on a variety of nuclei, and spin-lattice relaxation studies. This approach can provide
information about local molecular mobility of different components and phases for multi-
component systems across a wide range of timescales [41, 146, 160, 245, 281] (see chapter 4).
Relaxation studies are used as a complimentary technique alongside DSC and DRS [146].
8.1.2.1 Changes in local mobility of amorphous dispersions
Spin-Lattice T1ρ
H temperature dependence curves were collected for the three drug/ polymer
systems across a range of temperatures. T1ρ
H probes the slower motions on a kHz timescale
times, providing information about overall molecular mobility [146], representing the ‘freeing
up’ of mobility as the properties of the sample change with increasing temperature [187].
These mobility processes are of particular interest around and below the Tg, which allows
the possibility of a relationship with the likelihood of crystallisation and therefore physical
stability of amorphous dispersions [146,161].
We found that the T1ρ
H times of all fully amorphous dispersions across the IMC, FFA and
TLB/PVP-VA systems exhibited a distinct ’non-typical’ temperature dependence in the
the VT relaxation curves. We consistently observed the presence of at least two overlapping
mobility regimes, with a crossover point (TMAX), and represented by a dramatic change in
temperature dependence with increasing temperature. A clear explanation for the
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non-typical behaviour was difficult to find in the literature. Similar examples of such
relaxation behaviour were observed for the following systems: polymers [245]; protein
lyophilized formulations [279]; amorphous APIs, and drug/polymer dispersions [46, 47].
From this literature, we constructed a unified scheme which helped form a clearer
understanding of the different components of the non-typical relaxation curve (figure 8.1),
relating to changes of mobility in the dispersions with increasing temperature.
Figure 8.1: Explanation for the occurrence of a maximum point on the relaxation temperature dependence
curve
In previous literature, TMAX was not specifically named, instead referred to as the
temperature at which a ’break in the Arrhenius plots’ was observed [47]. It is clearer to see
by studying figure 8.1 that the non-typical behaviour occurs as a result of two overlapping
motional regimes, each following the expected classical temperature dependence of
relaxation times (chapter 4, figure 4.8). TMAX therefore represents the point at which the
two regimes coincide. Using this approach, it seems feasible to calculate apparent
activation energies (EAapp) either side of TMAX , representing the kinetic response of the
dispersions under the influence of each motional regime. The values of EAapp therefore
allows a comparative measure of stability across the different amorphous drug/polymer
systems, with EAapp(LT) being particularly informative of the mobility behaviour at
temperatures below Tg.
An example of the calculated EAapp for our three drug/polymer systems can be seen in
table 8.5. Only the dispersions found to be fully amorphous upon initial characterisation
with PXRD and solid-state NMR were included, as the presence of differing quantities of
crystalline material in the highest drug loading dispersions further complicated the
temperature dependence curves.
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Table 8.5: Comparison of EAapp in kJ mol−1 (LT and HT) for all amorphous IMC, FFA and TLB/PVP-VA
dispersions. *HT EAapp measurements were excluded if crystallisation occurred with increased temperature.
PC = partially crystalline
IMC FFA TLB
EAapp (LT) EAapp (HT) EAapp (LT) EAapp (HT) EAapp (LT) EAapp (HT)
20/80 8.7 35.3 N/A N/A 8.0 54.7
40/60 24.0 55.7 12.9 61.7 6.8 22.2
60/40 26.6 65.9 4.8 55.4 – X (*)
80/20 15.5 X (*) PC PC PC PC
The mid-loading IMC/PVP-VA dispersions (40/60 and 60/40) had much higher LT EAapp
values than the other systems. High EAapp indicates a more restricted mobility, requiring a
higher input of energy to excite. This correlates well with the VT 1H-13C CP/MAS NMR
studies, as the IMC/PVP-VA mid-loading dispersions showed no change in mobility with
increasing temperature of either drug or polymer, indicating the formation of a highly stable
dispersion. Additionally, no crystallisation was detected in the stability study across the
range of temperature conditions employed.
The IMC, FFA and TLB systems where LT EAapp was measurable had similar values of
between 5 - 13 kJ mol−1, indicating that the motion associated with this EAapp is easier to
excite, leading to higher mobility in the system. This again correlated well with the VT 13C
MAS NMR, as at these drug concentrations, higher mobility of the drug phase was detected as
compared to the mid-loading IMC systems. This indicates that at lower drug concentration,
the likelihood of high molecular mobility was greater. This does not necessarily correlate
directly to the deterioration of physical stability resulting in crystallisation, as crystallisation
is also dependent on drug concentration, as nucleation is more likely to occur with increasing
drug content. However, the difference in molecular mobility demonstrated through analysis
of VT relaxation curves could be an important part of the initial assessment of amorphous
forms, and provides insight through an additional parameter not detectable using other
thermal analysis techniques.
As discussed above, the kHz regime probed by VT T1ρ
H studies is sensitive to increases
in mobility associated with the glass transition. The temperature at which TMAX (or the
’break in Arrhenius behaviour’) occurs has been correlated with the Tg of amorphous APIs
[29,47,161] and amorphous dispersions [46,187] in a handful of studies via NMR relaxation
times. The general consensus is that detection of increased mobility below Tg could be a
useful tool in the prediction of physical stability of amorphous systems. TMAX represents
the point of change in relaxation behaviour in the system, therefore it makes sense that an
increase in molecular mobility at temperatures below Tg could indicate reduced physical
stability.
In all our systems studied, a dramatic change in mobility behaviour at temperatures below
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Tg was detected for fully amorphous dispersions. It was found that TMAX occurred at
temperatures below Tg, independent of physical stability highlighted by our accelerated
stability study. For example, the difference between Tg and TMAX of the IMC/PVP-VA
40/60 and 60/40 dispersions suggests increased mobility should occur from ca.313 and 326
K respectively. However, despite being exposed to temperatures up to 373 K in situ in the
rotor and in the accelerated stability study, no recrystallisation was detected. Additionally,
the 60/40 FFA/PVP-VA dispersion had lower physical stability in the stability study,
crystallising to form III after storage at 313 K, but the Tg-TMAX for this system was 19 K,
much closer to the Tg value than for higher stability dispersions which remained stable up
to 373 K in VT 1H-13C CP/MAS NMR and the stability study. The largest difference
between TMAX and Tg occurred in the IMC 20/80 and 40/60 dispersions, with TMAX
occurring ca. 50 and 40 K below Tg respectively. It would therefore appear that increased
molecular mobility below Tg is not a straightforward indication of reduced physical
stability for our dispersions.
Two previous literature studies have been carried out to apply this method to amorphous
dispersions. Forster et al. [187] investigated NIF/PVP and IMC/PVP 50/50 dispersions,
which have similar Tg values. They found that TMAX occurred at a lower temperature
for the NIF/PVP dispersion compared to IMC/PVP dispersion, which correlated with the
lower physical stability after 5 weeks storage at 303 K/75 % RH. However, in a more recent
study of the effect of drug loading level in NIF/PVP dispersions by Yuan et al. [46], the
correlation was not obvious. They again observed a change in mobility in 50/50, 60/40 and
75/25 NIF/PVP dispersions at temperatures below Tg through analysis of VT T1ρ
H times.
The difference between TMAX and Tg was slightly greater with decreasing drug content.
Unfortunately no stability data, or VT 13C solid-state NMR data were included to relate
this to likelihood of crystallisation, although the trend of physical stability would be expected
in the opposite direction: lower stability with increasing drug content. Additionally all three
dispersions were found to be fully miscible on the T1ρ
H timescale (2 - 6 nm).
A comparison of the difference between Tg and TMAX values for our IMC, FFA and TLB
dispersions, amorphous IMC and PVP-VA alone; and literature nifedipine/PVP [46]
dispersions and amorphous nifedipine [47, 187] can be seen in figure 8.2. The majority of
systems, covering a variety of different drug loadings, appear to fall into a narrow range,
with TMAX occurring ca.15 - 20 K below the Tg.
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Figure 8.2: Comparison of the difference between TMAX and Tg for IMC/PVP-VA, FFA/PVP-VA,
TLB/PVP-VA and NIF/PVP [46] dispersions; and for amorphous IMC and NIF [47]
It is possible that the prediction of stability based on difference between Tg and TMAX
may be relevant for amorphous drugs without polymer stabilisation, with correlation found
for indomethacin, nifedipine and phenobarbital [29, 47, 161]. However, our larger scale
study compared to previous literature suggests this prediction does not translate for use in
drug/polymer dispersions, instead the calculation of EAapp may be more useful as a
predictive tool. The best example of this hypothesis being that the IMC/PVP-VA 40/60
dispersion showed no crystallisation or increased mobility in VT 1H-13C CP/MAS, 1H
MAS and no crystallisation in the accelerated stability study, but still TMAX occurred at
40 K below Tg. Conversely the EAapp predicted this dispersion to be highly stable.
VT spin-lattice relaxation time measurements have proven to give a different insight into
mobility of drug/polymer dispersions, compared to the measurement of Tg with DSC. The
calculation of EAapp shows promise as a technique to assess the likelihood of molecular
mobility, as a comparative technique between drug/polymer systems. This could be
especially useful in assessing how much of an impact a potential change to the formulation,
or manufacturing process has on mobility, and therefore physical stability risk. Further
research is required in this area, through investigation of EAapp analysis across a wider
range of systems.
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8.2 Detection of miscibility in drug/polymer dispersions
Phase separation in drug/polymer solid dispersions generally occurs due to amorphous or
crystalline drug domains occurring in the polymer matrix [11]. Such domains are not
always evenly distributed, with the presence of drug concentration gradients between drug
and polymer-rich domains in paracetamol/EUDRAGIT dispersions previously
demonstrated by Qi et al. [103]. The detection of miscibility and phase separation of solid
dispersions is therefore a vital part of formulation development, as successful formulation of
miscible drug/polymer amorphous dispersions is crucial for maintaining acceptable physical
stability during manufacture and storage of pharmaceuticals [62, 108]. The miscibility of
solid dispersions has traditionally been studied using DSC, where a single Tg value
(intermediate between the Tgs of the individual components) is thought to indicate
molecular level homogeneity [78, 106, 108, 163], with a detection limit of 20-30
nm [46,164–166].
However, the detection of miscibility using DSC has been shown to be unreliable, with
phase separation of amorphous dispersions detected, despite the presence of single Tg
values [67, 108, 144]. Therefore, a distinctive single Tg value can often be a misleading
identifier of physical stability of amorphous drug/polymer systems [108]. The use of
spin-lattice relaxation times (T1ρ
H and T1
H) in the solid-state has proven to be extremely
useful in providing additional information about the miscibility and phase separation of
solid dispersions, with differences in T1ρ
H times allowing estimation of much smaller
domains than with DSC; with a demonstrated detection down to ca.2 nm in size [46,62,88].
8.2.1 Thermal Analysis
The experimental and predicted Tg values for our three drug/polymer systems can be seen in
figure 8.3. Density measurements of the three amorphous drugs were not possible, therefore
predictions were made using the Gordon-Taylor/Kelley-Bueche (G-T/K-B) and Couchman-
Karasz (C-K) equations only (equations 2.17 with 2.19 and 2.20 respectively - see chapter
3).
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Figure 8.3: Glass transition temperatures for IMC/PVP-VA, FFA/PVP-VA and TLB/PVP-VA
dispersions at different drug loadings, compared to values predicted by the Gordon-Taylor/Kelley-Bueche
(G-T/K-B) and Couchman-Karasz (C-K) equations
For fully amorphous solid dispersions, deviation from predicted Tg values can indicate the
presence of immiscible, or incompatible components [192]. Deviations of ± 5 - 8 K between
theoretical and experimental Tg values is considered to be good agreement for ’ideal’ mixing
[78, 108]. Using this approach, all three drug/polymer systems showed negligible deviation
from predicted values across all drug/polymer ratios. This method indicates that these
systems are not dominated by intermolecular interactions, and instead are considered to be
’ideally’ mixed from the DSC perspective. Additionally, the presence of one single Tg value
was found in all our fully amorphous dispersions, at an intermediate temperature between
the drug and polymer Tg values. This indicates miscibility between amorphous drug and
polymer, with a domain size detection limit of 20-30 nm [165].
8.2.2 Detection of miscibility using relaxation times studies
Variable temperature solid-state NMR relaxation studies have highlighted a number of
important observations with regard to the miscibility and phase separation of the IMC,
FFA and TLB/PVP-VA drug/polymer systems, including not using T1ρ
H times to detect
phase separation between drug and polymer upon heating fully miscible dispersions; but
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also using T1
F times to identify phase separation between different drug phases (crystalline
and amorphous) at high temperatures.
The majority of literature studies employing spin-lattice relaxation times to detect
miscibility in drug/polymer systems have focussed on measurements at ambient
temperatures. We demonstrated in section 8.1.2.1 that relaxation time is highly dependent
on temperature. The detection of miscibility and phase separation based upon relaxation
times is therefore also highly temperature dependent. Additionally, it is crucial to fully
investigate the behaviour of amorphous dispersions across the full range of temperatures
likely to be experienced throughout manufacture and storage, in order to identify and
understand changes to miscibility occurring in formulations.
8.2.2.1 Drug/polymer miscibility
Firstly, changes in relaxation times (T1ρ
H and T1
H) were used for the detection of phase
separation between drug and polymer components in solid dispersions. At ambient
temperatures, all dispersions with drug loadings of 60 wt. % and below were found to be
miscible (down to 2-6 nm domain sizes) using ∆T1ρ
H times, which correlated with the
amorphous nature of these dispersions shown through DSC, PXRD and 1H-13C CP/MAS
NMR. Of the highest drug loadings (70 % and above), the IMC/PVP-VA dispersions
showed the smallest level of phase separation with ∆ T1ρ
H of 10 ms, compared to ca. 50
ms (FFA) and 60 ms (TLB) at 80 wt. % drug loading (figure 8.4), which again correlates
well with the level of crystalline drug detected upon initial characterisation: the larger the
proportion of crystalline drug present within the dispersion, the larger the separation of
T1ρ
H times detected though T1ρ
H time analysis. No significant differences in ∆T1
H were
detected for all dispersions studied, suggesting miscibility on the 6 - 24 nm lengthscale,
despite the presence of crystalline drug in the higher drug loading dispersions.
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Figure 8.4: Miscibility of drug and polymer at 293 K, as predicted through ∆T1ρH times for IMC, FFA
and TLB/PVP-VA dispersions at varying drug loadings
Solid-state NMR was first used to demonstrate miscibility in polymer blends and alloys
[282, 283]. Pignatello et al. [90] demonstrated this method to be useful for the detection of
homogeneity in pharmaceutical solid dispersions with diflusinal and Eudragit, formulated
via solvent evaporation. A large separation of T1
H between drug and polymer was observed
for physical mixtures, as compared to one common T1
H time for each component within the
solid dispersion, indicating intimate mixing. Aso et al. [152] further expanded the method,
to assess the sensitivity of spin-lattice relaxation in detecting miscibility in nifedipine solid
dispersions, as compared to DSC. Relaxation decay curves were used to detect miscibility,
where mono-exponential decay described homogeneity to the detection limit of T1ρ
H (less
than 5 nm) and T1
H (smaller than 50 nm), with larger domains described by bi-exponential
equations. Nifedipine/PHPA (40/60 and 50/50 w/w) contained domains 5-50 nm in size,
despite displaying a single Tg values, demonstrating that NMR provides a more detailed
level of miscibility information compared to DSC.
Pham et al. [88] studied a range of pharmaceutical formulations extensively with a variety
of solid-state NMR techniques, including the detection of phase separation through
spin-lattice relaxation. Trehalose/Dextran solid dispersions were found to be miscible with
domains of less than 82 nm (50/50 w/w) and 55 nm (30/70 w/w) via T1
H relaxation time
measurements at 273 K. Both dispersions were found to be miscible by DSC [144]. Kojima
et al. [86] found one common T1
H time in mefenamic acid/Eudragit EPO (24/76 w/w)
cryogenically ground dispersions, which indicated domains of less than 100 nm. Litvinov et
al. [101] used T1ρ
H times to demonstrate the formation of 1.6 nm amorphous nanoclusters
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dispersed within the polymer phase of miconazole/PEG-gPVA (10/90 w/w) dispersions.
The most extensive studies to detect molecular level miscibility in solid dispersions via
spin-lattice relaxation (combining analysis of both ∆ T1ρ
H and T1
H) were carried out by
Yuan et al. [46] and Song et al. [62]. Both groups investigated the effect of drug loading on
miscibility at ambient temperature, probing a range of dispersions of nifedipine/PVP and
lapatinib/HPMC-P respectively (figure 8.5).
Figure 8.5: Differences in A) T1ρH and B) T1H between nifedipine and PVP in melt quenched solid
dispersions, adapted from [46] and Differences in A) T1ρ
H and B) T1
H between lapatinib and HPMC-P in
spray dried solid dispersions, adapted from [46]
Nifedipine/PVP melt quenched dispersions were found to be homogenous at 75/25, 60/40 and
50/50 (w/w) loadings, with domains of less than 4.5 nm. Only extremely high drug loadings
(90 - 95 wt. %) displayed immiscibility on this scale, with estimated domain sizes between
20 - 50 nm. Spray dried dispersions showed an even higher level of mixing, with 90 % drug
loading showing no difference in T1ρ
H between drug and polymer [46]. Lapatinib/HPMC-P
spray dried dispersions were miscible by T1
H up to 80 % drug loading, but ∆T1ρ
H times
highlighted the separation of drug and polymer at both low and high drug loadings. ∆T1ρ
H
was smallest for the 40/60 lapatinib/HPMC-P dispersion, enabling them to choose this as
the optimum drug loading level for formulation in terms of miscibility. The multiple phases
in the low (10/90 and 20/80) and high (80/20) loading dispersions were attributed to the
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presence of excess amorphous drug/polymer salt alongside un-ionized excess polymer and
some drug/polymer salt alongside excess un-ionized drug respectively [62].
By combining both T1
H and T1ρ
H measurements with DSC analysis we gain a more complete
picture of the level of homogeneity within solid dispersions, allowing detection of miscibility
to ca. 2 nm lengthscale. Measuring differences in spin-lattice relaxation times to detect
miscibility in solid dispersions has therefore been shown to be an effective tool, with higher
detection sensitivity than DSC in our results and in previous literature studies.
However, the in-depth analysis of the miscibility of different drug/polymer dispersions with
varying temperature is still lacking. This is extremely important, as throughout
formulation and storage, components of solid dispersions can be exposed to a variety of
different temperature conditions. Here we demonstrate the importance of probing the
miscibility of drug/polymer dispersions across a temperature range, as although a
dispersion may appear to be intimately mixed at ambient temperature, a small change in
temperature can lead to phase separation, crystallisation, and ultimately changes in
properties affecting dissolution rate and physical stability. To the best of our knowledge,
our work presents the first comprehensive studies of changes in miscibility (under 30 nm) of
polymer/drug dispersions across different temperatures.
Both the 60/40 and 70/30 TLB/PVP-VA dispersions were found to be miscible on the
lengthscale sensitive to T1ρ
H times at 293 K (figure 8.6). Above 293 K, a clear phase
separation of drug and polymer was detected for the 70/30 dispersion, as the temperature
induced crystallisation to form IH TLB occurred. The 60/40 dispersion was also fully
miscible at ambient temperatures, with phase separation detected as the dispersion was
heated through Tg (ca.313 K: Tg + 4 K). At this point, crystallisation from amorphous to
form IH TLB was identified through VT 1H-13C CP/MAS NMR.
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Figure 8.6: Difference in T1ρH times between TLB and PVP-VA in the 60/40 and 70/30 dispersions
between 253 and 343 K. Error bars represent 95 % confidence intervals of the difference between means
For the IMC/PVP-VA 80/20 dispersion, partial phase separation was detected at ambient
temperatures (∆T1ρ
H ca.10 ms), but increased at higher temperature, particularly ca. 343
K (Tg + 18 K), when crystallisation from amorphous to α-IMC was detected. The highest
loading FFA/PVP-VA dispersions (70/30 and 80/20) were immiscible (via T1ρ
H times)
across the entire temperature range, with clear phase separation identified, and a greater
separation of T1ρ
H times with increasing crystalline content.
The measurement of T1ρ
H times has been shown to be a very sensitive technique as
compared to DSC and T1
H , as it enabled the estimation of domain sizes down to as little
as 2 nm. The combination of relaxation time difference measurements alongside
temperature dependence relaxation curves and VT 1H-13C CP/MAS NMR, provides an
extremely useful visual tool to identify phase separation, homogeneity and crystallisation
behaviour in solid dispersions. Identification of these attributes is important during initial
formulation development to identify both ideal and maximum drug loading levels.
8.2.2.2 Understanding solid forms of drugs within dispersions at high
temperatures
Solid-state NMR can additionally be used for the identification and quantification of different
solid forms of API present in dispersions. We observed the presence of both amorphous and
crystalline forms in the TLB/PVP-VA and FFA/PVP-VA 70 and 80 wt. % dispersions
through DSC and 1H-13C CP/MAS NMR at ambient temperatures, and monitored the
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crystallisation and polymorphic behaviour with increasing temperature. However, due to
the high mobility of both FFA and PVP-VA at high temperatures, this method proved more
challenging for the FFA/PVP-VA dispersions.
At high temperatures, we were able to detect form IH TLB in the 60, 70 and 80 wt. %
dispersions; and α-IMC in the wt. 80 % dispersion with 1H-13C CP/MAS NMR, however
the FFA/PVP-VA dispersions proved more problematic to characterise. As the FFA/PVP-
VA dispersions crossed to a high mobility regime, the 13C signal was undetectable, but the
presence of 19F provided an alternative way to detect and characterise the drug via 19F MAS
NMR and T1
F .
This method clearly highlighted two distinct fluorine environments, corresponding to
crystalline (form I) and amorphous FFA, both at 373 K, and upon cooling to ambient
temperatures (figure 8.7). There are no previously reported examples of the detection of
phase separated drug phases with T1
F , although Pham et al. [88] identified two drug
phases in high drug loaded paracetamol/Eudragit dispersions via 13C detected T1
H
analysis.
Figure 8.7: Arrhenius plots outlining the temperature dependence of T1F times of 80/20 dispersion,
heated between 293 K and 373 K, then cooled back to 293 K. Relevant 19F MAS NMR spectra for 373 K and
upon cooling back to 293 K are shown to highlight the origins of phase separation
8.2.2.3 Limitations of the detection of miscibility with ∆T1ρ
H
The 70/30 TLB/PVP-VA dispersion was found to contain form IL TLB, alongside amorphous
TLB upon formulation via DSC, PXRD and solid-state NMR. However, within experimental
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error at 293 K, there was no difference in T1ρ
H between crystalline drug and polymer, with
the level of amorphous TLB too low to accurately measure T1ρ
H times. Therefore it would be
incorrect to apply ∆T1ρ
H time measurements in this case. This method is highly dependent
on different phases having different individual T1ρ
H times, so that a difference of zero gives
a meaningful result. In this case, the individual T1ρ
H times of the crystalline form IL and
PVP-VA were highly similar at 293 K. The possibility of T1ρ times which are statistically
indistinguishable between components is therefore a limitation of this technique [146]. In
this case, more complex 2D solid-state NMR techniques such as multinuclear HETeronuclear
Correlation (HETCOR) could be employed to provide additional miscibility information
[88,284,285].
Measuring the difference in T1ρ
H times across a range of temperatures provides a more
complete picture of the level of phase separation under different conditions. In the 70/30
TLB/PVP-VA dispersion, increasing the temperature uncovered a difference in T1ρ
H times
of the drug (form IL) and polymer, as they display completely different temperature
dependencies at higher temperatures. Relying on one temperature point measurement
provides only a snapshot of the behaviour of the individual components under one specific
environment. When the temperature dependence relaxation curves of TLB and PVP-VA in
the 70/30 dispersion were studied separately, it became clear that the two phases had
completely different temperature dependencies, despite appearing to have similar
relaxation times at 293 K. This highlights the importance of studying the temperature
dependence of relaxation.
VT 1H-13C CP/MAS NMR did show an increased level of form IL TLB within the 70/30
dispersion with increasing temperature, followed by a polymorphic transition to form IH .
Despite having similar crystal structures, it has been demonstrated here that the
enantiomeric polymorphs have very different T1ρ
H times. It is unlikely that upon
conversion from form IL → form IH the domain sizes of crystalline TLB drastically
changed, but the difference in T1ρ
H times between drug and polymer was only detectable
following the polymorphic transition.
This observation highlights the importance of investigating the miscibility information gained
through ∆T1ρ
H and ∆T1
H analysis, alongside the full temperature dependence relaxation
curves, and VT 1H-13C CP/MAS NMR to provide a more comprehensive understanding of
the behaviour of the different solid dispersion components, particularly when drug loading
approaches the maximum loading limit, increasing the likelihood of the presence of more
complex phase transitions.
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8.2.3 Mapping polymorphic transitions in dispersions with high drug
loadings
Both IMC and TLB proved to be interesting systems at high drug loading levels, with both
amorphous, and partially crystalline dispersions enabling the mapping of crystallisation and
polymorphic transitions with VT 1H-13C CP/MAS NMR and T1ρ
H relaxation studies.
IMC was a useful proof of concept system. We were able to clearly observe the
crystallisation of amorphous to α-IMC from the amorphous drug by acquiring 1H-13C
CP/MAS NMR spectra with increasing temperature. Amorphous IMC has been shown to
convert to α-IMC when stored at temperatures above Tg, as this is the more
thermodynamically stable polymorph at high temperatures. We also found that the same
polymorphic transition occurred from amorphous IMC dispersed in low levels of PVP-VA
(80/20 dispersion), showing that polymorphic phase diagrams are still relevant to predict
transitions in drug/polymer systems under conditions where crystallisation can occur.
Additionally, the transition was clearly observed in both VT 1H-13C CP/MAS NMR and
relaxation studies, which demonstrates the usefulness of both solid-state NMR techniques.
Using the TLB system, we were able to clearly monitor a number of different polymorphic
transitions in both the pure crystalline form and in the highest drug loaded dispersions. The
transition of form IL → IH is known to occur reliably upon heating and cooling through
ca. 311 K due to a conformational change to the butyl chain associated with an enthalpy
of ca. 2 kJ mol−1 [43]. The changes to the structure were clearly seen in the 13C solid-
state NMR spectrum, through changes in chemical shift in the aliphatic region. Heating and
cooling form I TLB in situ in the rotor reliably induced these changes in the chemical shift
positions, in agreement with the study by Hasegawa et al. [43].
Throughout the full temperature range, we observed the presence of two different motional
regimes, via spin-lattice relaxation and 1H-13C CP/MAS NMR studies.
• Low temperature motional regime ca.263 K, on the kHz timescale, which
has not been reported before and is thought to be associated with slow oscillations of
the aromatic ring
• Higher temperature motional regime ca.313 K on the MHz timescale,
associated with the motion of the butyl chain during the form IL → IH transition.
• The same motional regimes were clearly observed in both the pure crystalline form I,
and the 70/30 TLB/PVP-VA dispersion which contained both form I and amorphous
TLB alongside PVP-VA
Using VT 1H-13C CP/MAS NMR we were able to monitor the more complex polymorphic
transitions between forms I, II and V in the 80/20 TLB/PVP-VA dispersion (figure 8.8).
Form V has been described previously, but was found to be very unstable, converting to
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form I within two hours at ambient temperature [44, 57]. Cooling to low temperatures
resulted in conversion of form IL → V, which was reversible upon heating back to ambient
temperatures, indicating this is a temperature dependent reversible polymorphic transition.
Form V also appeared to be more stable in the dispersion under dry conditions at room
temperature in comparison to pure form V. Slow conversion from form V → to form IL did
occur, but form V was still detectable via PXRD after 8 weeks of storage.
Figure 8.8: Schematic representation of the polymorphic transitions mapped in 80/20 TLB/PVP-VA
dispersion
The FFA system proved much more difficult to study, especially in terms of polymorphic
transitions. FFA is known to exhibit complex polymorphism [39], having the highest number
of solved polymorphic structures in the Cambridge Structural Database. Through heating
pure form III FFA, we were able to detect the transition from form III → form I via VT
1H-13C CP/MAS and 19F MAS NMR. The highest drug loading dispersions contained form
III on formulation alongside amorphous FFA, but the same transition to form I was not
detectable in VT 1H-13C CP/MAS NMR, due to loss of signal through high mobility of
drug and polymer. The VT 19F MAS NMR identifed the presence of form I FFA in the
dispersions at 373 K, which was confirmed with VT PXRD studies. In all three systems,
the polymorphic transition (form III → I) occurred at a much higher temperature than the
expected literature transition temperature.
This extends work done in previous studies of crystallisation from high drug loaded
dispersions, by identifying and characterising different polymorphic forms. Currently,
polymorphic screening of API is carried out from solvent, but not in the presence of
polymer. Therefore, unidentified polymorphs can sometimes be missed in early
development, only appearing at later stages, which can cause huge problems in terms of
physical stability and dissolution of formulations.
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Here we have three different systems, where we see crystallisation and phase separation
at high drug loading levels. Through application of VT solid-state NMR techniques, we
were able to sensitively monitor a number of polymorphic transitions which agreed with
known thermodynamic stabilities; identify different polymorphs within complex polymorphic
mixtures; and observe the stabilisation of previously unstable polymorphs within dispersions.
8.3 Prediction of outcomes of accelerated stability studies
The physical stability of the amorphous and partially crystalline solid dispersions was
monitored at elevated temperatures over a period of 8 - 12 weeks. We aimed to predict the
outcome of the stability study, in terms of physical stability, crystallisation of amorphous
API, and occurrence of polymorphic transitions between crystalline phases of the various
solid dispersions with variable temperature 1H-13C CP/MAS NMR.
The majority of the fully amorphous dispersions remained physically stable upon storage
at elevated temperature and humidity, throughout the study period. Crystallisation was
detected in the IMC/PVP-VA 80/20, FFA/PVP-VA 60/40 and TLB/PVP-VA 60/40
dispersions after storage at 363 K, 313 K and RT 75 % RH respectively. Further
polymorphic transitions of the partially crystalline high loading dispersions were also
detected, providing useful additional data relating to polymorphism within solid
dispersions.
The crystallisation outcomes of the dispersions in the accelerated stability study and in situ in
the NMR rotor via VT 1H-13C CP/MAS NMR can be seen in tables 8.6 and 8.7 respectively.
These results demonstrate that VT NMR accurately predicted the crystallisation outcome of
the IMC/PVP-VA, FFA/PVP-VA and TLB/PVP-VA dispersions occurring in the stability
study, unless the 13C signal was absent through high sample mobility. This was a particular
problem at higher temperatures with FFA/PVP-VA dispersions above 40 wt. % drug loading.
In this case, we were able to use a multinuclear approach to detect crystallisation outcomes
with 19F MAS NMR.
The 13C VT MAS NMR method was therefore able to identify:
1. The stable dispersions which remained amorphous
2. Lower stability dispersions which showed crystallisation at increased temperature
3. Further polymorphic transitions of the partially crystalline dispersions
These findings mirror both the stability study and VT PXRD. VT 1H-13C CP/MAS NMR
therefore shows great promise as a toolset for the prediction of stability study outcome of
solid dispersions, achieving reliable results in around 8 hours in situ, compared to up to 8 - 12
weeks in the oven, provided signal does not break down through increased sample mobility.
261
Table 8.6: Composition of IMC/PVP-VA, FFA/PVP-VA and TLB/PVP-VA dispersions before and after
storage at various conditions in the accelerated stability study (12 weeks) as detected by PXRD and solid-
state NMR. Amorphous → Crystalline Dispersion was considered to be crystalline if crystalline peaks of the
drug were detectable by PXRD and 1H-13C CP/MAS NMR
Start RT 0 % RT 75 % 313 K 333 K 353 K 363 K
IMC 20 A A A A A
IMC 40 A A A A A
IMC 60 A A A A A
IMC 70 A A A A A
IMC 80 A A A A A α-IMC
FFA 20 A A A A A
FFA 40 A A A A A
FFA 60 A A A III III
FFA 70 III III III III
FFA 80 III III III III III
TLB 20 A A A A A
TLB 40 A A A A A
TLB 60 A A IL IL IL
TLB 70 IL IL IL IL
TLB 80 V, II, IL V (↓), II, IL II, IL II, IL II, IL IL
Table 8.7: Composition of IMC/PVP-VA, FFA/PVP-VA and TLB/PVP-VA dispersions with increasing
temperature in situ in the NMR rotor detected via 1H-13C CP/MAS NMR Amorphous → Crystalline
293 K 313 K 333 K 353 K 373 K
13C 19F
IMC 20 A A A A A
IMC 40 A A A A A
IMC 60 A A A A No signal
IMC 80 A A A α α
FFA 20 A A A A A A
FFA 40 A A A A No signal A
FFA 60 A A A No signal No signal A
FFA 70 III III III No signal No signal I
FFA 80 III III III III No signal I
TLB 20 A A A A A
TLB 40 A A A A No signal
TLB 60 A IH IH IH No signal
TLB 70 IL IH IH IH IH
TLB 80 V, II, IL V, II, IH II, IH IH IH
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8.4 Overall Conclusions
1. Amorphous solid dispersions were successfully formulated with PVP-VA for three
contrasting amorphous pharmaceuticals: IMC, FFA and TLB. Differences in
maximum drug loading level were identified for each. The combined use of different
spectroscopic, structural and thermal methods allowed successful, and varied
investigations of the local structure and mobility of the drug/polymer systems across
a range of timescales. Such a combined approach is essential in understanding the
complexities of polymer drug dispersions.
2. Each drug/polymer system proved valuable to this study in a different way. IMC
proved to be a useful proof of concept system; providing a high stability comparison
against the FFA and TLB systems. The use of 19F NMR spectroscopy enabled us
to gain a unique insight in the very complex behaviour of FFA/PVP-VA dispersions
at high temperature. TLB provided a useful probe of polymorphic transitions in the
presence of polymer, due to the high crystalline content, and complex polymorphic
behaviour of these dispersions. Additionally, the presence of motional regimes across
a range of timescales were demonstrated in this system.
3. All fully amorphous dispersions followed similar ’non-typical’ relaxation time
temperature dependence, which we clarified through creation of a unified scheme.
The calculation of apparent activation energies EAapp showed the most promise as a
tool to relate local mobility with the prediction of physical stability of amorphous
solid dispersions, as some correlation between these parameters was demonstrated.
This requires further study across a wider range of drug/polymer dispersions to
increase the dataset with which more definite conclusions can be drawn. The use of
TMAX - Tg to assess physical stability should be taken with more caution.
4. Variable temperature studies highlighted changes in miscibility for a number of
dispersions, reinforcing the importance of studying local structure and mobility at a
range of temperatures. Throughout manufacturing and storage, solid formulations
can be exposed to a variety of different temperature conditions: although a dispersion
may appear to be intimately mixed at ambient temperatures, a small change can lead
to phase separation, and ultimately changes in dissolution rate and physical stability.
5. The combination of relaxation time difference measurements, temperature
dependence relaxation curves and VT 1H-13C CP/MAS NMR provided a clear visual
tool to identify phase separation and crystallisation behaviour in solid dispersions,
Early identification of these attributes is important during initial formulation
development to identify both ideal, and maximum drug loading levels. VT 13C MAS
NMR has additionally shown great promise as a tool for the prediction of
crystallisation outcomes of high temperature stability studies. This could also prove
263
to be a useful technique in highlighting unusual polymorphic behaviour of early
development compounds, essentially eliminating problem APIs from further
development at the earliest possible stage.
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